The present invention relates generally to biosynthetic processes, and more specifically to organisms having 1,4-butanediol and gamma-butyrolactone biosynthetic capability.
1,4-Butanediol (14-BDO) is a polymer intermediate and industrial solvent with a global market of about 3 billion lb/year. 14-BDO is currently produced from petrochemical precursors, primarily acetylene, maleic anhydride, and propylene oxide. For example, acetylene is reacted with 2 molecules of formaldehyde in the Reppe synthesis reaction (Kroschwitz and Grant, Encyclopedia of Chem. Tech., John Wiley and Sons, Inc., New York (1999)), followed by catalytic hydrogenation to form 1,4-butanediol. Downstream, 14-BDO can be further transformed; for example, by oxidation to gamma-butyrolactone (GBL) or hydrogenolysis to tetrahydrofuran (THF). These compounds have varied uses as polymer intermediates, solvents, and additives, and have a combined market of nearly 2 billion lb/year.
Gamma-butyrolactone (GBL) is a chemical intermediate and common solvent with a global market of about 0.5 billion lb/year. GBL has wide applications. GBL serves as a chemical intermediate in the manufacture of pyrrolidones that are widely used in the pharmaceutical industry. It can be used in the production of pesticides, herbicides and plant growth regulators. GBL is also used as an aroma compound, as a stain remover, as a superglue remover, as a paint stripper, and as a solvent in some wet aluminum electrolytic capacitors. Currently, GBL is mainly synthesized through 14-BDO from crude oil and/or natural gas derived feedstocks by the Reppe acetylene chemistry.
Microbial organisms and methods for effectively co-producing commercial quantities of 14-BDO and GBL are described herein and include related advantages.
The invention provides non-naturally occurring microbial organisms containing 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL) pathways comprising at least one exogenous nucleic acid encoding a 14-BDO pathway enzyme and at least one exogenous nucleic acid encoding a GBL pathway enzyme each expressed in a sufficient amount to produce 14-BDO and GBL. The invention additionally provides methods of using such microbial organisms to produce 14-BDO and GBL, which in some embodiments includes the non-enzymatic lactonization of 4-hydroxybutyryl-phosphate or 4-hydroxybutyryl-CoA to form GBL.
The present invention is directed to the design and production of cells and organisms having biosynthetic production capabilities for 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL). The invention, in particular, relates to the design of microbial organisms capable of producing 14-BDO and GBL by introducing one or more nucleic acids encoding a 14-BDO and GBL pathway enzyme.
In one embodiment, the invention utilizes in silico stoichiometric models of Escherichia coli metabolism that identify metabolic designs for biosynthetic production of 14-BDO and GBL. The results described herein indicate that metabolic pathways can be designed and recombinantly engineered to achieve the biosynthesis of 14-BDO and GBL in Escherichia coli and other cells or organisms. Biosynthetic production of 14-BDO and GBL, for example, for the in silico designs can be confirmed by construction of strains having the designed metabolic genotype. These metabolically engineered cells or organisms also can be subjected to adaptive evolution to further augment 14-BDO and GBL biosynthesis, including under conditions approaching theoretical maximum growth.
In certain embodiments, the 14-BDO and GBL biosynthesis characteristics of the designed strains make them genetically stable and particularly useful in continuous bioprocesses. Separate strain design strategies were identified with incorporation of different non-native or heterologous reaction capabilities into E. coli or other host organisms leading to 14-BDO and GBL producing metabolic pathways from either succinate, succinyl-CoA or alpha-ketoglutarate. In silico metabolic designs were identified that resulted in the biosynthesis of 14-BDO and GBL in microorganisms from each of these metabolic intermediates. Embodiments of the invention include the controlled production of 14-BDO and GBL at a predetermined ratio. As described herein, this ratio can be regulated by, for example, introducing an exogenous nucleic acid encoding an enzyme or protein with an increased or decreased activity or specificity for one or more intermediates in the respective 14-BDO or GBL pathways or modulating the expression of an enzyme or protein in a 14-BDO or GBL pathway, thereby regulating the production of 14-BDO and GBL.
Strains identified via the computational component of the platform can be put into actual production by genetically engineering any of the predicted metabolic alterations which lead to the biosynthetic production of 14-BDO and GBL or other intermediate and/or downstream products. In yet a further embodiment, strains exhibiting biosynthetic production of these compounds can be further subjected to adaptive evolution to further augment product biosynthesis. The levels of product biosynthesis yield following adaptive evolution also can be predicted by the computational component of the system.
Embodiments of the invention also provide methods for co-production of 14-BDO and GBL. Co-production of 14-BDO and GBL is attractive due to the following advantages: 1) co-production will satisfy the needs of both chemicals and reduce the cost and environmental impact of the transformation of 14-BDO to GBL; 2) construction of a single large regional facility for co-production will save capital investment and reduce fixed cost comparing to separate productions; 3) separating the two co-products from fermentation broth can be easily achieve through distillation due to their boiling points (14-BDO at 230° C. and GBL at 204° C.).
As used herein, the term “non-naturally occurring” when used in reference to a microbial organism or microorganism of the invention is intended to mean that the microbial organism has at least one genetic alteration not normally found in a naturally occurring strain of the referenced species, including wild-type strains of the referenced species. Genetic alterations include, for example, modifications introducing expressible nucleic acids encoding metabolic polypeptides, other nucleic acid additions, nucleic acid deletions and/or other functional disruption of the microbial organism's genetic material. Such modifications include, for example, coding regions and functional fragments thereof, for heterologous, homologous or both heterologous and homologous polypeptides for the referenced species. Additional modifications include, for example, non-coding regulatory regions in which the modifications alter expression of a gene or operon. Exemplary metabolic polypeptides include enzymes or proteins within a 14-BDO and GBL biosynthetic pathway.
A metabolic modification refers to a biochemical reaction that is altered from its naturally occurring state. Therefore, non-naturally occurring microorganisms can have genetic modifications to nucleic acids encoding metabolic polypeptides or, functional fragments thereof. Exemplary metabolic modifications are disclosed herein.
As used herein, the term “isolated” when used in reference to a microbial organism is intended to mean an organism that is substantially free of at least one component as the referenced microbial organism is found in nature. The term includes a microbial organism that is removed from some or all components as it is found in its natural environment. The term also includes a microbial organism that is removed from some or all components as the microbial organism is found in non-naturally occurring environments. Therefore, an isolated microbial organism is partly or completely separated from other substances as it is found in nature or as it is grown, stored or subsisted in non-naturally occurring environments. Specific examples of isolated microbial organisms include partially pure microbes, substantially pure microbes and microbes cultured in a medium that is non-naturally occurring.
As used herein, the terms “microbial,” “microbial organism” or “microorganism” is intended to mean any organism that exists as a microscopic cell that is included within the domains of archaea, bacteria or eukarya. Therefore, the term is intended to encompass prokaryotic or eukaryotic cells or organisms having a microscopic size and includes bacteria, archaea and eubacteria of all species as well as eukaryotic microorganisms such as yeast and fungi. The term also includes cell cultures of any species that can be cultured for the production of a biochemical.
As used herein, the term “1,4-butanediol” is intended to mean an alcohol derivative of the alkane butane, carrying two hydroxyl groups which has the chemical formula C4H10O2 and a molecular mass of 90.12 g/mol. The chemical compound 1,4-butanediol also is known in the art as 14-BDO or BDO and is a chemical intermediate or precursor for a family of compounds referred to herein as BDO family of compounds
As used herein, the term “gamma-butyrolactone” is intended to mean a lactone having the chemical formula C4H6O2 and a molecular mass of 86.089 g/mol. The chemical compound gamma-butyrolactone also is know in the art as GBL, butyrolactone, 1,4-lactone, 4-butyrolactone, 4-hydroxybutyric acid lactone, and gamma-hydroxybutyric acid lactone. The term as it is used herein is intended to include any of the compound's various salt forms.
As used herein, the term “4-hydroxybutanoic acid” is intended to mean a 4-hydroxy derivative of butyric acid having the chemical formula C4H8O3 and a molecular mass of 104.11 g/mol (126.09 g/mol for its sodium salt). The chemical compound 4-hydroxybutanoic acid also is known in the art as 4-HB, 4-hydroxybutyrate, gamma-hydroxybutyric acid or GHB. The term as it is used herein is intended to include any of the compound's various salt forms and include, for example, 4-hydroxybutanoate and 4-hydroxybutyrate. Specific examples of salt forms for 4-HB include sodium 4-HB and potassium 4-HB. Therefore, the terms 4-hydroxybutanoic acid, 4-HB, 4-hydroxybutyrate, 4-hydroxybutanoate, gamma-hydroxybutyric acid and GHB as well as other art recognized names are used synonymously herein.
As used herein, the term “CoA” or “coenzyme A” is intended to mean an organic cofactor or prosthetic group (nonprotein portion of an enzyme) whose presence is required for the activity of many enzymes (the apoenzyme) to form an active enzyme system. Coenzyme A functions in certain condensing enzymes, acts in acetyl or other acyl group transfer and in fatty acid synthesis and oxidation, pyruvate oxidation and in other acetylation. Coenzyme A can also function as an activating group for a spontaneous intramolecular chemical reaction, such as, circulazation or lactonization.
As used herein, the term “phosphate” is intended to mean an inorganic chemical ion of the empirical formula PO3−4 and a molar mass of 94.973 g/mol. A phosphate can act as a functional group when added to a compound. A phosphate can function as an activating group for a spontaneous intramolecular chemical reaction, such as, cirulazation or lactonization.
As used herein, the term “substantially anaerobic” when used in reference to a culture or growth condition is intended to mean that the amount of oxygen is less than about 10% of saturation for dissolved oxygen in liquid media. The term also is intended to include sealed chambers of liquid or solid medium maintained with an atmosphere of less than about 1% oxygen.
As used herein, the term “predetermined ratio” when used in reference to the amount of one compound relative to the amount of another compound is intended to mean a ratio of compounds that is established in advance that can be produced by a non-naturally occurring microorganism described herein through prior experimental determination for each compound separately or in combination. A predetermined ratio can also be established in advance by determining the maximum theoretical yield for a non-naturally occurring microorganism to produce 14-BDO and GBL as described herein. Embodiments described herein include that the predetermined ratio intends there is at least some detectable amount of one product relative to the amount of a second, third, or fourth product up to any number of products or intermediate compounds in a 14-BDO or GBL pathway produced by a non-naturally occurring microorganism described herein. Embodiments described herein include the amount of intracellular 14-BDO or GBL produced by the microorganisms is at least 0.001 mM, or alternatively at least 0.01 mM, or alternatively at least 0.1 mM, or alternatively at least 1.0 mM or alternatively at least 10 mM or alternatively at least 100 mM, or alternatively at least 1M. Embodiments described herein also include the amount of intracellular 14-BDO or GBL produced by the microorganisms is at least 1%, or alternatively at least 5%, or alternatively at least 10%, or alternatively at least 15%, or alternatively at least 20%, or alternatively at least 25%, or alternatively at least 30%, or alternatively at least 35%, or alternatively at least 40%, or alternatively at least 45%, or alternatively at least 50%, or alternatively at least 55%, or alternatively at least 60%, or alternatively at least 65%, or alternatively at least 70%, or alternatively at least 75%, or alternatively at least 80%, or alternatively at least 85%, or alternatively at least 90%, or alternatively at least 95%, or alternatively at least 98%, or alternatively at least 100% of the maximum theoretical yield. Embodiments described herein include the predetermined ratio of intracellular 14-BDO to GLB produced by the microorganisms is 1:1, or alternatively 1:2, or alternatively 1:3, or alternatively 1:4, or alternatively 1:5, or alternatively 1:6, or alternatively 1:7, or alternatively 1:8, or alternatively 1:9, or alternatively 1:10, or alternatively 1:15, or alternatively about 1:20, or alternatively 1:25, or alternatively 1:30, or alternatively 1:35, or alternatively 1:40, or alternatively 1:45, or alternatively about 1:50, or alternatively 1:60, or alternatively 1:70, or alternatively 1:80, or alternatively 1:90, or alternatively 1:100. Embodiments described herein include the predetermined ratio of intracellular 14-BDO to GLB produced by the microorganisms is 2:1, or alternatively 3:1, or alternatively 4:1, or alternatively 5:1, or alternatively 6:1, or alternatively 7:1, or alternatively 8:1, or alternatively 9:1, or alternatively 10:1, or alternatively 15:1, or alternatively about 20:1, or alternatively 25:1, or alternatively 30:1, or alternatively 35:1, or alternatively 40:1, or alternatively 45:1, or alternatively about 50:1, or alternatively 60:1, or alternatively 70:1, or alternatively 80:1, or alternatively 90:1, or alternatively 100:1.
“Exogenous” as it is used herein is intended to mean that the referenced molecule or the referenced activity is introduced into the host microbial organism. The molecule can be introduced, for example, by introduction of an encoding nucleic acid into the host genetic material such as by integration into a host chromosome or as non-chromosomal genetic material such as a plasmid. Therefore, the term as it is used in reference to expression of an encoding nucleic acid refers to introduction of the encoding nucleic acid in an expressible form into the microbial organism. When used in reference to a biosynthetic activity, the term refers to an activity that is introduced into the host reference organism. The source can be, for example, a homologous or heterologous encoding nucleic acid that expresses the referenced activity following introduction into the host microbial organism. Therefore, the term “endogenous” refers to a referenced molecule or activity that is present in the host. Similarly, the term when used in reference to expression of an encoding nucleic acid refers to expression of an encoding nucleic acid contained within the microbial organism. The term “heterologous” refers to a molecule or activity derived from a source other than the referenced species whereas “homologous” refers to a molecule or activity derived from the host microbial organism. Accordingly, exogenous expression of an encoding nucleic acid of the invention can utilize either or both a heterologous or homologous encoding nucleic acid.
It is understood that when more than one exogenous nucleic acid is included in a microbial organism that the more than one exogenous nucleic acids refers to the referenced encoding nucleic acid or biosynthetic activity, as discussed above. It is further understood, as disclosed herein, that such more than one exogenous nucleic acids can be introduced into the host microbial organism on separate nucleic acid molecules, on polycistronic nucleic acid molecules, or a combination thereof, and still be considered as more than one exogenous nucleic acid. For example, as disclosed herein a microbial organism can be engineered to express two or more exogenous nucleic acids encoding a desired pathway enzyme or protein. In the case where two exogenous nucleic acids encoding a desired activity are introduced into a host microbial organism, it is understood that the two exogenous nucleic acids can be introduced as a single nucleic acid, for example, on a single plasmid, on separate plasmids, can be integrated into the host chromosome at a single site or multiple sites, and still be considered as two exogenous nucleic acids. Similarly, it is understood that more than two exogenous nucleic acids can be introduced into a host organism in any desired combination, for example, on a single plasmid, on separate plasmids, can be integrated into the host chromosome at a single site or multiple sites, and still be considered as two or more exogenous nucleic acids, for example three exogenous nucleic acids. Thus, the number of referenced exogenous nucleic acids or biosynthetic activities refers to the number of encoding nucleic acids or the number of biosynthetic activities, not the number of separate nucleic acids introduced into the host organism.
The non-naturally occurring microbial organisms of the invention can contain stable genetic alterations, which refers to microorganisms that can be cultured for greater than five generations without loss of the alteration. Generally, stable genetic alterations include modifications that persist greater than 10 generations, particularly stable modifications will persist more than about 25 generations, and more particularly, stable genetic modifications will be greater than 50 generations, including indefinitely.
Those skilled in the art will understand that the genetic alterations, including metabolic modifications exemplified herein, are described with reference to a suitable host organism such as E. coli and their corresponding metabolic reactions or a suitable source organism for desired genetic material such as genes for a desired metabolic pathway. However, given the complete genome sequencing of a wide variety of organisms and the high level of skill in the area of genomics, those skilled in the art will readily be able to apply the teachings and guidance provided herein to essentially all other organisms. For example, the E. coli metabolic alterations exemplified herein can readily be applied to other species by incorporating the same or analogous encoding nucleic acid from species other than the referenced species. Such genetic alterations include, for example, genetic alterations of species homologs, in general, and in particular, orthologs, paralogs or nonorthologous gene displacements.
An ortholog is a gene or genes that are related by vertical descent and are responsible for substantially the same or identical functions in different organisms. For example, mouse epoxide hydrolase and human epoxide hydrolase can be considered orthologs for the biological function of hydrolysis of epoxides. Genes are related by vertical descent when, for example, they share sequence similarity of sufficient amount to indicate they are homologous, or related by evolution from a common ancestor. Genes can also be considered orthologs if they share three-dimensional structure but not necessarily sequence similarity, of a sufficient amount to indicate that they have evolved from a common ancestor to the extent that the primary sequence similarity is not identifiable. Genes that are orthologous can encode proteins with sequence similarity of about 25% to 100% amino acid sequence identity. Genes encoding proteins sharing an amino acid similarity less that 25% can also be considered to have arisen by vertical descent if their three-dimensional structure also shows similarities. Members of the serine protease family of enzymes, including tissue plasminogen activator and elastase, are considered to have arisen by vertical descent from a common ancestor.
Orthologs include genes or their encoded gene products that through, for example, evolution, have diverged in structure or overall activity. For example, where one species encodes a gene product exhibiting two functions and where such functions have been separated into distinct genes in a second species, the three genes and their corresponding products are considered to be orthologs. For the production of a biochemical product, those skilled in the art will understand that the orthologous gene harboring the metabolic activity to be introduced or disrupted is to be chosen for construction of the non-naturally occurring microorganism. An example of orthologs exhibiting separable activities is where distinct activities have been separated into distinct gene products between two or more species or within a single species. A specific example is the separation of elastase proteolysis and plasminogen proteolysis, two types of serine protease activity, into distinct molecules as plasminogen activator and elastase. A second example is the separation of mycoplasma 5′-3′ exonuclease and Drosophila DNA polymerase III activity. The DNA polymerase from the first species can be considered an ortholog to either or both of the exonuclease or the polymerase from the second species and vice versa.
In contrast, paralogs are homologs related by, for example, duplication followed by evolutionary divergence and have similar or common, but not identical functions. Paralogs can originate or derive from, for example, the same species or from a different species. For example, microsomal epoxide hydrolase (epoxide hydrolase I) and soluble epoxide hydrolase (epoxide hydrolase II) can be considered paralogs because they represent two distinct enzymes, co-evolved from a common ancestor, that catalyze distinct reactions and have distinct functions in the same species. Paralogs are proteins from the same species with significant sequence similarity to each other suggesting that they are homologous, or related through co-evolution from a common ancestor. Groups of paralogous protein families include HipA homologs, luciferase genes, peptidases, and others.
A nonorthologous gene displacement is a nonorthologous gene from one species that can substitute for a referenced gene function in a different species. Substitution includes, for example, being able to perform substantially the same or a similar function in the species of origin compared to the referenced function in the different species. Although generally, a nonorthologous gene displacement will be identifiable as structurally related to a known gene encoding the referenced function, less structurally related but functionally similar genes and their corresponding gene products nevertheless will still fall within the meaning of the term as it is used herein. Functional similarity requires, for example, at least some structural similarity in the active site or binding region of a nonorthologous gene product compared to a gene encoding the function sought to be substituted. Therefore, a nonorthologous gene includes, for example, a paralog or an unrelated gene.
Therefore, in identifying and constructing the non-naturally occurring microbial organisms of the invention having 14-BDO and GBL biosynthetic capability, those skilled in the art will understand with applying the teaching and guidance provided herein to a particular species that the identification of metabolic modifications can include identification and inclusion or inactivation of orthologs. To the extent that paralogs and/or nonorthologous gene displacements are present in the referenced microorganism that encode an enzyme catalyzing a similar or substantially similar metabolic reaction, those skilled in the art also can utilize these evolutionally related genes.
Orthologs, paralogs and nonorthologous gene displacements can be determined by methods well known to those skilled in the art. For example, inspection of nucleic acid or amino acid sequences for two polypeptides will reveal sequence identity and similarities between the compared sequences. Based on such similarities, one skilled in the art can determine if the similarity is sufficiently high to indicate the proteins are related through evolution from a common ancestor. Algorithms well known to those skilled in the art, such as Align, BLAST, Clustal W and others compare and determine a raw sequence similarity or identity, and also determine the presence or significance of gaps in the sequence which can be assigned a weight or score. Such algorithms also are known in the art and are similarly applicable for determining nucleotide sequence similarity or identity. Parameters for sufficient similarity to determine relatedness are computed based on well known methods for calculating statistical similarity, or the chance of finding a similar match in a random polypeptide, and the significance of the match determined. A computer comparison of two or more sequences can, if desired, also be optimized visually by those skilled in the art. Related gene products or proteins can be expected to have a high similarity, for example, 25% to 100% sequence identity. Proteins that are unrelated can have an identity which is essentially the same as would be expected to occur by chance, if a database of sufficient size is scanned (about 5%). Sequences between 5% and 24% may or may not represent sufficient homology to conclude that the compared sequences are related. Additional statistical analysis to determine the significance of such matches given the size of the data set can be carried out to determine the relevance of these sequences.
Exemplary parameters for determining relatedness of two or more sequences using the BLAST algorithm, for example, can be as set forth below. Briefly, amino acid sequence alignments can be performed using BLASTP version 2.0.8 (Jan. 5, 1999) and the following parameters: Matrix: 0 BLOSUM62; gap open: 11; gap extension: 1; x_dropoff: 50; expect: 10.0; wordsize: 3; filter: on. Nucleic acid sequence alignments can be performed using BLASTN version 2.0.6 (Sep. 16, 1998) and the following parameters: Match: 1; mismatch: −2; gap open: 5; gap extension: 2; x_dropoff: 50; expect: 10.0; wordsize: 11; filter: off. Those skilled in the art will know what modifications can be made to the above parameters to either increase or decrease the stringency of the comparison, for example, and determine the relatedness of two or more sequences.
In one embodiment, the invention provides a non-naturally occurring microbial organism, comprising a microbial organism having a 1,4-butanediol (14-BDO) pathway and a gamma-butyrolactone (GBL) pathway, said 14-BDO pathway comprising at least one exogenous nucleic acid encoding a 14-BDO pathway enzyme expressed in a sufficient amount to produce 14-BDO, said 14-BDO pathway comprising a succinyl-CoA reductase (aldehyde forming), an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate reductase, a 1,4-butanediol dehydrogenase, a succinate reductase, a succinyl-CoA transferase, a succinyl-CoA hydrolase, a succinyl-CoA synthetase, a glutamate dehydrogenase, a glutamate transaminase, a glutamate decarboxylase, an 4-aminobutyrate dehydrogenase, an 4-aminobutyrate transaminase, a 4-hydroxybutyrate kinase, a phosphotrans-4-hydroxybutyrylase, a 4-hydroxybutyryl-CoA reductase (aldehyde forming), a 4-hydroxybutyryl-phosphate reductase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase, a 4-hydroxybutyryl-CoA synthetase, a 4-hydroxybutyryl-CoA reductase (alcohol forming), an alpha-ketoglutarate reductase, a 5-hydroxy-2-oxopentanoate dehydrogenase, a 5-hydroxy-2-oxopentanoate decarboxylase or a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase, or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyrate kinase, a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and E) 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a glutamate dehydrogenase or glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further embodiment, the non-naturally occurring microbial organism has a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate decarboxylase; and a 1,4-butanediol dehydrogenase (see
In a further embodiment, the non-naturally occurring microbial organism has a GBL pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate lactonase (see
In a further embodiment, the non-naturally occurring microbial organism has a GBL pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase and a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); and a 4-hydroxybutyrate lactonase (see
In a further embodiment, the non-naturally occurring microbial organism has a GBL pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate lactonase (see
In a further embodiment, the non-naturally occurring microbial organism has a GBL pathway comprising an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase and a 4-hydroxybutyrate lactonase (see
In a further embodiment, the non-naturally occurring microbial organism has a GBL pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate lactonase (see
In one embodiment, the invention provides a non-naturally occurring microbial organism, comprising a microbial organism having a 1,4-butanediol (14-BDO) pathway and a gamma-butyrolactone (GBL) pathway, said 14-BDO pathway comprising a first set of exogenous nucleic acids encoding 14-BDO pathway enzymes expressed in a sufficient amount to produce 14-BDO, wherein said first set is selected from the group consisting of: [a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase)] (see
In a further aspect of each of the above embodiments, the exogenous nucleic acid is a heterologous nucleic acid.
In a further aspect of each of the above embodiments, the non-naturally occurring microbial organism is in a substantially anaerobic culture medium.
In a further aspect of each of the above embodiments, the 14-BDO and GBL products are produced at a predetermined ratio. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 1:1, or alternatively 1:2, or alternatively 1:3, or alternatively 1:4, or alternatively 1:5, or alternatively 1:6, or alternatively 1:7, or alternatively 1:8, or alternatively 1:9, or alternatively 1:10, or alternatively 1:15, or alternatively about 1:20, or alternatively 1:25, or alternatively 1:30, or alternatively 1:35, or alternatively 1:40, or alternatively 1:45, or alternatively about 1:50, or alternatively 1:60, or alternatively 1:70, or alternatively 1:80, or alternatively 1:90, or alternatively 1:100. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 2:1, or alternatively 3:1, or alternatively 4:1, or alternatively 5:1, or alternatively 6:1, or alternatively 7:1, or alternatively 8:1, or alternatively 9:1, or alternatively 10:1, or alternatively 15:1, or alternatively about 20:1, or alternatively 25:1, or alternatively 30:1, or alternatively 35:1, or alternatively 40:1, or alternatively 45:1, or alternatively about 50:1, or alternatively 60:1, or alternatively 70:1, or alternatively 80:1, or alternatively 90:1, or alternatively 100:1.
It is understood by one of skill in the art that the non-naturally occurring microorganisms described herein, having a 14-BDO and a GBL pathway, can have exogenous nucleic acids encoding enzymes or proteins of more than one pathway described herein. For example, a microorganism can have exogenous nucleic acids encoding enzymes or proteins for steps G/H/I, A, C, O, P, Q, and E of
In an additional embodiment, the invention provides a non-naturally occurring microbial organism having a 14-BDO and GBL pathway, wherein the non-naturally occurring microbial organism comprises at least one exogenous nucleic acid encoding an enzyme or protein that converts a substrate to a product selected from the group consisting of succinate to succinyl-CoA, succinate to succinic semialdehyde, succinyl-CoA to succinic semialdehyde, succinyl-CoA to 4-hydroxybutyrate, succinic semialdehyde to 4-hydroxybutyrate, alpha-ketoglutarate to succinic semialdehyde, alpha-ketoglutarate to glutamate, glutamate to 4-aminobutyrate, 4-aminobutyrate to succinic semialdehyde, alpha-ketoglutarate to 2,5-dioxopentanoic acid, 2,5-dioxopentanoic acid to 5-hydroxy-2-oxopentanoic acid, 5-hydroxy-2-oxopentanoic acid to 4-hydroxybutanal, 4-hydroxybutyrate to 4-hydroxybutanal, 4-hydroxybutyrate to 4-hydroxybutyryl-phosphate, 4-hydroxybutyryl-phosphate to 4-hydroxybutyryl-CoA, 4-hydroxybutyryl-phosphate to 4-hydroxybutanal, 5-hydroxy-2oxopentanoic acid to 4-hydroxybutyryl-CoA, 4-hydroxybutyryl-CoA to 4-hydroxybutanal, 4-hydroxybutyrate to 4-hydroxybutyryl-CoA, 4-hydroxybutyryl-CoA to 1,4-butanediol, 4-hydroxybutanal to 1,4-butanediol and 4-hydroxybutyrate to gamma-butyrolactone. One skilled in the art will understand that these are merely exemplary and that any of the substrate-product pairs disclosed herein suitable to produce a desired product and for which an appropriate activity is available for the conversion of the substrate to the product can be readily determined by one skilled in the art based on the teachings herein. Thus, the invention provides a non-naturally occurring microbial organism containing at least one exogenous nucleic acid encoding an enzyme or protein, where the enzyme or protein converts the substrates and products of a 14-BDO and GBL pathway, such as that shown in
While generally described herein as a microbial organism that contains a 14-BDO and GBL pathway, it is understood that the invention additionally provides a non-naturally occurring microbial organism comprising at least one exogenous nucleic acid encoding a 14-BDO or GBL pathway enzyme expressed in a sufficient amount to produce an intermediate of a 14-BDO or GBL pathway. For example, as disclosed herein, 14-BDO and GBL pathways are exemplified in
It is understood that any of the pathways disclosed herein, as described in the Examples and exemplified in the Figures, including the pathways of
The invention is described herein with general reference to the metabolic reaction, reactant or product thereof, or with specific reference to one or more nucleic acids or genes encoding an enzyme associated with or catalyzing, or a protein associated with, the referenced metabolic reaction, reactant or product. Unless otherwise expressly stated herein, those skilled in the art will understand that reference to a reaction also constitutes reference to the reactants and products of the reaction. Similarly, unless otherwise expressly stated herein, reference to a reactant or product also references the reaction, and reference to any of these metabolic constituents also references the gene or genes encoding the enzymes that catalyze or proteins involved in the referenced reaction, reactant or product. Likewise, given the well known fields of metabolic biochemistry, enzymology and genomics, reference herein to a gene or encoding nucleic acid also constitutes a reference to the corresponding encoded enzyme and the reaction it catalyzes or a protein associated with the reaction as well as the reactants and products of the reaction.
Exemplary alcohol and aldehyde dehydrogenases that can be used for in vivo conversions described herein from 4-HB to 14-BDO are listed below in Table 1.
Other exemplary enzymes and pathways are disclosed herein (see Examples). Furthermore, it is understood that enzymes can be utilized for carry out reactions for which the substrate is not the natural substrate. While the activity for the non-natural substrate may be lower than the natural substrate, it is understood that such enzymes can be utilized, either as naturally occurring or modified using the directed evolution or adaptive evolution, as disclosed herein.
14-BDO and GBL production through any of the pathways disclosed herein are based, in part, on the identification of the appropriate enzymes for conversion of precursors to 14-BDO and GBL. A number of specific enzymes for several of the reaction steps have been identified. For those transformations where enzymes specific to the reaction precursors have not been identified, enzyme candidates have been identified that are best suited for catalyzing the reaction steps. Enzymes have been shown to operate on a broad range of substrates, as discussed below. In addition, advances in the field of protein engineering also make it feasible to alter enzymes to act efficiently on substrates, even if not a natural substrate. Described below are several examples of broad-specificity enzymes from diverse classes suitable for a 14-BDO and GBL pathway as well as methods that have been used for evolving enzymes to act on non-natural substrates.
A key class of enzymes in 14-BDO and GBL pathways is the oxidoreductases that interconvert ketones or aldehydes to alcohols (1.1.1). Numerous exemplary enzymes in this class can operate on a wide range of substrates. An alcohol dehydrogenase (1.1.1.1) purified from the soil bacterium Brevibacterium sp KU 1309 (Hirano et al., J. Biosc. Bioeng. 100:318-322 (2005)) was shown to operate on a plethora of aliphatic as well as aromatic alcohols with high activities. Table 2 shows the activity of the enzyme and its Km on different alcohols. The enzyme is reversible and has very high activity on several aldehydes also (Table 3).
Brevibacterium sp KU to oxidize various alcohols.
Lactate dehydrogenase (1.1.1.27) from Ralstonia eutropha is another enzyme that has been demonstrated to have high activities on several 2-oxoacids such as 2-oxobutyrate, 2-oxopentanoate and 2-oxoglutarate (a C5 compound analogous to 2-oxoadipate) (Steinbuchel and Schlegel, Eur. J. Biochem. 130:329-334 (1983)). Column 2 in Table 4 demonstrates the activities of ldhA from R. eutropha (formerly A. eutrophus) on different substrates (Steinbuchel and Schlegel, supra, 1983).
A. eutrophus
L. leichmanii
Oxidoreductases that can convert 2-oxoacids to their acyl-CoA counterparts (1.2.1) have been shown to accept multiple substrates as well. For example, branched-chain 2-keto-acid dehydrogenase complex (BCKAD), also known as 2-oxoisovalerate dehydrogenase (1.2.1.25), participates in branched-chain amino acid degradation pathways, converting 2-keto acids derivatives of valine, leucine and isoleucine to their acyl-CoA derivatives and CO2. In some organisms including Rattus norvegicus (Paxton et al., Biochem. J. 234:295-303 (1986)) and Saccharomyces cerevisiae (Sinclair et al., Biochem. Mol. Biol. Int. 32:911-922 (1993), this complex has been shown to have a broad substrate range that includes linear oxo-acids such as 2-oxobutanoate and alpha-ketoglutarate, in addition to the branched-chain amino acid precursors.
Members of yet another class of enzymes, namely aminotransferases (2.6.1), have been reported to act on multiple substrates. Aspartate aminotransferase (aspAT) from Pyrococcus fursious has been identified, expressed in E. coli and the recombinant protein characterized to demonstrate that the enzyme has the highest activities towards aspartate and alpha-ketoglutarate but lower, yet significant activities towards alanine, glutamate and the aromatic amino acids (Ward et al., Archaea 133-141 (2002)). In another instance, an aminotransferase indentified from Leishmania mexicana and expressed in E. coli (Vernal et al., FEMS Microbiol. Lett. 229:217-222 (2003)) was reported to have a broad substrate specificity towards tyrosine (activity considered 100% on tyrosine), phenylalanine (90%), tryptophan (85%), aspartate (30%), leucine (25%) and methionine (25%), respectively (Vernal et al., Mol. Biochem. Parasitol 96:83-92 (1998)). Similar broad specificity has been reported for a tyrosine aminotransferase from Trypanosoma cruzi, even though both of these enzymes have a sequence homology of only 6%. The latter enzyme can accept leucine, methionine as well as tyrosine, phenylalanine, tryptophan and alanine as efficient amino donors (Nowicki et al., Biochim. Biophys. Acta 1546: 268-281 (2001)).
CoA transferases (2.8.3) have been demonstrated to have the ability to act on more than one substrate. Specifically, a CoA transferase was purified from Clostridium acetobutylicum and was reported to have the highest activities on acetate, propionate, and butyrate. It also had significant activities with valerate, isobutyrate, and crotonate (Wiesenborn et al., Appl. Environ. Microbiol. 55:323-329 (1989)). In another study, the E. coli enzyme acyl-CoA:acetate-CoA transferase, also known as acetate-CoA transferase (EC 2.8.3.8), has been shown to transfer the CoA moiety to acetate from a variety of branched and linear acyl-CoA substrates, including isobutyrate (Matthies and Schink, App. Environm. Microbiol. 58:1435-1439 (1992)), valerate (Vanderwinkel et al., Biochem. Biophys. Res Commun. 33:902-908 (1968b)) and butanoate (Vanderwinkel et al., Biochem. Biophys. Res Commun. 33:902-908 (1968a).
Another class of enzymes useful in 14-BDO and GBL pathways is the acid-thiol ligases (6.2.1). Like enzymes in other classes, certain enzymes in this class have been determined to have broad substrate specificity. For example, acyl CoA ligase from Pseudomonas putida has been demonstrated to work on several aliphatic substrates including acetic, propionic, butyric, valeric, hexanoic, heptanoic, and octanoic acids and on aromatic compounds such as phenylacetic and phenoxyacetic acids (Fernandez-Valverde et al., Appl. Environ. Microbiol. 59:1149-1154 (1993)). A related enzyme, malonyl CoA synthetase (6.3.4.9) from Rhizobium trifolii could convert several diacids, namely, ethyl-, propyl-, allyl-, isopropyl-, dimethyl-, cyclopropyl-, cyclopropylmethylene-, cyclobutyl-, and benzyl-malonate into their corresponding monothioesters (Pohl et al., J. Am. Chem. Soc. 123:5822-5823 (2001)). Similarly, decarboxylases (4.1.1) have also been found with broad substrate ranges. Pyruvate decarboxylase (PDC), also termed keto-acid decarboxylase, is a key enzyme in alcoholic fermentation, catalyzing the decarboxylation of pyruvate to acetaldehyde. The enzyme isolated from Saccharomyces cerevisiae has a broad substrate range for aliphatic 2-keto acids including 2-ketobutyrate, 2-ketovalerate, and 2-phenylpyruvate (Li and Jordan, Biochemistry 38:10004-10012 (1999)). Similarly, benzoylformate decarboxylase has a broad substrate range and has been the target of enzyme engineering studies. The enzyme from Pseudomonas putida has been extensively studied and crystal structures of this enzyme are available (Polovnikova et al., Biochemistry 42:1820-1830 (2003); Hasson et al., Biochemistry 37:9918-9930 (1998)). Branched chain alpha-ketoacid decarboxylase (BCKA) has been shown to act on a variety of compounds varying in chain length from 3 to 6 carbons (Oku and Kaneda, J. Biol. Chem. 263:18386-18396 (1998); Smit et al., Appl. Environ. Microbiol. 71:303-311 (2005b)). The enzyme in Lactococcus lactis has been characterized on a variety of branched and linear substrates including 2-oxobutanoate, 2-oxohexanoate, 2-oxopentanoate, 3-methyl-2-oxobutanoate, 4-methyl-2-oxobutanoate and isocaproate (Smit et al., Appl. Environ. Microbiol. 71:303-311 (2005a).
Interestingly, enzymes known to have one dominant activity have also been reported to catalyze a very different function. For example, the cofactor-dependent phosphoglycerate mutase (5.4.2.1) from Bacillus stearothermophilus and Bacillus subtilis is known to function as a phosphatase as well (Rigden et al., Protein Sci. 10:1835-1846 (2001)). The enzyme from B. stearothermophilus is known to have activity on several substrates, including 3-phosphoglycerate, alpha-napthylphosphate, p-nitrophenylphosphate, AMP, fructose-6-phosphate, ribose-5-phosphate and CMP.
The non-naturally occurring microbial organisms of the invention can be produced by introducing expressible nucleic acids encoding one or more of the enzymes or proteins participating in one or more 14-BDO or GBL biosynthetic pathways. Depending on the host microbial organism chosen for biosynthesis, nucleic acids for some or all of a particular 14-BDO or GBL biosynthetic pathway can be expressed. For example, if a chosen host is deficient in one or more enzymes or proteins for a desired biosynthetic pathway, then expressible nucleic acids for the deficient enzyme(s) or protein(s) are introduced into the host for subsequent exogenous expression. Alternatively, if the chosen host exhibits endogenous expression of some pathway genes, but is deficient in others, then an encoding nucleic acid is needed for the deficient enzyme(s) or protein(s) to achieve 14-BDO and GBL biosynthesis. Thus, a non-naturally occurring microbial organism of the invention can be produced by introducing exogenous enzyme or protein activities to obtain a desired biosynthetic pathway or a desired biosynthetic pathway can be obtained by introducing one or more exogenous enzyme or protein activities that, together with one or more endogenous enzymes or proteins, produces a desired product such as 14-BDO or GBL.
Host microbial organisms can be selected from, and the non-naturally occurring microbial organisms generated in, for example, bacteria, yeast, fungus or any of a variety of other microorganisms applicable to fermentation processes. Exemplary bacteria include species selected from Escherichia coli, Klebsiella oxytoca, Anaerobiospirillum succiniciproducens, Actinobacillus succinogenes, Mannheimia succiniciproducens, Rhizobium etli, Bacillus subtilis, Corynebacterium glutamicum, Gluconobacter oxydans, Zymomonas mobilis, Lactococcus lactis, Lactobacillus plantarum, Streptomyces coelicolor, Clostridium acetobutylicum, Pseudomonas fluorescens, and Pseudomonas putida. Exemplary yeasts or fungi include species selected from Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Kluyveromyces marxianus, Aspergillus terreus, Aspergillus niger, Pichia pastoris, Rhizopus arrhizus, Rhizobus oryzae, and the like. E. coli is a particularly useful host organisms since it is a well characterized microbial organism suitable for genetic engineering. Other particularly useful host organisms include yeast such as Saccharomyces cerevisiae. It is understood that any suitable microbial host organism can be used to introduce metabolic and/or genetic modifications to produce a desired product.
Depending on the 14-BDO and GBL biosynthetic pathway constituents of a selected host microbial organism, the non-naturally occurring microbial organisms of the invention will include at least one exogenously expressed 14-BDO or GBL pathway-encoding nucleic acid and up to all encoding nucleic acids for one or more 14-BDO and GBL biosynthetic pathway. For example, 14-BDO and GBL biosynthesis can be established in a host deficient in a pathway enzyme or protein through exogenous expression of the corresponding encoding nucleic acid. In a host deficient in all enzymes or proteins of a 14-BDO or GBL pathway, exogenous expression of all enzymes or proteins in the pathway can be included, although it is understood that all enzymes or proteins of a pathway can be expressed even if the host contains at least one of the pathway enzymes or proteins. For example, exogenous expression of all enzymes or proteins in a pathway for production of 14-BDO and GBL can be included, such as a succinyl-CoA reductase (aldehyde forming), an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate reductase, a 1,4-butanediol dehydrogenase, a succinate reductase, a succinyl-CoA transferase, a succinyl-CoA hydrolase, a succinyl-CoA synthetase (or succinyl-CoA ligase), a glutamate dehydrogenase, a glutamate transaminase, a glutamate decarboxylase, a 4-aminobutyrate dehydrogenase, a 4-aminobutyrate transaminase, a 4-hydroxybutyrate kinase, a phosphotrans-4-hydroxybutyrylase, a 4-hydroxybutyryl-CoA reductase (aldehyde forming), a 4-hydroxybutyryl-phosphate reductase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase, a 4-hydroxybutyryl-CoA synthetase (or 4-hydroxybutyryl-CoA ligase), a 4-hydroxybutyryl-CoA reductase (alcohol forming), an alpha-ketoglutarate reductase, a 5-hydroxy-2-oxopentanoate dehydrogenase, a 5-hydroxy-2-oxopentanoate decarboxylase, a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation) or a 4-hydroxybutyrate lactonase.
Given the teachings and guidance provided herein, those skilled in the art will understand that the number of encoding nucleic acids to introduce in an expressible form will, at least, parallel the 14-BDO and GBL pathway deficiencies of the selected host microbial organism. Therefore, a non-naturally occurring microbial organism of the invention can have one, two, three, four, five, six, seven or eight up to all nucleic acids encoding the enzymes or proteins constituting a 14-BDO or GBL biosynthetic pathway disclosed herein. In some embodiments, the non-naturally occurring microbial organisms also can include other genetic modifications that facilitate or optimize 14-BDO and GBL biosynthesis or that confer other useful functions onto the host microbial organism. One such other functionality can include, for example, augmentation of the synthesis of one or more of the 14-BDO or GBL pathway precursors such as succinate, succinyl-CoA or alpha-ketoglutarate.
Generally, a host microbial organism is selected such that it produces the precursor of a 14-BDO or GBL pathway, either as a naturally produced molecule or as an engineered product that either provides de novo production of a desired precursor or increased production of a precursor naturally produced by the host microbial organism. For example, succinate is produced naturally in a host organism such as E. coli. A host organism can be engineered to increase production of a precursor, as disclosed herein. In addition, a microbial organism that has been engineered to produce a desired precursor can be used as a host organism and further engineered to express enzymes or proteins of a 14-BDO or GBL pathway.
In some embodiments, a non-naturally occurring microbial organism of the invention is generated from a host that contains the enzymatic capability to synthesize 14-BDO and GBL and in some embodiments synthesizing 14-BDO and GBL at a predetermined ratio. In this specific embodiment it can be useful to increase the synthesis or accumulation of a 14-BDO or GBL pathway product to, for example, drive 14-BDO and GBL pathway reactions toward 14-BDO and GBL production. Increased synthesis or accumulation can be accomplished by, for example, overexpression of nucleic acids encoding one or more of the above-described 14-BDO or GBL pathway enzymes or proteins. Over expression of the enzyme or enzymes and/or protein or proteins of the 14-BDO or GBL pathway can occur, for example, through exogenous expression of the endogenous gene or genes, or through exogenous expression of the heterologous gene or genes. Therefore, naturally occurring organisms can be readily generated to be non-naturally occurring microbial organisms of the invention, for example, producing 14-BDO and GBL, through overexpression of one, two, three, four, five, six, seven or eight, that is, up to all nucleic acids encoding 14-BDO or GBL biosynthetic pathway enzymes or proteins. In addition, a non-naturally occurring organism can be generated by mutagenesis of an endogenous gene that results in an increase in activity of an enzyme in the 14-BDO or GBL biosynthetic pathway.
In particularly useful embodiments, exogenous expression of the encoding nucleic acids is employed. Exogenous expression confers the ability to custom tailor the expression and/or regulatory elements to the host and application to achieve a desired expression level that is controlled by the user, which can be used to produce a predetermined ratio of 14-BDO to GBL. However, endogenous expression also can be utilized in other embodiments such as by removing a negative regulatory effector or induction of the gene's promoter when linked to an inducible promoter or other regulatory element. Thus, an endogenous gene having a naturally occurring inducible promoter can be up-regulated by providing the appropriate inducing agent, or the regulatory region of an endogenous gene can be engineered to incorporate an inducible regulatory element, thereby allowing the regulation of increased expression of an endogenous gene at a desired time. Similarly, an inducible promoter can be included as a regulatory element for an exogenous gene introduced into a non-naturally occurring microbial organism. It is also understood that increasing the expression of an enzyme or protein can alter the ratio of 14-BDO to GBL produced by the non-naturally occurring microorganisms described herein by enzymatically converting one or more pathway intermediates, which are shared between the 14-BDO and GBL pathways, towards the production of one of the products. In this embodiment, the pool of intermediates for production of one product can be shifted toward the production of another product ultimately resulting in change in the ratio of 14-BDO and GBL produced by the microorganisms or methods described herein.
It is understood that, in methods of the invention, any of the one or more exogenous nucleic acids can be introduced into a microbial organism to produce a non-naturally occurring microbial organism of the invention. The nucleic acids can be introduced so as to confer, for example, a 14-BDO and GBL biosynthetic pathway onto the microbial organism. Alternatively, encoding nucleic acids can be introduced to produce an intermediate microbial organism having the biosynthetic capability to catalyze some of the required reactions to confer 14-BDO and GBL biosynthetic capability. For example, a non-naturally occurring microbial organism having 14-BDO and GBL biosynthetic pathways can comprise at least two exogenous nucleic acids encoding desired enzymes or proteins, such as the combination of a succinyl-CoA transferase and a 4-hydroxybutyrate kinase, or alternatively a 4-hydroxybutyrate lactonase and a 1,4-butanediol dehydrogenase, or alternatively a glutamate decarboxylase and a 5-hydroxy-2-oxopentanoate decarboxylase, and the like. Thus, it is understood that any combination of two or more enzymes or proteins of a biosynthetic pathway can be included in a non-naturally occurring microbial organism of the invention. Similarly, it is understood that any combination of three or more enzymes or proteins of a biosynthetic pathway can be included in a non-naturally occurring microbial organism of the invention, for example, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase and a 4-hydroxybutyrate lactonase, or alternatively a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation), a succinate reductase and a phosphotrans-4-hydroxybutyrylase, or alternatively an alpha-ketoglutarate reductase, a 1,4-butanediol dehydrogenase and a 4-hydroxybutyrate lactonase, and so forth, as desired, so long as the combination of enzymes and/or proteins of the desired biosynthetic pathway results in production of the corresponding desired product. Similarly, any combination of four, a succinate reductase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate kinase and a 4-hydroxybutyryl-CoA reductase (alcohol forming), or alternatively a 4-hydroxybutyrate lactonase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA synthetase and a 4-hydroxybutyryl-CoA reductase (alcohol forming), or alternatively a 4-aminobutyrate dehydrogenase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate lactonase and a 4-hydroxybutyryl-CoA reductase (aldehyde forming), or more enzymes or proteins of a biosynthetic pathway as disclosed herein can be included in a non-naturally occurring microbial organism of the invention, as desired, so long as the combination of enzymes and/or proteins of the desired biosynthetic pathway results in production of the corresponding desired product.
In addition to the biosynthesis of 14-BDO and GBL as described herein, the non-naturally occurring microbial organisms and methods of the invention also can be utilized in various combinations with each other and with other microbial organisms and methods well known in the art to achieve product biosynthesis by other routes. For example, one alternative to produce 14-BDO and GBL other than use of the 14-BDO and GBL producers is through addition of another microbial organism capable of converting a 14-BDO or GBL pathway intermediate to 14-BDO or GBL. One such procedure includes, for example, the fermentation of a microbial organism that produces a 14-BDO or GBL pathway intermediate. The 14-BDO or GBL pathway intermediate can then be used as a substrate for a second microbial organism that converts the 14-BDO or GBL pathway intermediate to 14-BDO and GBL. The 14-BDO or GBL pathway intermediate can be added directly to another culture of the second organism or the original culture of the 14-BDO or GBL pathway intermediate producers can be depleted of these microbial organisms by, for example, cell separation, and then subsequent addition of the second organism to the fermentation broth can be utilized to produce the final product without intermediate purification steps.
In other embodiments, the non-naturally occurring microbial organisms and methods of the invention can be assembled in a wide variety of subpathways to achieve biosynthesis of, for example, 14-BDO and GBL. In these embodiments, biosynthetic pathways for a desired product of the invention can be segregated into different microbial organisms, and the different microbial organisms can be co-cultured to produce the final product. In such a biosynthetic scheme, the product of one microbial organism is the substrate for a second microbial organism until the final products are synthesized. For example, the biosynthesis of 14-BDO and GBL can be accomplished by constructing a microbial organism that contains biosynthetic pathways for conversion of one pathway intermediate to another pathway intermediate or the product. Alternatively, 14-BDO and GBL also can be biosynthetically produced from microbial organisms through co-culture or co-fermentation using two organisms in the same vessel, where the first microbial organism produces a 14-BDO or GBL intermediate and the second microbial organism converts the intermediate to 14-BDO and GBL.
Given the teachings and guidance provided herein, those skilled in the art will understand that a wide variety of combinations and permutations exist for the non-naturally occurring microbial organisms and methods of the invention together with other microbial organisms, with the co-culture of other non-naturally occurring microbial organisms having subpathways and with combinations of other chemical and/or biochemical procedures well known in the art to produce 14-BDO and GBL.
Sources of encoding nucleic acids for a 14-BDO or GBL pathway enzyme or protein can include, for example, any species where the encoded gene product is capable of catalyzing the referenced reaction. Such species include both prokaryotic and eukaryotic organisms including, but not limited to, bacteria, including archaea and eubacteria, and eukaryotes, including yeast, plant, insect, animal, and mammal, including human. Exemplary species for such sources include, for example, Escherichia coli, Acinetobacter sp. Strain M-1, Acetobacter pasteurians, Achromobacter denitrificans, Acidaminococcus fermentans, Acinetobacter baumanii, Acinetobacter baylyi, Acinetobacter calcoaceticus, Acinetobacter sp. Strain M-1, Aeropyrum pernix K1, Agrobacterium tumefaciens, Arabidopsis thaliana, Archaeoglobus fulgidus DSM 4304, Aspergillus niger, Bacillus cereus, Bacillus megaterium, Bacillus subtilis, Bos taurus, Bradyrhizobium japonicum, butyrate-producing bacterium L2-50, Campylobacter jejuni, Candida albicans, Candida Antarctica, Chloroflexus aurantiacus, Clostridium acetobutylicum, Clostridium acetobutylicum ATCC 824, Clostridium aminobutyricum, Clostridium beijerinckii, Clostridium beijerinckii, Clostridium difficile, Clostridium kluyveri, Clostridium kluyveri DSM 555, Clostridium perfringens, Clostridium saccharoperbutylacetonicum, Clostridium tetani, Clostridium thermocellum, Corynebacterium glutamicum, Erythrobacter sp. NAP1, Escherichia coli str. K12, Euglena gracilis, Flavobacterium lutescens, Fusarium oxysporum, Fusobacterium nucleatum, Geobacillus stearothermophilus, Geobacillus thermoglucosidasius M10EXG, Haemophilus influenzae, Haloarcula marismortui ATCC 43049, Halobacterium salinarum, Haloferax mediterranei, Heliobacter pylori, Homo sapiens, isolated from metalibrary of anaerobic sewage digester microbial consortia, Klebsiella pneumonia MGH78578, Kluyveromyces lactis, Lachancea kluyveri, Lactococcus lactis, Leuconostoc mesenteroides, marine gamma proteobacterium HTCC2080, Mesorhizobium loti, Metallosphaera sedula, Mus musculus, Mycobacterium bovis BCG, Mycobacterium tuberculosis, Myxococcus xanthus, Nicotiana tabacum, Nocardia farcinica IFM 10152, Nocardia iowensis (sp. NRRL 5646), Oryctolagus cuniculus, Oryza sativa, Penicillium chrysogenum, Porphyromonas gingivalis, Porphyromonas gingivalis W83, Pseudomonas aeruginosa, Pseudomonas aeruginosa PAO1, Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas putida E23, Pseudomonas putida KT2440, Pseudomonas sp, Pseudomonas stutzeri, Pyrobaculum aerophilum str. IM2, Ralstonia eutropha, Ralstonia eutropha H16, Rattus norvegicus, Rhodobacter spaeroides, Roseiflexus castenholzii, Saccharomyces cerevisiae, Salmonella typhimurium, Schizosaccharomyces pombe, Simmondsia chinensis, Streptomyces clavuligenus, Streptomyces griseus subsp. griseus NBRC 13350, Sulfolobus acidocaldarius, Sulfolobus solfataricus, Sulfolobus tokodaii, Sulfolobus tokodaii 7, Sus scrofa, Thermotoga maritime, Therms thermophilus, Trichomonas vaginalis G3, Trypanosoma brucei, Uncultured bacterium, Vibrio cholera, Xanthomonas campestris, Zymomonas mobilus, as well as other exemplary species disclosed herein or available as source organisms for corresponding genes. However, with the complete genome sequence available for now more than 550 species (with more than half of these available on public databases such as the NCBI), including 395 microorganism genomes and a variety of yeast, fungi, plant, and mammalian genomes, the identification of genes encoding the requisite 14-BDO or GBL biosynthetic activity for one or more genes in related or distant species, including for example, homologues, orthologs, paralogs and nonorthologous gene displacements of known genes, and the interchange of genetic alterations between organisms is routine and well known in the art. Accordingly, the metabolic alterations allowing biosynthesis of 14-BDO and GBL described herein with reference to a particular organism such as E. coli can be readily applied to other microorganisms, including prokaryotic and eukaryotic organisms alike. Given the teachings and guidance provided herein, those skilled in the art will know that a metabolic alteration exemplified in one organism can be applied equally to other organisms.
In some instances, such as when an alternative 14-BDO or GBL biosynthetic pathway exists in an unrelated species, 14-BDO or GBL biosynthesis can be conferred onto the host species by, for example, exogenous expression of a paralog or paralogs from the unrelated species that catalyzes a similar, yet non-identical metabolic reaction to replace the referenced reaction. Because certain differences among metabolic networks exist between different organisms, those skilled in the art will understand that the actual gene usage between different organisms may differ. However, given the teachings and guidance provided herein, those skilled in the art also will understand that the teachings and methods of the invention can be applied to all microbial organisms using the cognate metabolic alterations to those exemplified herein to construct a microbial organism in a species of interest that will synthesize 14-BDO and GBL.
Methods for constructing and testing the expression levels of a non-naturally occurring 14-BDO and GBL co-producing host can be performed, for example, by recombinant and detection methods well known in the art. Such methods can be found described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001); and Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1999).
Exogenous nucleic acid sequences involved in a pathway for production of 14-BDO and GBL can be introduced stably or transiently into a host cell using techniques well known in the art including, but not limited to, conjugation, electroporation, chemical transformation, transduction, transfection, and ultrasound transformation. For exogenous expression in E. coli or other prokaryotic cells, some nucleic acid sequences in the genes or cDNAs of eukaryotic nucleic acids can encode targeting signals such as an N-terminal mitochondrial or other targeting signal, which can be removed before transformation into prokaryotic host cells, if desired. For example, removal of a mitochondrial leader sequence led to increased expression in E. coli (Hoffmeister et al., J. Biol. Chem. 280:4329-4338 (2005)). For exogenous expression in yeast or other eukaryotic cells, genes can be expressed in the cytosol without the addition of leader sequence, or can be targeted to mitochondrion or other organelles, or targeted for secretion, by the addition of a suitable targeting sequence such as a mitochondrial targeting or secretion signal suitable for the host cells. Thus, it is understood that appropriate modifications to a nucleic acid sequence to remove or include a targeting sequence can be incorporated into an exogenous nucleic acid sequence to impart desirable properties. Furthermore, genes can be subjected to codon optimization with techniques well known in the art to achieve optimized expression of the proteins.
An expression vector or vectors can be constructed to include one or more 14-BDO or GBL biosynthetic pathway encoding nucleic acids as exemplified herein operably linked to expression control sequences functional in the host organism. Expression vectors applicable for use in the microbial host organisms of the invention include, for example, plasmids, phage vectors, viral vectors, episomes and artificial chromosomes, including vectors and selection sequences or markers operable for stable integration into a host chromosome. Additionally, the expression vectors can include one or more selectable marker genes and appropriate expression control sequences. Selectable marker genes also can be included that, for example, provide resistance to antibiotics or toxins, complement auxotrophic deficiencies, or supply critical nutrients not in the culture media. Expression control sequences can include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like which are well known in the art. When two or more exogenous encoding nucleic acids are to be co-expressed, both nucleic acids can be inserted, for example, into a single expression vector or in separate expression vectors. For single vector expression, the encoding nucleic acids can be operationally linked to one common expression control sequence or linked to different expression control sequences, such as one inducible promoter and one constitutive promoter. The transformation of exogenous nucleic acid sequences involved in a metabolic or synthetic pathway can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis such as Northern blots or polymerase chain reaction (PCR) amplification of mRNA, or immunoblotting for expression of gene products, or other suitable analytical methods to test the expression of an introduced nucleic acid sequence or its corresponding gene product. It is understood by those skilled in the art that the exogenous nucleic acid is expressed in a sufficient amount to produce the desired product, and it is further understood that expression levels can be optimized to obtain sufficient expression using methods well known in the art and as disclosed herein.
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism, including a microbial organism having a 14-BDO pathway and a GBL pathway, said 14-BDO pathway comprising at least one exogenous nucleic acid encoding a 14-BDO pathway enzyme expressed in a sufficient amount to produce 14-BDO, said 14-BDO pathway comprising a succinyl-CoA reductase (aldehyde forming), an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate reductase, a 1,4-butanediol dehydrogenase, a succinate reductase, a succinyl-CoA transferase, a succinyl-CoA hydrolase, a succinyl-CoA synthetase, a glutamate dehydrogenase, a glutamate transaminase, a glutamate decarboxylase, an 4-aminobutyrate dehydrogenase, an 4-aminobutyrate transaminase, a 4-hydroxybutyrate kinase, a phosphotrans-4-hydroxybutyrylase, a 4-hydroxybutyryl-CoA reductase (aldehyde forming), a 4-hydroxybutyryl-phosphate reductase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase, a 4-hydroxybutyryl-CoA synthetase, a 4-hydroxybutyryl-CoA reductase (alcohol forming), an alpha-ketoglutarate reductase, a 5-hydroxy-2-oxopentanoate dehydrogenase, a 5-hydroxy-2-oxopentanoate decarboxylase or a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase, or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 1,4-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyrate kinase, a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising. an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and E) 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming), (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate decarboxylase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a GBL pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate lactonase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a GBL pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase and a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); and a 4-hydroxybutyrate lactonase, (see
In a further aspect of the above embodiment, the method includes a microbial organism having a GBL pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate lactonase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a GBL pathway comprising an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase and a 4-hydroxybutyrate lactonase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a GBL pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate lactonase (see
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism, including a microbial organism having a 1,4-butanediol (14-BDO) pathway and a gamma-butyrolactone (GBL) pathway, said 14-BDO pathway comprising a first set of exogenous nucleic acids encoding 14-BDO pathway enzymes expressed in a sufficient amount to produce 14-BDO, wherein said first set is selected from the group consisting of: [a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase)] (see
In a further aspect of each of the above embodiments, the exogenous nucleic acid is a heterologous nucleic acid.
In a further aspect of each of the above embodiments, the conditions include substantially anaerobic culture conditions.
In a further aspect of each of the above embodiments, the 14-BDO and GBL products are produced at a predetermined ratio. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 1:1, or alternatively 1:2, or alternatively 1:3, or alternatively 1:4, or alternatively 1:5, or alternatively 1:6, or alternatively 1:7, or alternatively 1:8, or alternatively 1:9, or alternatively 1:10, or alternatively 1:15, or alternatively about 1:20, or alternatively 1:25, or alternatively 1:30, or alternatively 1:35, or alternatively 1:40, or alternatively 1:45, or alternatively about 1:50, or alternatively 1:60, or alternatively 1:70, or alternatively 1:80, or alternatively 1:90, or alternatively 1:100. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 2:1, or alternatively 3:1, or alternatively 4:1, or alternatively 5:1, or alternatively 6:1, or alternatively 7:1, or alternatively 8:1, or alternatively 9:1, or alternatively 10:1, or alternatively 15:1, or alternatively about 20:1, or alternatively 25:1, or alternatively 30:1, or alternatively 35:1, or alternatively 40:1, or alternatively 45:1, or alternatively about 50:1, or alternatively 60:1, or alternatively 70:1, or alternatively 80:1, or alternatively 90:1, or alternatively 100:1.
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce 14-BDO and 4-hydroxybutyryl-phosphate followed by spontaneous lactonization of 4-hydroxybutyryl-phosphate to form GBL, wherein said non-naturally occurring microbial organism comprise a microbial organism having a 14-BDO pathway and a 4-hydroxybutyryl-phosphate pathway, said 14-BDO pathway comprising at least one exogenous nucleic acid encoding a 14-BDO pathway enzyme expressed in a sufficient amount to produce 14-BDO, said 14-BDO pathway comprising a succinyl-CoA reductase (aldehyde forming), an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate reductase, a 1,4-butanediol dehydrogenase, a succinate reductase, a succinyl-CoA transferase, a succinyl-CoA hydrolase, a succinyl-CoA synthetase, a glutamate dehydrogenase, a glutamate transaminase, a glutamate decarboxylase, an 4-aminobutyrate dehydrogenase, an 4-aminobutyrate transaminase, a 4-hydroxybutyrate kinase, a phosphotrans-4-hydroxybutyrylase, a 4-hydroxybutyryl-CoA reductase (aldehyde forming), a 4-hydroxybutyryl-phosphate reductase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase, a 4-hydroxybutyryl-CoA synthetase, a 4-hydroxybutyryl-CoA reductase (alcohol forming), an alpha-ketoglutarate reductase, a 5-hydroxy-2-oxopentanoate dehydrogenase, a 5-hydroxy-2-oxopentanoate decarboxylase or a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase, or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 1,4-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyrate kinase, a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and E) 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate decarboxylase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-phosphate pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; and 4-hydroxybutyrate kinase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-phosphate pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); and a 4-hydroxybutyrate kinase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-phosphate pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate kinase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-phosphate pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate kinase (
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-phosphate pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; an 4-aminobutyrate dehydrogenase or an 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate kinase (see
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce 14-BDO and 4-hydroxybutyryl-phosphate followed by spontaneous lactonization of 4-hydroxybutyryl-phosphate to form GBL, wherein said non-naturally occurring microbial organism comprise a microbial organism having a 14-BDO pathway and a 4-hydroxybutyryl-phosphate pathway, said 14-BDO pathway comprising a first set of exogenous nucleic acids encoding 14-BDO pathway enzymes expressed in a sufficient amount to produce 14-BDO, said first set is selected from the group consisting of [a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase)] (see
In a further aspect of each of the above embodiments, the exogenous nucleic acid is a heterologous nucleic acid.
In a further aspect of each of the above embodiments, the conditions include substantially anaerobic culture conditions.
In a further aspect of each of the above embodiments, the 14-BDO and GBL products are produced at a predetermined ratio. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 1:1, or alternatively 1:2, or alternatively 1:3, or alternatively 1:4, or alternatively 1:5, or alternatively 1:6, or alternatively 1:7, or alternatively 1:8, or alternatively 1:9, or alternatively 1:10, or alternatively 1:15, or alternatively about 1:20, or alternatively 1:25, or alternatively 1:30, or alternatively 1:35, or alternatively 1:40, or alternatively 1:45, or alternatively about 1:50, or alternatively 1:60, or alternatively 1:70, or alternatively 1:80, or alternatively 1:90, or alternatively 1:100. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 2:1, or alternatively 3:1, or alternatively 4:1, or alternatively 5:1, or alternatively 6:1, or alternatively 7:1, or alternatively 8:1, or alternatively 9:1, or alternatively 10:1, or alternatively 15:1, or alternatively about 20:1, or alternatively 25:1, or alternatively 30:1, or alternatively 35:1, or alternatively 40:1, or alternatively 45:1, or alternatively about 50:1, or alternatively 60:1, or alternatively 70:1, or alternatively 80:1, or alternatively 90:1, or alternatively 100:1.
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce 14-BDO and 4-hydroxybutyryl-CoA followed by spontaneous lactonization of 4-hydroxybutyryl-phosphate to form GBL, wherein said non-naturally occurring microbial organism comprise a microbial organism having a 14-BDO pathway and a 4-hydroxybutyryl-CoA pathway, said 14-BDO pathway comprising at least one exogenous nucleic acid encoding a 14-BDO pathway enzyme expressed in a sufficient amount to produce 14-BDO, said 14-BDO pathway comprising a succinyl-CoA reductase (aldehyde forming), an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate reductase, a 1,4-butanediol dehydrogenase, a succinate reductase, a succinyl-CoA transferase, a succinyl-CoA hydrolase, a succinyl-CoA synthetase, a glutamate dehydrogenase, a glutamate transaminase, a glutamate decarboxylase, an 4-aminobutyrate dehydrogenase, an 4-aminobutyrate transaminase, a 4-hydroxybutyrate kinase, a phosphotrans-4-hydroxybutyrylase, a 4-hydroxybutyryl-CoA reductase (aldehyde forming), a 4-hydroxybutyryl-phosphate reductase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase, a 4-hydroxybutyryl-CoA synthetase, a 4-hydroxybutyryl-CoA reductase (alcohol forming), an alpha-ketoglutarate reductase, a 5-hydroxy-2-oxopentanoate dehydrogenase, a 5-hydroxy-2-oxopentanoate decarboxylase or a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation), said 4-hydroxybutyryl-CoA pathway comprising at least one exogenous nucleic acid encoding an 4-hydroxybutyryl-CoA pathway enzyme expressed in a sufficient amount to produce 4-hydroxybutyryl-CoA, (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase, or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 1,4-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyrate kinase, a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and E) 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a phosphotrans-4-hydroxybutyrylase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; a 4-hydroxybutyryl-phosphate reductase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; a 4-aminobutyrate dehydrogenase or a 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase; and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation); and a 4-hydroxybutyryl-CoA reductase (alcohol forming) (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase; a 5-hydroxy-2-oxopentanoate decarboxylase; and a 1,4-butanediol dehydrogenase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 14-BDO pathway comprising comprises a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; and a phosphotrans-4-hydroxybutyrylase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); a 4-hydroxybutyrate kinase; and a phosphotrans-4-hydroxybutyrylase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (alcohol forming); and a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase and a phosphotrans-4-hydroxybutyrylase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a succinate reductase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; and a phosphotrans-4-hydroxybutyrylase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; an 4-aminobutyrate dehydrogenase or an 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate kinase; and a phosphotrans-4-hydroxybutyrylase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising a glutamate dehydrogenase or a glutamate transaminase; a glutamate decarboxylase; an 4-aminobutyrate dehydrogenase or an 4-aminobutyrate transaminase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or a 4-hydroxybutyryl-CoA synthetase (see
In a further aspect of the above embodiment, the method includes a microbial organism having a 4-hydroxybutyryl-CoA pathway comprising an alpha-ketoglutarate reductase; a 5-hydroxy-2-oxopentanoate dehydrogenase and a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation) (see
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce 14-BDO and 4-hydroxybutyryl-CoA followed by spontaneous lactonization of 4-hydroxybutyryl-phosphate to form GBL, wherein said non-naturally occurring microbial organism comprise a microbial organism having a 14-BDO pathway and a 4-hydroxybutyryl-CoA pathway, said 14-BDO pathway comprising a first set of exogenous nucleic acids encoding 14-BDO pathway enzymes expressed in a sufficient amount to produce 14-BDO, said first set is selected from the group consisting of [a succinyl-CoA transferase, a succinyl-CoA hydrolase or a succinyl-CoA synthetase; a succinyl-CoA reductase (aldehyde forming); a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyrate reductase; and a 1,4-butanediol dehydrogenase)] (see
In a further aspect of each of the above embodiments, the exogenous nucleic acid is a heterologous nucleic acid.
In a further aspect of each of the above embodiments, the conditions include substantially anaerobic culture conditions.
In a further aspect of each of the above embodiments, the 14-BDO and GBL products are produced at a predetermined ratio. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 1:1, or alternatively 1:2, or alternatively 1:3, or alternatively 1:4, or alternatively 1:5, or alternatively 1:6, or alternatively 1:7, or alternatively 1:8, or alternatively 1:9, or alternatively 1:10, or alternatively 1:15, or alternatively about 1:20, or alternatively 1:25, or alternatively 1:30, or alternatively 1:35, or alternatively 1:40, or alternatively 1:45, or alternatively about 1:50, or alternatively 1:60, or alternatively 1:70, or alternatively 1:80, or alternatively 1:90, or alternatively 1:100. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 2:1, or alternatively 3:1, or alternatively 4:1, or alternatively 5:1, or alternatively 6:1, or alternatively 7:1, or alternatively 8:1, or alternatively 9:1, or alternatively 10:1, or alternatively 15:1, or alternatively about 20:1, or alternatively 25:1, or alternatively 30:1, or alternatively 35:1, or alternatively 40:1, or alternatively 45:1, or alternatively about 50:1, or alternatively 60:1, or alternatively 70:1, or alternatively 80:1, or alternatively 90:1, or alternatively 100:1.
In one embodiment, the invention provides a method for producing 14-BDO and GBL that includes culturing a non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce 14-BDO and 4-hydroxybutyryl-phosphate followed by spontaneous lactonization of 4-hydroxybutyryl-phosphate to form GBL, wherein said non-naturally occurring microbial organism comprise a microbial organism having a 14-BDO pathway and a 4-hydroxybutyryl-phosphate pathway, said 14-BDO pathway comprising at least one exogenous nucleic acid encoding a 14-BDO pathway enzyme expressed in a sufficient amount to produce 14-BDO, wherein the 14-BDO pathway comprises an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase or 4-hydroxybutyryl-CoA synthetase; a 4-hydroxybutyryl-CoA reductase (aldehyde forming); and said 4-hydroxybutyryl-phosphate pathway comprising at least one exogenous nucleic acid encoding an 4-hydroxybutyryl-phosphate pathway enzyme expressed in a sufficient amount to produce 4-hydroxybutyryl-phosphate (see steps B, C, T/U/V, Q, E), said 4-hydroxybutyryl-phosphate pathway comprising an alpha-ketoglutarate decarboxylase; a 4-hydroxybutyrate dehydrogenase; and a 4-hydroxybutyrate kinase[see steps B, C, O).
In a further aspect of the above embodiment, the non-naturally occurring microbial organism does not comprise an exogenous nucleic acid encoding a phosphotrans-4-hydroxybutyrylase. In one aspect, the microbial organism comprises a gene disruption in a gene encoding a phosphotrans-4-hydroxybutyrylase, wherein the gene disruption confers production of a predetermined ratio of 14-BDO to GBL. In some aspects of the invention, the predetermined ratio is 1:1, or alternatively 1:2, or alternatively 1:3, or alternatively 1:4, or alternatively 1:5, or alternatively 1:6, or alternatively 1:7, or alternatively 1:8, or alternatively 1:9, or alternatively 1:10, or alternatively 1:15, or alternatively about 1:20, or alternatively 1:25, or alternatively 1:30, or alternatively 1:35, or alternatively 1:40, or alternatively 1:45, or alternatively about 1:50, or alternatively 1:60, or alternatively 1:70, or alternatively 1:80, or alternatively 1:90, or alternatively 1:100. In some aspects of the invention, the predetermined ratio of 14-BDO to GBL is 2:1, or alternatively 3:1, or alternatively 4:1, or alternatively 5:1, or alternatively 6:1, or alternatively 7:1, or alternatively 8:1, or alternatively 9:1, or alternatively 10:1, or alternatively 15:1, or alternatively about 20:1, or alternatively 25:1, or alternatively 30:1, or alternatively 35:1, or alternatively 40:1, or alternatively 45:1, or alternatively about 50:1, or alternatively 60:1, or alternatively 70:1, or alternatively 80:1, or alternatively 90:1, or alternatively 100:1.
In a further aspect of the above embodiment, the exogenous nucleic acid is a heterologous nucleic acid.
In a further aspect of the above embodiment, the conditions include substantially anaerobic culture conditions.
Embodiments described herein include the down stream compound that can be produced from the 14-BDO and GBL producing non-naturally occurring microbial organisms of the invention, for example, 14-BDO. This compound can be synthesized by, for example, chemical hydrogenation of GBL. Chemical hydrogenation reactions are well known in the art. One exemplary procedure includes the chemical reduction of GBL or a mixture of GBL and 14-BDO deriving from the culture using a heterogeneous or homogeneous hydrogenation catalyst together with hydrogen, or a hydride-based reducing agent used stoichiometrically or catalytically, to produce 14-BDO.
Other procedures well known in the art are equally applicable for the above chemical reaction and include, for example, WO No. 82/03854 (Bradley, et al.), which describes the hydrogenolysis of gamma-butyrolactone in the vapor phase over a copper oxide and zinc oxide catalyst. British Pat. No. 1,230,276, which describes the hydrogenation of gamma-butyrolactone using a copper oxide-chromium oxide catalyst. The hydrogenation is carried out in the liquid phase. Batch reactions also are exemplified having high total reactor pressures. Reactant and product partial pressures in the reactors are well above the respective dew points. British Pat. No. 1,314,126, which describes the hydrogenation of gamma-butyrolactone in the liquid phase over a nickel-cobalt-thorium oxide catalyst. Batch reactions are exemplified as having high total pressures and component partial pressures well above respective component dew points. British Pat. No. 1,344,557, which describes the hydrogenation of gamma-butyrolactone in the liquid phase over a copper oxide-chromium oxide catalyst. A vapor phase or vapor-containing mixed phase is indicated as suitable in some instances. A continuous flow tubular reactor is exemplified using high total reactor pressures. British Pat. No. 1,512,751, which describes the hydrogenation of gamma-butyrolactone to 1,4-butanediol in the liquid phase over a copper oxide-chromium oxide catalyst. Batch reactions are exemplified with high total reactor pressures and, where determinable, reactant and product partial pressures well above the respective dew points. U.S. Pat. No. 4,301,077, which describes the hydrogenation to 1,4-butanediol of gamma-butyrolactone over a Ru—Ni—Co—Zn catalyst. The reaction can be conducted in the liquid or gas phase or in a mixed liquid-gas phase. Exemplified are continuous flow liquid phase reactions at high total reactor pressures and relatively low reactor productivities. U.S. Pat. No. 4,048,196, which describes the production of 1,4-butanediol by the liquid phase hydrogenation of gamma-butyrolactone over a copper oxide-zinc oxide catalyst. Further exemplified is a continuous flow tubular reactor operating at high total reactor pressures and high reactant and product partial pressures. And U.S. Pat. No. 4,652,685, which describes the hydrogenation of lactones to glycols.
Suitable purification and/or assays to test for the production of 14-BDO and GBL can be performed using well known methods. Suitable replicates such as triplicate cultures can be grown for each engineered strain to be tested. For example, product and byproduct formation in the engineered production host can be monitored. The final product and intermediates, and other organic compounds, can be analyzed by methods such as HPLC (High Performance Liquid Chromatography), GC-MS (Gas Chromatography-Mass Spectroscopy) and LC-MS (Liquid Chromatography-Mass Spectroscopy) or other suitable analytical methods using routine procedures well known in the art. The release of product in the fermentation broth can also be tested with the culture supernatant. Byproducts and residual glucose can be quantified by HPLC using, for example, a refractive index detector for glucose and alcohols, and a UV detector for organic acids (Lin et al., Biotechnol. Bioeng. 90:775-779 (2005)), or other suitable assay and detection methods well known in the art. The individual enzyme or protein activities from the exogenous DNA sequences can also be assayed using methods well known in the art.
The 14-BDO and GBL products can be separated from other components in the culture using a variety of methods well known in the art. Such separation methods include, for example, extraction procedures as well as methods that include continuous liquid-liquid extraction, pervaporation, membrane filtration, membrane separation, reverse osmosis, electrodialysis, distillation, crystallization, centrifugation, extractive filtration, ion exchange chromatography, size exclusion chromatography, adsorption chromatography, and ultrafiltration. All of the above methods are well known in the art.
The 14-BDO and GBL can be separated from other components in the culture using a variety of methods well known in the art. Such separation methods include, for example, extraction procedures as well as methods that include continuous liquid-liquid extraction, pervaporation, membrane filtration, membrane separation, reverse osmosis, electrodialysis, distillation, crystallization, centrifugation, extractive filtration, ion exchange chromatography, size exclusion chromatography, adsorption chromatography, and ultrafiltration. All of the above methods are well known in the art.
Any of the non-naturally occurring microbial organisms described herein can be cultured to produce and/or secrete the biosynthetic products of the invention. For example, the 14-BDO and GBL producers can be cultured for the biosynthetic production of 14-BDO and GBL.
For the production of 14-BDO and GBL, the recombinant strains are cultured in a medium with carbon source and other essential nutrients. It is sometimes desirable and can be highly desirable to maintain anaerobic conditions in the fermenter to reduce the cost of the overall process. Such conditions can be obtained, for example, by first sparging the medium with nitrogen and then sealing the flasks with a septum and crimp-cap. For strains where growth is not observed anaerobically, microaerobic or substantially anaerobic conditions can be applied by perforating the septum with a small hole for limited aeration. Exemplary anaerobic conditions have been described previously and are well-known in the art. Exemplary aerobic and anaerobic conditions are described, for example, in United State publication 2009/0047719, filed Aug. 10, 2007. Fermentations can be performed in a batch, fed-batch or continuous manner, as disclosed herein.
If desired, the pH of the medium can be maintained at a desired pH, in particular neutral pH, such as a pH of around 7 by addition of a base, such as NaOH or other bases, or acid, as needed to maintain the culture medium at a desirable pH. The growth rate can be determined by measuring optical density using a spectrophotometer (600 nm), and the glucose uptake rate by monitoring carbon source depletion over time.
The growth medium can include, for example, any carbohydrate source which can supply a source of carbon to the non-naturally occurring microorganism. Such sources include, for example, sugars such as glucose, xylose, arabinose, galactose, mannose, fructose, sucrose and starch. Other sources of carbohydrate include, for example, renewable feedstocks and biomass. Exemplary types of biomasses that can be used as feedstocks in the methods of the invention include cellulosic biomass, hemicellulosic biomass and lignin feedstocks or portions of feedstocks. Such biomass feedstocks contain, for example, carbohydrate substrates useful as carbon sources such as glucose, xylose, arabinose, galactose, mannose, fructose and starch. Given the teachings and guidance provided herein, those skilled in the art will understand that renewable feedstocks and biomass other than those exemplified above also can be used for culturing the microbial organisms of the invention for the production of 14-BDO and GBL.
In addition to renewable feedstocks such as those exemplified above, the 14-BDO and GBL microbial organisms of the invention also can be modified for growth on syngas as its source of carbon. In this specific embodiment, one or more proteins or enzymes are expressed in the 14-BDO and GBL producing organisms to provide a metabolic pathway for utilization of syngas or other gaseous carbon source.
Synthesis gas, also known as syngas or producer gas, is the major product of gasification of coal and of carbonaceous materials such as biomass materials, including agricultural crops and residues. Syngas is a mixture primarily of H2 and CO and can be obtained from the gasification of any organic feedstock, including but not limited to coal, coal oil, natural gas, biomass, and waste organic matter. Gasification is generally carried out under a high fuel to oxygen ratio. Although largely H2 and CO, syngas can also include CO2 and other gases in smaller quantities. Thus, synthesis gas provides a cost effective source of gaseous carbon such as CO and, additionally, CO2.
The Wood-Ljungdahl pathway catalyzes the conversion of CO and H2 to acetyl-CoA and other products such as acetate. Organisms capable of utilizing CO and syngas also generally have the capability of utilizing CO2 and CO2/H2 mixtures through the same basic set of enzymes and transformations encompassed by the Wood-Ljungdahl pathway. H2-dependent conversion of CO2 to acetate by microorganisms was recognized long before it was revealed that CO also could be used by the same organisms and that the same pathways were involved. Many acetogens have been shown to grow in the presence of CO2 and produce compounds such as acetate as long as hydrogen is present to supply the necessary reducing equivalents (see for example, Drake, Acetogenesis, pp. 3-60 Chapman and Hall, New York, (1994)). This can be summarized by the following equation:
2CO2+4H2+nADP+nPi→CH3COOH+2H2O+nATP
Hence, non-naturally occurring microorganisms possessing the Wood-Ljungdahl pathway can utilize CO2 and H2 mixtures as well for the production of acetyl-CoA and other desired products.
The Wood-Ljungdahl pathway is well known in the art and consists of 12 reactions which can be separated into two branches: (1) methyl branch and (2) carbonyl branch. The methyl branch converts syngas to methyl-tetrahydrofolate (methyl-THF) whereas the carbonyl branch converts methyl-THF to acetyl-CoA. The reactions in the methyl branch are catalyzed in order by the following enzymes or proteins: ferredoxin oxidoreductase, formate dehydrogenase, formyltetrahydrofolate synthetase, methenyltetrahydrofolate cyclodehydratase, methylenetetrahydrofolate dehydrogenase and methylenetetrahydrofolate reductase. The reactions in the carbonyl branch are catalyzed in order by the following enzymes or proteins: methyltetrahydrofolate:corrinoid protein methyltransferase (for example, AcsE), corrinoid iron-sulfur protein, nickel-protein assembly protein (for example, AcsF), ferredoxin, acetyl-CoA synthase, carbon monoxide dehydrogenase and nickel-protein assembly protein (for example, CooC). Following the teachings and guidance provided herein for introducing a sufficient number of encoding nucleic acids to generate a 14-BDO and GBL pathway, those skilled in the art will understand that the same engineering design also can be performed with respect to introducing at least the nucleic acids encoding the Wood-Ljungdahl enzymes or proteins absent in the host organism. Therefore, introduction of one or more encoding nucleic acids into the microbial organisms of the invention such that the modified organism contains the complete Wood-Ljungdahl pathway will confer syngas utilization ability.
Additionally, the reductive (reverse) tricarboxylic acid cycle is and/or hydrogenase activities can also be used for the conversion of CO, CO2 and/or H2 to acetyl-CoA and other products such as acetate. Organisms capable of fixing carbon via the reductive TCA pathway can utilize one or more of the following enzymes: ATP citrate-lyase, citrate lyase, aconitase, isocitrate dehydrogenase, alpha-ketoglutarate:ferredoxin oxidoreductase, succinyl-CoA synthetase, succinyl-CoA transferase, fumarate reductase, fumarase, malate dehydrogenase, NAD(P)H:ferredoxin oxidoreductase, carbon monoxide dehydrogenase, and hydrogenase. Specifically, the reducing equivalents extracted from CO and/or H2 by carbon monoxide dehydrogenase and hydrogenase are utilized to fix CO2 via the reductive TCA cycle into acetyl-CoA or acetate. Acetate can be converted to acetyl-CoA by enzymes such as acetyl-CoA transferase, acetate kinase/phosphotransacetylase, and acetyl-CoA synthetase. Acetyl-CoA can be converted to the 14-BDO or GBL precursors, glyceraldehyde-3-phosphate, phosphoenolpyruvate, and pyruvate, by pyruvate:ferredoxin oxidoreductase and the enzymes of gluconeogenesis. Following the teachings and guidance provided herein for introducing a sufficient number of encoding nucleic acids to generate a 14, BDO or GBL pathway, those skilled in the art will understand that the same engineering design also can be performed with respect to introducing at least the nucleic acids encoding the reductive TCA pathway enzymes or proteins absent in the host organism. Therefore, introduction of one or more encoding nucleic acids into the microbial organisms of the invention such that the modified organism contains the complete reductive TCA pathway will confer syngas utilization ability.
Accordingly, given the teachings and guidance provided herein, those skilled in the art will understand that a non-naturally occurring microbial organism can be produced that secretes the biosynthesized compounds of the invention when grown on a carbon source such as a carbohydrate. Such compounds include, for example, 14-BDO, GBL and any of the intermediate metabolites in the 14-BDO or GBL pathway. All that is required is to engineer in one or more of the required enzyme or protein activities to achieve biosynthesis of the desired compound or intermediate including, for example, inclusion of some or all of the 14-BDO and GBL biosynthetic pathways. Accordingly, the invention provides a non-naturally occurring microbial organism that produces and/or secretes 14-BDO and GBL when grown on a carbohydrate or other carbon source and produces and/or secretes any of the intermediate metabolites shown in the 14-BDO or GBL pathway when grown on a carbohydrate or other carbon source. The 14-BDO and GBL producing microbial organisms of the invention can initiate synthesis from an intermediate, for example, a succinyl-CoA reductase (aldehyde forming), an alpha-ketoglutarate decarboxylase, a 4-hydroxybutyrate dehydrogenase, a 4-hydroxybutyrate reductase, a 1,4-butanediol dehydrogenase, a succinate reductase, a succinyl-CoA transferase, a succinyl-CoA hydrolase, a succinyl-CoA synthetase (or succinyl-CoA ligase), a glutamate dehydrogenase, a glutamate transaminase, a glutamate decarboxylase, a 4-aminobutyrate dehydrogenase, a 4-aminobutyrate transaminase, a 4-hydroxybutyrate kinase, a phosphotrans-4-hydroxybutyrylase, a 4-hydroxybutyryl-CoA reductase (aldehyde forming), a 4-hydroxybutyryl-phosphate reductase, a succinyl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA transferase, a 4-hydroxybutyryl-CoA hydrolase, a 4-hydroxybutyryl-CoA synthetase (or 4-hydroxybutyryl-CoA ligase), a 4-hydroxybutyryl-CoA reductase (alcohol forming), an alpha-ketoglutarate reductase, a 5-hydroxy-2-oxopentanoate dehydrogenase, a 5-hydroxy-2-oxopentanoate decarboxylase, a 5-hydroxy-2-oxopentanoate dehydrogenase (decarboxylation) or a 4-hydroxybutyrate lactonase.
The non-naturally occurring microbial organisms of the invention are constructed using methods well known in the art as exemplified herein to exogenously express at least one nucleic acid encoding a 14-BDO and GBL pathway enzyme or protein in sufficient amounts to produce 14-BDO and GBL. It is understood that the microbial organisms of the invention are cultured under conditions sufficient to produce 14-BDO and GBL. Following the teachings and guidance provided herein, the non-naturally occurring microbial organisms of the invention can achieve biosynthesis of 14-BDO and GBL resulting in intracellular concentrations between about 0.1-200 mM or more. Generally, the intracellular concentration of 14-BDO and GBL is between about 0.01-1000 mM, particularly 3-150 mM, more particularly between about 5-125 mM and more particularly between about 8-100 mM, including about 10 mM, 20 mM, 50 mM, 80 mM, or more. Intracellular concentrations between and above each of these exemplary ranges also can be achieved from the non-naturally occurring microbial organisms of the invention.
In some embodiments, culture conditions include anaerobic or substantially anaerobic growth or maintenance conditions. Exemplary anaerobic conditions have been described previously and are well known in the art. Exemplary anaerobic conditions for fermentation processes are described herein and are described, for example, in U.S. publication 2009/0047719, filed Aug. 10, 2007. Any of these conditions can be employed with the non-naturally occurring microbial organisms as well as other anaerobic conditions well known in the art. Under such anaerobic or substantially anaerobic conditions, the 14-BDO and GBL producers can synthesize 14-BDO and GBL at intracellular concentrations of 5-10 mM or more as well as all other concentrations exemplified herein. It is understood that, even though the above description refers to intracellular concentrations, 14-BDO and GBL producing microbial organisms can produce 14-BDO and GBL intracellularly and/or secrete the products into the culture medium.
In addition to the culturing and fermentation conditions disclosed herein, growth condition for achieving biosynthesis of 14-BDO and GBL can include the addition of an osmoprotectant to the culturing conditions. In certain embodiments, the non-naturally occurring microbial organisms of the invention can be sustained, cultured or fermented as described herein in the presence of an osmoprotectant. Briefly, an osmoprotectant refers to a compound that acts as an osmolyte and helps a microbial organism as described herein survive osmotic stress. Osmoprotectants include, but are not limited to, betaines, amino acids, and the sugar trehalose. Non-limiting examples of such are glycine betaine, praline betaine, dimethylthetin, dimethylslfonioproprionate, 3-dimethylsulfonio-2-methylproprionate, pipecolic acid, dimethylsulfonioacetate, choline, L-carnitine and ectoine. In one aspect, the osmoprotectant is glycine betaine. It is understood to one of ordinary skill in the art that the amount and type of osmoprotectant suitable for protecting a microbial organism described herein from osmotic stress will depend on the microbial organism used. The amount of osmoprotectant in the culturing conditions can be, for example, no more than about 0.1 mM, no more than about 0.5 mM, no more than about 1.0 mM, no more than about 1.5 mM, no more than about 2.0 mM, no more than about 2.5 mM, no more than about 3.0 mM, no more than about 5.0 mM, no more than about 7.0 mM, no more than about 10 mM, no more than about 50 mM, no more than about 100 mM or no more than about 500 mM.
The culture conditions can include, for example, liquid culture procedures as well as fermentation and other large scale culture procedures. As described herein, particularly useful yields of the biosynthetic products of the invention can be obtained under anaerobic or substantially anaerobic culture conditions.
As described herein, one exemplary growth condition for achieving biosynthesis of 14-BDO and GBL includes anaerobic culture or fermentation conditions. In certain embodiments, the non-naturally occurring microbial organisms of the invention can be sustained, cultured or fermented under anaerobic or substantially anaerobic conditions. Briefly, anaerobic conditions refers to an environment devoid of oxygen. Substantially anaerobic conditions include, for example, a culture, batch fermentation or continuous fermentation such that the dissolved oxygen concentration in the medium remains between 0 and 10% of saturation. Substantially anaerobic conditions also includes growing or resting cells in liquid medium or on solid agar inside a sealed chamber maintained with an atmosphere of less than 1% oxygen. The percent of oxygen can be maintained by, for example, sparging the culture with an N2/CO2 mixture or other suitable non-oxygen gas or gases.
The culture conditions described herein can be scaled up and grown continuously for manufacturing of 14-BDO and GBL. Exemplary growth procedures include, for example, fed-batch fermentation and batch separation; fed-batch fermentation and continuous separation, or continuous fermentation and continuous separation. All of these processes are well known in the art. Fermentation procedures are particularly useful for the biosynthetic production of commercial quantities of 14-BDO and GBL. Generally, and as with non-continuous culture procedures, the continuous and/or near-continuous production of 14-BDO and GBL will include culturing a non-naturally occurring 14-BDO and GBL producing organism of the invention in sufficient nutrients and medium to sustain and/or nearly sustain growth in an exponential phase. Continuous culture under such conditions can be include, for example, growth for 1 day, 2, 3, 4, 5, 6 or 7 days or more. Additionally, continuous culture can include longer time periods of 1 week, 2, 3, 4 or 5 or more weeks and up to several months. Alternatively, organisms of the invention can be cultured for hours, if suitable for a particular application. It is to be understood that the continuous and/or near-continuous culture conditions also can include all time intervals in between these exemplary periods. It is further understood that the time of culturing the microbial organism of the invention is for a sufficient period of time to produce a sufficient amount of product for a desired purpose.
Fermentation procedures are well known in the art. Briefly, fermentation for the biosynthetic production of 14-BDO and GBL can be utilized in, for example, fed-batch fermentation and batch separation; fed-batch fermentation and continuous separation, or continuous fermentation and continuous separation. Examples of batch and continuous fermentation procedures are well known in the art.
In addition to the above fermentation procedures using the 14-BDO and GBL producers of the invention for continuous production of substantial quantities of 14-BDO and GBL, the 14-BDO and GBL producers also can be, for example, simultaneously subjected to chemical synthesis procedures to convert the product to other compounds or the product can be separated from the fermentation culture and sequentially subjected to chemical conversion to convert the product to other compounds, if desired.
In addition to the above fermentation procedures using the 14-BDO and GBL producers of the invention for continuous production of substantial quantities of 14-BDO and GBL, 14-BDO and 4-hydroxybutyryl-phosphate producers or 14-BDO and 4-hydroxybutyryl-CoA producers also can be, for example, simultaneously subjected to spontaneous lactonization procedures to convert the products 4-hydroxybutyryl-phosphate or 4-hydroxybutyryl-CoA to GBL as described herein. In some aspects, the spontaneous lactonization of 4-hydroxybutyryl-phosphate or 4-hydroxybutyryl-CoA to form GBL can occur intracellularly. Alternatively, if the products 4-hydroxybutyryl-phosphate or 4-hydroxybutyryl-CoA are secreted, the spontaneous lactonization of these products can occur extracellularly.
To generate better producers, metabolic modeling can be utilized to optimize growth conditions. Modeling can also be used to design gene knockouts that additionally optimize utilization of the pathway (see, for example, U.S. patent publications US 2002/0012939, US 2003/0224363, US 2004/0029149, US 2004/0072723, US 2003/0059792, US 2002/0168654 and US 2004/0009466, and U.S. Pat. No. 7,127,379). Modeling analysis allows reliable predictions of the effects on cell growth of shifting the metabolism towards more efficient production of 14-BDO and GBL.
One computational method for identifying and designing metabolic alterations favoring biosynthesis of a desired product is the OptKnock computational framework (Burgard et al., Biotechnol. Bioeng. 84:647-657 (2003)). OptKnock is a metabolic modeling and simulation program that suggests gene deletion or disruption strategies that result in genetically stable microorganisms which overproduce the target product. Specifically, the framework examines the complete metabolic and/or biochemical network of a microorganism in order to suggest genetic manipulations that force the desired biochemical to become an obligatory byproduct of cell growth. By coupling biochemical production with cell growth through strategically placed gene deletions or other functional gene disruption, the growth selection pressures imposed on the engineered strains after long periods of time in a bioreactor lead to improvements in performance as a result of the compulsory growth-coupled biochemical production. Lastly, when gene deletions are constructed there is a negligible possibility of the designed strains reverting to their wild-type states because the genes selected by OptKnock are to be completely removed from the genome. Therefore, this computational methodology can be used to either identify alternative pathways that lead to biosynthesis of a desired product or used in connection with the non-naturally occurring microbial organisms for further optimization of biosynthesis of a desired product.
Briefly, OptKnock is a term used herein to refer to a computational method and system for modeling cellular metabolism. The OptKnock program relates to a framework of models and methods that incorporate particular constraints into flux balance analysis (FBA) models. These constraints include, for example, qualitative kinetic information, qualitative regulatory information, and/or DNA microarray experimental data. OptKnock also computes solutions to various metabolic problems by, for example, tightening the flux boundaries derived through flux balance models and subsequently probing the performance limits of metabolic networks in the presence of gene additions or deletions. OptKnock computational framework allows the construction of model formulations that allow an effective query of the performance limits of metabolic networks and provides methods for solving the resulting mixed-integer linear programming problems. The metabolic modeling and simulation methods referred to herein as OptKnock are described in, for example, U.S. publication 2002/0168654, filed Jan. 10, 2002, in International Patent No. PCT/US02/00660, filed Jan. 10, 2002, and U.S. publication 2009/0047719, filed Aug. 10, 2007.
Another computational method for identifying and designing metabolic alterations favoring biosynthetic production of a product is a metabolic modeling and simulation system termed SimPheny®. This computational method and system is described in, for example, U.S. publication 2003/0233218, filed Jun. 14, 2002, and in International Patent Application No. PCT/US03/18838, filed Jun. 13, 2003. SimPheny® is a computational system that can be used to produce a network model in silico and to simulate the flux of mass, energy or charge through the chemical reactions of a biological system to define a solution space that contains any and all possible functionalities of the chemical reactions in the system, thereby determining a range of allowed activities for the biological system. This approach is referred to as constraints-based modeling because the solution space is defined by constraints such as the known stoichiometry of the included reactions as well as reaction thermodynamic and capacity constraints associated with maximum fluxes through reactions. The space defined by these constraints can be interrogated to determine the phenotypic capabilities and behavior of the biological system or of its biochemical components.
These computational approaches are consistent with biological realities because biological systems are flexible and can reach the same result in many different ways. Biological systems are designed through evolutionary mechanisms that have been restricted by fundamental constraints that all living systems must face. Therefore, constraints-based modeling strategy embraces these general realities. Further, the ability to continuously impose further restrictions on a network model via the tightening of constraints results in a reduction in the size of the solution space, thereby enhancing the precision with which physiological performance or phenotype can be predicted.
Given the teachings and guidance provided herein, those skilled in the art will be able to apply various computational frameworks for metabolic modeling and simulation to design and implement biosynthesis of a desired compound in host microbial organisms. Such metabolic modeling and simulation methods include, for example, the computational systems exemplified above as SimPheny® and OptKnock. For illustration of the invention, some methods are described herein with reference to the OptKnock computation framework for modeling and simulation. Those skilled in the art will know how to apply the identification, design and implementation of the metabolic alterations using OptKnock to any of such other metabolic modeling and simulation computational frameworks and methods well known in the art.
The methods described above will provide one set of metabolic reactions to disrupt. Elimination of each reaction within the set or metabolic modification can result in a desired product as an obligatory product during the growth phase of the organism. Because the reactions are known, a solution to the bilevel OptKnock problem also will provide the associated gene or genes encoding one or more enzymes that catalyze each reaction within the set of reactions. Identification of a set of reactions and their corresponding genes encoding the enzymes participating in each reaction is generally an automated process, accomplished through correlation of the reactions with a reaction database having a relationship between enzymes and encoding genes.
Once identified, the set of reactions that are to be disrupted in order to achieve production of a desired product are implemented in the target cell or organism by functional disruption of at least one gene encoding each metabolic reaction within the set. One particularly useful means to achieve functional disruption of the reaction set is by deletion of each encoding gene. However, in some instances, it can be beneficial to disrupt the reaction by other genetic aberrations including, for example, mutation, deletion of regulatory regions such as promoters or cis binding sites for regulatory factors, or by truncation of the coding sequence at any of a number of locations. These latter aberrations, resulting in less than total deletion of the gene set can be useful, for example, when rapid assessments of the coupling of a product are desired or when genetic reversion is less likely to occur.
To identify additional productive solutions to the above described bilevel OptKnock problem which lead to further sets of reactions to disrupt or metabolic modifications that can result in the biosynthesis, including growth-coupled biosynthesis of a desired product, an optimization method, termed integer cuts, can be implemented. This method proceeds by iteratively solving the OptKnock problem exemplified above with the incorporation of an additional constraint referred to as an integer cut at each iteration. Integer cut constraints effectively prevent the solution procedure from choosing the exact same set of reactions identified in any previous iteration that obligatorily couples product biosynthesis to growth. For example, if a previously identified growth-coupled metabolic modification specifies reactions 1, 2, and 3 for disruption, then the following constraint prevents the same reactions from being simultaneously considered in subsequent solutions. The integer cut method is well known in the art and can be found described in, for example, Burgard et al., Biotechnol. Prog. 17:791-797 (2001). As with all methods described herein with reference to their use in combination with the OptKnock computational framework for metabolic modeling and simulation, the integer cut method of reducing redundancy in iterative computational analysis also can be applied with other computational frameworks well known in the art including, for example, SimPheny®.
The methods exemplified herein allow the construction of cells and organisms that biosynthetically produce a desired product, including the obligatory coupling of production of a target biochemical product to growth of the cell or organism engineered to harbor the identified genetic alterations. Therefore, the computational methods described herein allow the identification and implementation of metabolic modifications that are identified by an in silico method selected from OptKnock or SimPheny®. The set of metabolic modifications can include, for example, addition of one or more biosynthetic pathway enzymes and/or functional disruption of one or more metabolic reactions including, for example, disruption by gene deletion.
As discussed above, the OptKnock methodology was developed on the premise that mutant microbial networks can be evolved towards their computationally predicted maximum-growth phenotypes when subjected to long periods of growth selection. In other words, the approach leverages an organism's ability to self-optimize under selective pressures. The OptKnock framework allows for the exhaustive enumeration of gene deletion combinations that force a coupling between biochemical production and cell growth based on network stoichiometry. The identification of optimal gene/reaction knockouts requires the solution of a bilevel optimization problem that chooses the set of active reactions such that an optimal growth solution for the resulting network overproduces the biochemical of interest (Burgard et al., Biotechnol. Bioeng. 84:647-657 (2003)).
An in silico stoichiometric model of E. coli metabolism can be employed to identify essential genes for metabolic pathways as exemplified previously and described in, for example, U.S. patent publications US 2002/0012939, US 2003/0224363, US 2004/0029149, US 2004/0072723, US 2003/0059792, US 2002/0168654 and US 2004/0009466, and in U.S. Pat. No. 7,127,379. As disclosed herein, the OptKnock mathematical framework can be applied to pinpoint gene deletions leading to the growth-coupled production of a desired product. Further, the solution of the bilevel OptKnock problem provides only one set of deletions. To enumerate all meaningful solutions, that is, all sets of knockouts leading to growth-coupled production formation, an optimization technique, termed integer cuts, can be implemented. This entails iteratively solving the OptKnock problem with the incorporation of an additional constraint referred to as an integer cut at each iteration, as discussed above.
As disclosed herein, a nucleic acid encoding a desired activity of a 14-BDO or GBL pathway can be introduced into a host organism. In some cases, it can be desirable to modify an activity of a 14-BDO or GBL pathway enzyme or protein to increase production of 14-BDO and GBL. For example, known mutations that increase the activity of a protein or enzyme can be introduced into an encoding nucleic acid molecule. Additionally, optimization methods can be applied to increase the activity of an enzyme or protein and/or decrease an inhibitory activity, for example, decrease the activity of a negative regulator.
One such optimization method is directed evolution. Directed evolution is a powerful approach that involves the introduction of mutations targeted to a specific gene in order to improve and/or alter the properties of an enzyme. Improved and/or altered enzymes can be identified through the development and implementation of sensitive high-throughput screening assays that allow the automated screening of many enzyme variants (for example, >104). Iterative rounds of mutagenesis and screening typically are performed to afford an enzyme with optimized properties. Computational algorithms that can help to identify areas of the gene for mutagenesis also have been developed and can significantly reduce the number of enzyme variants that need to be generated and screened. Numerous directed evolution technologies have been developed (for reviews, see Hibbert et al., Biomol. Eng 22:11-19 (2005); Huisman and Lalonde, In Biocatalysis in the pharmaceutical and biotechnology industries pgs. 717-742 (2007), Patel (ed.), CRC Press; Otten and Quax. Biomol. Eng 22:1-9 (2005); and Sen et al., Appl Biochem. Biotechnol 143:212-223 (2007)) to be effective at creating diverse variant libraries, and these methods have been successfully applied to the improvement of a wide range of properties across many enzyme classes. Enzyme characteristics that have been improved and/or altered by directed evolution technologies include, for example: selectivity/specificity, for conversion of non-natural substrates; temperature stability, for robust high temperature processing; pH stability, for bioprocessing under lower or higher pH conditions; substrate or product tolerance, so that high product titers can be achieved; binding (Km), including broadening substrate binding to include non-natural substrates; inhibition (Ki), to remove inhibition by products, substrates, or key intermediates; activity (kcat), to increases enzymatic reaction rates to achieve desired flux; expression levels, to increase protein yields and overall pathway flux; oxygen stability, for operation of air sensitive enzymes under aerobic conditions; and anaerobic activity, for operation of an aerobic enzyme in the absence of oxygen.
A number of exemplary methods have been developed for the mutagenesis and diversification of genes to target desired properties of specific enzymes. Such methods are well known to those skilled in the art. Any of these can be used to alter and/or optimize the activity of a 14-BDO or GBL pathway enzyme or protein. Such methods include, but are not limited to EpPCR, which introduces random point mutations by reducing the fidelity of DNA polymerase in PCR reactions (Pritchard et al., J Theor. Biol. 234:497-509 (2005)); Error-prone Rolling Circle Amplification (epRCA), which is similar to epPCR except a whole circular plasmid is used as the template and random 6-mers with exonuclease resistant thiophosphate linkages on the last 2 nucleotides are used to amplify the plasmid followed by transformation into cells in which the plasmid is re-circularized at tandem repeats (Fujii et al., Nucleic Acids Res. 32:e145 (2004); and Fujii et al., Nat. Protoc. 1:2493-2497 (2006)); DNA or Family Shuffling, which typically involves digestion of two or more variant genes with nucleases such as Dnase I or EndoV to generate a pool of random fragments that are reassembled by cycles of annealing and extension in the presence of DNA polymerase to create a library of chimeric genes (Stemmer, Proc Natl Acad Sci USA 91:10747-10751 (1994); and Stemmer, Nature 370:389-391 (1994)); Staggered Extension (StEP), which entails template priming followed by repeated cycles of 2 step PCR with denaturation and very short duration of annealing/extension (as short as 5 sec) (Zhao et al., Nat. Biotechnol. 16:258-261 (1998)); Random Priming Recombination (RPR), in which random sequence primers are used to generate many short DNA fragments complementary to different segments of the template (Shao et al., Nucleic Acids Res 26:681-683 (1998)).
Additional methods include Heteroduplex Recombination, in which linearized plasmid DNA is used to form heteroduplexes that are repaired by mismatch repair (Volkov et al, Nucleic Acids Res. 27:e18 (1999); and Volkov et al., Methods Enzymol. 328:456-463 (2000)); Random Chimeragenesis on Transient Templates (RACHITT), which employs Dnase I fragmentation and size fractionation of single stranded DNA (ssDNA) (Coco et al., Nat. Biotechnol. 19:354-359 (2001)); Recombined Extension on Truncated templates (RETT), which entails template switching of unidirectionally growing strands from primers in the presence of unidirectional ssDNA fragments used as a pool of templates (Lee et al., J. Molec. Catalysis 26:119-129 (2003)); Degenerate Oligonucleotide Gene Shuffling (DOGS), in which degenerate primers are used to control recombination between molecules; (Bergquist and Gibbs, Methods Mol. Biol. 352:191-204 (2007); Bergquist et al., Biomol. Eng 22:63-72 (2005); Gibbs et al., Gene 271:13-20 (2001)); Incremental Truncation for the Creation of Hybrid Enzymes (ITCHY), which creates a combinatorial library with 1 base pair deletions of a gene or gene fragment of interest (Ostermeier et al., Proc. Natl. Acad. Sci. USA 96:3562-3567 (1999); and Ostermeier et al., Nat. Biotechnol. 17:1205-1209 (1999)); Thio-Incremental Truncation for the Creation of Hybrid Enzymes (THIO-ITCHY), which is similar to ITCHY except that phosphothioate dNTPs are used to generate truncations (Lutz et al., Nucleic Acids Res 29:E16 (2001)); SCRATCHY, which combines two methods for recombining genes, ITCHY and DNA shuffling (Lutz et al., Proc. Natl. Acad. Sci. USA 98:11248-11253 (2001)); Random Drift Mutagenesis (RNDM), in which mutations made via epPCR are followed by screening/selection for those retaining usable activity (Bergquist et al., Biomol. Eng. 22:63-72 (2005)); Sequence Saturation Mutagenesis (SeSaM), a random mutagenesis method that generates a pool of random length fragments using random incorporation of a phosphothioate nucleotide and cleavage, which is used as a template to extend in the presence of “universal” bases such as inosine, and replication of an inosine-containing complement gives random base incorporation and, consequently, mutagenesis (Wong et al., Biotechnol. J. 3:74-82 (2008); Wong et al., Nucleic Acids Res. 32:e26 (2004); and Wong et al., Anal. Biochem. 341:187-189 (2005)); Synthetic Shuffling, which uses overlapping oligonucleotides designed to encode “all genetic diversity in targets” and allows a very high diversity for the shuffled progeny (Ness et al., Nat. Biotechnol. 20:1251-1255 (2002)); Nucleotide Exchange and Excision Technology NexT, which exploits a combination of dUTP incorporation followed by treatment with uracil DNA glycosylase and then piperidine to perform endpoint DNA fragmentation (Muller et al., Nucleic Acids Res. 33:e117 (2005)).
Further methods include Sequence Homology-Independent Protein Recombination (SHIPREC), in which a linker is used to facilitate fusion between two distantly related or unrelated genes, and a range of chimeras is generated between the two genes, resulting in libraries of single-crossover hybrids (Sieber et al., Nat. Biotechnol. 19:456-460 (2001)); Gene Site Saturation Mutagenesis™ (GSSM™), in which the starting materials include a supercoiled double stranded DNA (dsDNA) plasmid containing an insert and two primers which are degenerate at the desired site of mutations (Kretz et al., Methods Enzymol. 388:3-11 (2004)); Combinatorial Cassette Mutagenesis (CCM), which involves the use of short oligonucleotide cassettes to replace limited regions with a large number of possible amino acid sequence alterations (Reidhaar-Olson et al. Methods Enzymol. 208:564-586 (1991); and Reidhaar-Olson et al. Science 241:53-57 (1988)); Combinatorial Multiple Cassette Mutagenesis (CMCM), which is essentially similar to CCM and uses epPCR at high mutation rate to identify hot spots and hot regions and then extension by CMCM to cover a defined region of protein sequence space (Reetz et al., Angew. Chem. Int. Ed Engl. 40:3589-3591 (2001)); the Mutator Strains technique, in which conditional is mutator plasmids, utilizing the mutD5 gene, which encodes a mutant subunit of DNA polymerase III, to allow increases of 20 to 4000-X in random and natural mutation frequency during selection and block accumulation of deleterious mutations when selection is not required (Selifonova et al., Appl. Environ. Microbiol. 67:3645-3649 (2001)); Low et al., J. Mol. Biol. 260:359-3680 (1996)).
Additional exemplary methods include Look-Through Mutagenesis (LTM), which is a multidimensional mutagenesis method that assesses and optimizes combinatorial mutations of selected amino acids (Rajpal et al., Proc. Natl. Acad. Sci. USA 102:8466-8471 (2005)); Gene Reassembly, which is a DNA shuffling method that can be applied to multiple genes at one time or to create a large library of chimeras (multiple mutations) of a single gene (Tunable GeneReassembly™ (TGR™) Technology supplied by Verenium Corporation), in Silico Protein Design Automation (PDA), which is an optimization algorithm that anchors the structurally defined protein backbone possessing a particular fold, and searches sequence space for amino acid substitutions that can stabilize the fold and overall protein energetics, and generally works most effectively on proteins with known three-dimensional structures (Hayes et al., Proc. Natl. Acad. Sci. USA 99:15926-15931 (2002)); and Iterative Saturation Mutagenesis (ISM), which involves using knowledge of structure/function to choose a likely site for enzyme improvement, performing saturation mutagenesis at chosen site using a mutagenesis method such as Stratagene QuikChange (Stratagene; San Diego Calif.), screening/selecting for desired properties, and, using improved clone(s), starting over at another site and continue repeating until a desired activity is achieved (Reetz et al., Nat. Protoc. 2:891-903 (2007); and Reetz et al., Angew. Chem. Int. Ed Engl. 45:7745-7751 (2006)).
Any of the aforementioned methods for mutagenesis can be used alone or in any combination. Additionally, any one or combination of the directed evolution methods can be used in conjunction with adaptive evolution techniques, as described herein.
It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also provided within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.
The 14-BDO and GBL coproduction pathways are exemplified in
4-HB is an important intermediate for both 14-BDO and GBL production. For 14-BDO production, 4-HB can be converted to 4-hydroxybutyrul-phosphate (Step O) then to 4-hydroxybutyryl-CoA (Step P) then to 4-hydroxybutanal (Step Q) and finally to 14-BDO (Step E). There are several possible alternative routes for the conversion from 4-HB to 14-BDO, such as the direct conversions from 4-HB to 4-hydroxybutanal (Step D), or from 4-hydroxybutyryl-phosphate to 4-hydroxylbutanal (Step R), or from 4-HB to 4-hydrobutyryl-CoA (Steps T or U or V), or from 4-hydrobutyryl-CoA to 14-BDO (Step W). Additionally, alpha-ketoglutarate can be converted to 2,5-dioxopentanoic acid (Step X), then to 5-hydroxy-2-oxopentanoic acid (Step Y), then further to 14-BDO (Step Z). An alternative route for this pathway will transform 5-hydroxy-2-oxopentanoic acid to 4-hydroxybutyryl-CoA (Step AA) that will be further converted to 14-BDO as described herein.
For GBL production, 4-HB can be directly converted to GBL through Step AB, or both 4-hydroxybutyryl-phosphate and 4-hydrobutyryl-CoA can be converted to GBL by non-enzymatic transformations (Step AC and Step AD).
Under anaerobic growth conditions, the production of 14-BDO and GBL using the above describe pathways can be redox-balanced. The coproduction strain can produce both 14-BDO and GBL at different ratios based on the activities of pathways for 14-BDO and GBL, which can be adjust using metabolic engineering techniques. Therefore, the ratios of 14-BDO and GBL can be modified in engineered coproduction strains. The maximum theoretical yields of 14-BDO and GBL in a coproduction strain can be found based on the following equation:
Glucose→1.09a 14-BDO+1.33b GBL+(1.64a+0.67b)CO2+(0.55a+2b)H2O
where a is the molar percentage of glucose converted to 14-BDO, and b is the percentage of glucose converted to GBL, and a+b=100%
For example, if 90% glucose is converted to 14-BDO and 10% glucose is converted to GBL, the maximum theoretical yields, in a coproduction strain, will be 0.981 moles 14-BDO and 0.133 moles GBL per mole glucose consumed. In another example, if 70% glucose is converted to 14-BDO and 30% glucose is converted to GBL, the maximum theoretical yields, in a coproduction strain, will be 0.763 moles 14-BDO and 0.4 moles GBL per mole glucose consumed.
For 14-BDO and GBL coproduction, all routes can lead to high theoretical yields for combined 14-BDO and GBL assuming glucose as the carbon source. Similar high theoretical yields can be obtained from additional substrates including sucrose, xylose, arabinose, synthesis gas, among many others.
This example describes the enzyme classification system for the exemplary pathways described in Example I for production of 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL). All transformations depicted in
Table 5 shows the enzyme types useful to convert common central metabolic intermediates into 14-BDO and GBL. The first three digits of each label correspond to the first three Enzyme Commission number digits which denote the general type of transformation independent of substrate specificity.
1.1.1.a Oxidoreductase (Oxo to Alcohol)
Aldehyde to Alcohol.
Three transformations described in
Acinetobacter sp. Strain M-1
Saccharymyces cerevisiae
Escherichia coli
Clostridium acetobutylicum
Clostridium acetobutylicum
Enzymes exhibiting 4-hydroxybutyrate dehydrogenase activity (EC 1.1.1.61) also fall into this category. Such enzymes have been characterized in Ralstonia eutropha (Bravo et al. J. Forensic Sci. 49:379-387 (2004), Clostridium kluyveri (Wolff et al. Protein Expr. Purif. 6:206-212 (1995)) and Arabidopsis thaliana (Breitkreuz et al. J. Biol. Chem. 278:41552-41556 (2003)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 7.
Ralstonia eutropha H16
Clostridium kluyveri DSM 555
Arabidopsis thaliana
The adh1 gene from Geobacillus thermoglucosidasius M10EXG (Jeon et al., J Biotechnol 135:127-133 (2008)) was shown to exhibit high activity on both 4-hydroxybutanal and butanal as shown in Example VIII. Thus this enzyme exhibits 1,4-butanediol dehydrogenase activity. The protein sequence for the exemplary gene product, if available, can be found using the following GenBank accession numbers shown in Table 8.
Geobacillus thermoglucosidasius
Another exemplary enzyme is 3-hydroxyisobutyrate dehydrogenase which catalyzes the reversible oxidation of 3-hydroxyisobutyrate to methylmalonate semialdehyde. This enzyme participates in valine, leucine and isoleucine degradation and has been identified in bacteria, eukaryotes, and mammals. The enzyme encoded by P84067 from Thermus thermophilus HB8 has been structurally characterized (Lokanath et al. J Mol Biol 352:905-17 (2005)). The reversibility of the human 3-hydroxyisobutyrate dehydrogenase was demonstrated using isotopically-labeled substrate (Manning et al. Biochem J 231:481-484 (1985)). Additional genes encoding this enzyme include 3hidh in Homo sapiens (Hawes et al. Methods Enzymol. 324:218-228 (2000)) and Oryctolagus cuniculus (Chowdhury et al. Biosci. Biotechnol Biochem. 60:2043-2047 (1996); Hawes et al. Methods Enzymol. 324:218-228 (2000)), mmsb in Pseudomonas aeruginosa, and dhat in Pseudomonas putida (Aberhart et al. J. Chem. Soc. [Perkin 1] 6:1404-1406 (1979); Chowdhury et al. Biosci. Biotechnol Biochem. 67:438-441 (2003); Chowdhury et al. Biosci. Biotechnol Biochem. 60:2043-2047 (1996)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 9.
Thermus thermophilus
Pseudomonas aeruginosa
Pseudomonas putida
Homo sapiens
Oryctolagus cuniculus
Several 3-hydroxyisobutyrate dehydrogenase enzymes have also been shown to convert malonic semialdehyde to 3-hydroxyproprionic acid (3-HP). Three gene candidates exhibiting this activity are mmsB from Pseudomonas aeruginosa PAO1(62), mmsB from Pseudomonas putida KT2440 (Liao et al., US Publication 2005/0221466) and mmsB from Pseudomonas putida E23 (Chowdhury et al., Biosci. Biotechnol. Biochem. 60:2043-2047 (1996)). An enzyme with 3-hydroxybutyrate dehydrogenase activity in Alcaligenes faecalis M3A has also been identified (Gokam et al., U.S. Pat. No. 7,393,676; Liao et al., US Publication No. 2005/0221466). Additional gene candidates from other organisms including Rhodobacter spaeroides can be inferred by sequence similarity. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 10.
Pseudomonas aeruginosa
Pseudomonas aeruginosa PAO1
Pseudomonas putida KT2440
Pseudomonas putida E23
Rhodobacter spaeroides
The conversion of malonic semialdehyde to 3-HP can also be accomplished by two other enzymes: NADH-dependent 3-hydroxypropionate dehydrogenase and NADPH-dependent malonate semialdehyde reductase. An NADH-dependent 3-hydroxypropionate dehydrogenase is thought to participate in beta-alanine biosynthesis pathways from propionate in bacteria and plants (Rathinasabapathi, B. Journal of Plant Pathology 159:671-674 (2002); Stadtman, E. R. J. Am. Chem. Soc. 77:5765-5766 (1955)). This enzyme has not been associated with a gene in any organism to date. NADPH-dependent malonate semialdehyde reductase catalyzes the reverse reaction in autotrophic CO2-fixing bacteria. Although the enzyme activity has been detected in Metallosphaera sedula, the identity of the gene is not known (Alber et al. J. Bacteriol. 188:8551-8559 (2006)).
1.1.1.c Oxidoreductase (2 Step, Acyl-CoA to Alcohol)
Steps S and W of
Escherichia coli
Clostridium acetobutylicum
Leuconostoc mesenteroides
Another exemplary enzyme can convert malonyl-CoA to 3-HP. An NADPH-dependent enzyme with this activity has characterized in Chloroflexus aurantiacus where it participates in the 3-hydroxypropionate cycle (Hugler et al., J. Bacteriol. 184:2404-2410 (2002); Strauss and Fuchs, Eur. J. Biochem. 215:633-643 (1993)). This enzyme, with a mass of 300 kDa, is highly substrate-specific and shows little sequence similarity to other known oxidoreductases (Hugler et al., J. Bacteriol. 184:2404-2410 (2002)). No enzymes in other organisms have been shown to catalyze this specific reaction; however there is bioinformatic evidence that other organisms may have similar pathways (Klatt et al., Environ. Microbiol. 9:2067-2078 (2007)). Enzyme candidates in other organisms including Roseiflexus castenholzii, Erythrobacter sp. NAP1 and marine gamma proteobacterium HTCC2080 can be inferred by sequence similarity. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 12.
Chloroflexus aurantiacus
Roseiflexus castenholzii
Erythrobacter sp. NAP1
Longer chain acyl-CoA molecules can be reduced by enzymes such as the jojoba (Simmondsia chinensis) FAR which encodes an alcohol-forming fatty acyl-CoA reductase. Its overexpression in E. coli resulted in FAR activity and the accumulation of fatty alcohol (Metz et al. Plant Physiology 122:635-644) 2000)). The protein sequence for the exemplary gene product, if available, can be found using the following GenBank accession numbers shown in Table 13.
Simmondsia chinensis
1.2.1.b Oxidoreductase (Acyl-CoA to Aldehyde)
Step A of
Acinetobacter calcoaceticus
Acinetobacter baylyi
Acinetobacter sp. Strain M-1
Clostridium kluyveri
Porphyromonas gingivalis
Pseudomonas sp
Leuconostoc mesenteroides
Clostridium
saccharoperbutylacetonicum
An additional enzyme type that converts an acyl-CoA to its corresponding aldehyde is malonyl-CoA reductase which transforms malonyl-CoA to malonic semialdehyde. Malonyl-CoA reductase is a key enzyme in autotrophic carbon fixation via the 3-hydroxypropionate cycle in thermoacidophilic archael bacteria (Berg et al. Science 318:1782-1786 (2007); Thauer, R. K. Science 318:1732-1733 (2007)). The enzyme utilizes NADPH as a cofactor and has been characterized in Metallosphaera and Sulfolobus spp (Alber et al. J. Bacteriol. 188:8551-8559 (2006); Hugler et al. J. Bacteriol. 184:2404-2410 (2002)). The enzyme is encoded by Msed—0709 in Metallosphaera sedula (Alber et al. J. Bacteriol. 188:8551-8559 (2006); Berg et al. Science 318:1782-1786 (2007)). A gene encoding a malonyl-CoA reductase from Sulfolobus tokodaii was cloned and heterologously expressed in E. coli (Alber et al. J. Bacteriol. 188:8551-8559 (2006)). Although the aldehyde dehydrogenase functionality of these enzymes is similar to the bifunctional dehydrogenase from Chloroflexus aurantiacus, there is little sequence similarity. Both malonyl-CoA reductase enzyme candidates have high sequence similarity to aspartate-semialdehyde dehydrogenase, an enzyme catalyzing the reduction and concurrent dephosphorylation of aspartyl-4-phosphate to aspartate semialdehyde. Additional gene candidates can be found by sequence homology to proteins in other organisms including Sulfolobus solfataricus and Sulfolobus acidocaldarius. Yet another candidate for CoA-acylating aldehyde dehydrogenase is the ald gene from Clostridium beijerinckii (Toth et al., Appl Environ. Microbiol 65:4973-4980 (1999)). This enzyme has been reported to reduce acetyl-CoA and butyryl-CoA to their corresponding aldehydes. This gene is very similar to eutE that encodes acetaldehyde dehydrogenase of Salmonella typhimurium and E. coli (Toth et al., Appl Environ. Microbiol 65:4973-4980 (1999)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 15.
Metallosphaera sedula
Sulfolobus tokodaii
Sulfolobus solfataricus
Sulfolobus
acidocaldarius
Clostridium beijerinckii
Salmonella typhimurium
Escherichia coli
1.2.1.c Oxidoreductase (2-Oxo Acid to Acyl-CoA, Decarboxylation).
Step AA in
Activity of enzymes in the 2-keto-acid dehydrogenase family is normally low or limited under anaerobic conditions in E. coli. Increased production of NADH (or NADPH) could lead to a redox-imbalance, and NADH itself serves as an inhibitor to enzyme function. Engineering efforts have increased the anaerobic activity of the E. coli pyruvate dehydrogenase complex (Kim et al. Appl. Environ. Microbiol. 73:1766-1771 (2007); Kim et al. J. Bacteriol. 190:3851-3858) 2008); Zhou et al. Biotechnol. Lett. 30:335-342 (2008)). For example, the inhibitory effect of NADH can be overcome by engineering an H322Y mutation in the E3 component (Kim et al. J. Bacteriol. 190:3851-3858 (2008)). Structural studies of individual components and how they work together in complex provide insight into the catalytic mechanisms and architecture of enzymes in this family (Aevarsson et al. Nat. Struct. Biol. 6:785-792 (1999); Zhou et al. Proc. Natl. Acad. Sci. U.S.A. 98:14802-14807 (2001)). The substrate specificity of the dehydrogenase complexes varies in different organisms, but generally branched-chain ketoacid dehydrogenases have the broadest substrate range.
Alpha-ketoglutarate dehydrogenase (AKGD) converts alpha-ketoglutarate to succinyl-CoA and is the primary site of control of metabolic flux through the TCA cycle (Hansford, R. G. Curr. Top. Bioenerg. 10:217-278 (1980)). Encoded by genes sucA, sucB and lpd in E. coli, AKGD gene expression is downregulated under anaerobic conditions and during growth on glucose (Park et al. Mol. Microbiol. 15:473-482 (1995)). Structural studies of the catalytic core of the E2 component pinpoint specific residues responsible for substrate specificity (Knapp et al. J. Mol. Biol. 280:655-668 (1998)). The Bacillus subtilis AKGD, encoded by odhAB (E1 and E2) and pdhD (E3, shared domain), is regulated at the transcriptional level and is dependent on the carbon source and growth phase of the organism (Resnekov et al. Mol. Gen. Genet. 234:285-296 (1992)). In yeast, the LPD1 gene encoding the E3 component is regulated at the transcriptional level by glucose (Roy and Dawes J. Gen. Microbiol. 133:925-933 (1987)). The E1 component, encoded by KGD1, is also regulated by glucose and activated by the products of HAP2 and HAP3 (Repetto and Tzagoloff Mol. Cell Biol. 9:2695-2705 (1989)). The AKGD enzyme complex, inhibited by products NADH and succinyl-CoA, is well-studied in mammalian systems, as impaired function of has been linked to several neurological diseases (Tretter and dam-Vizi Philos. Trans. R. Soc. Lond B Biol. Sci. 360:2335-2345 (2005)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 16.
Escherichia coli str. K12
Escherichia coli str. K12
Escherichia coli str. K12
Bacillus subtilis
Bacillus subtilis
Bacillus subtilis
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Branched-chain 2-keto-acid dehydrogenase complex (BCKAD), also known as 2-oxoisovalerate dehydrogenase, participates in branched-chain amino acid degradation pathways, converting 2-keto acids derivatives of valine, leucine and isoleucine to their acyl-CoA derivatives and CO2. The complex has been studied in many organisms including Bacillus subtilis (Wang et al. Eur. J. Biochem. 213:1091-1099 (1993)), Rattus norvegicus (Namba et al. J. Biol. Chem. 244:4437-4447 (1969)) and Pseudomonas putida (Sokatch J. Bacteriol. 148:647-652 (1981)). In Bacillus subtilis the enzyme is encoded by genes pdhD (E3 component), bfmBB (E2 component), bfmBAA and bfmBAB (E1 component) (Wang et al. Eur. J. Biochem. 213:1091-1099 (1993)). In mammals, the complex is regulated by phosphorylation by specific phosphatases and protein kinases. The complex has been studied in rat hepatocites (Chicco et al. J. Biol. Chem. 269:19427-19434 (1994)) and is encoded by genes Bckdha (E1 alpha), Bckdhb (E1 beta), Dbt (E2), and Dld (E3). The E1 and E3 components of the Pseudomonas putida BCKAD complex have been crystallized (Aevarsson et al. Nat. Struct. Biol. 6:785-792 (1999); Mattevi Science 255:1544-1550 (1992)) and the enzyme complex has been studied (Sokatch et al. J. Bacteriol. 148:647-652 (1981)). Transcription of the P. putida BCKAD genes is activated by the gene product of bkdR (Hester et al. Eur. J. Biochem. 233:828-836 (1995)). In some organisms including Rattus norvegicus (Paxton et al. Biochem. J. 234:295-303 (1986)) and Saccharomyces cerevisiae (Sinclair et al. Biochem. Mol. Biol. Int. 31:911-922 (1993)), this complex has been shown to have a broad substrate range that includes linear oxo-acids such as 2-oxobutanoate and alpha-ketoglutarate, in addition to the branched-chain amino acid precursors. The active site of the bovine BCKAD was engineered to favor alternate substrate acetyl-CoA (Meng and Chuang, Biochemistry 33:12879-12885 (1994)) The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 17.
Bacillus subtilis
Bacillus subtilis
Bacillus subtilis
Bacillus subtilis
Pseudomonas putida
Pseudomonas putida
Pseudomonas putida
Pseudomonas putida
Rattus norvegicus
Rattus norvegicus
Rattus norvegicus
Rattus norvegicus
The pyruvate dehydrogenase complex, catalyzing the conversion of pyruvate to acetyl-CoA, has also been extensively studied. In the E. coli enzyme, specific residues in the E1 component are responsible for substrate specificity (Bisswanger, H. J Biol. Chem. 256:815-822 (1981); Bremer, J. Eur. J Biochem. 8:535-540 (1969); Gong et al. J Biol. Chem. 275:13645-13653 (2000)). As mentioned previously, enzyme engineering efforts have improved the E. coli PDH enzyme activity under anaerobic conditions (Kim et al. Appl. Environ. Microbiol. 73:1766-1771 (2007); Kim J. Bacteriol. 190:3851-3858 (2008); Zhou et al. Biotechnol. Lett. 30:335-342 (2008)). In contrast to the E. coli PDH, the B. subtilis complex is active and required for growth under anaerobic conditions (Nakano J. Bacteriol. 179:6749-6755 (1997)). The Klebsiella pneumoniae PDH, characterized during growth on glycerol, is also active under anaerobic conditions (Menzel et al. J. Biotechnol. 56:135-142 (1997)). Crystal structures of the enzyme complex from bovine kidney (Zhou et al. Proc. Natl. Acad. Sci. U.S.A. 98:14802-14807 (2001)) and the E2 catalytic domain from Azotobacter vinelandii are available (Mattevi et al. Science 255:1544-1550 (1992)). Some mammalian PDH enzymes complexes can react on alternate substrates such as 2-oxobutanoate, although comparative kinetics of Rattus norvegicus PDH and BCKAD indicate that BCKAD has higher activity on 2-oxobutanoate as a substrate (Paxton et al. Biochem. J. 234:295-303 (1986)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 18.
Escherichia coli str. K12
Escherichia coli str. K12
Escherichia coli str. K12
Bacillus subtilis
Bacillus subtilis
Bacillus subtilis
Bacillus subtilis
Klebsiella pneumonia
Klebsiella pneumonia
Klebsiella pneumonia
Rattus norvegicus
Rattus norvegicus
Rattus norvegicus
Rattus norvegicus
As an alternative to the large multienzyme 2-keto-acid dehydrogenase complexes described above, some anaerobic organisms utilize enzymes in the 2-ketoacid oxidoreductase family (OFOR) to catalyze acylating oxidative decarboxylation of 2-keto-acids. Unlike the dehydrogenase complexes, these enzymes contain iron-sulfur clusters, utilize different cofactors, and use ferredoxin or flavodixin as electron acceptors in lieu of NAD(P)H. While most enzymes in this family are specific to pyruvate as a substrate (POR) some 2-keto-acid:ferredoxin oxidoreductases have been shown to accept a broad range of 2-ketoacids as substrates including alpha-ketoglutarate and 2-oxobutanoate (Fukuda and Wakagi Biochim. Biophys. Acta 1597:74-80 (2002); Zhang et al. J. Biochem. 120:587-599 (1996)). One such enzyme is the OFOR from the thermoacidophilic archaeon Sulfolobus tokodaii 7, which contains an alpha and beta subunit encoded by gene ST2300 (Fukuda and Wakagi Biochim. Biophys. Acta 1597:74-80 (2002); Zhang et al. J. Biochem. 120:587-599 (1996)). A plasmid-based expression system has been developed for efficiently expressing this protein in E. coli (Fukuda et al. Eur. J. Biochem. 268:5639-5646 (2001)) and residues involved in substrate specificity were determined (Fukuda and Wakagi Biochim. Biophys. Acta 1597:74-80 (2002)). Two OFORs from Aeropyrum pernix str. K1 have also been recently cloned into E. coli, characterized, and found to react with a broad range of 2-oxoacids (Nishizawa et al. FEBS Lett. 579:2319-2322 (2005)). The gene sequences of these OFOR candidates are available, although they do not have GenBank identifiers assigned to date. There is bioinformatic evidence that similar enzymes are present in all archaea, some anaerobic bacteria and amitochondrial eukarya (Fukuda and Wakagi Biochim. Biophys. Acta 1597:74-80 (2005)). This class of enzyme is also interesting from an energetic standpoint, as reduced ferredoxin could be used to generate NADH by ferredoxin-NAD reductase (Petitdemange et al. Biochim. Biophys. Acta 421:334-337 (1976)). Also, since most of the enzymes are designed to operate under anaerobic conditions, less enzyme engineering may be required relative to enzymes in the 2-keto-acid dehydrogenase complex family for activity in an anaerobic environment. The protein sequence for the exemplary gene product, if available, can be found using the following GenBank accession numbers shown in Table 19.
Sulfolobus tokodaii 7
1.2.1.d Oxidoreductase (Phosphonate Reductase)
The conversion of 4-hydroxybutyryl-phosphate to 4-hydroxybutanal (Step R) can be catalyzed by an oxidoreductase in the EC class 1.2.1. Aspartate semialdehyde dehydrogenase (ASD, EC 1.2.1.11) catalyzes the NADPH-dependent reduction of 4-aspartyl phosphate to aspartate-4-semialdehyde. ASD participates in amino acid biosynthesis and recently has been studied as an antimicrobial target (Hadfield et al., 40:14475-14483 (2001)). The E. coli ASD structure has been solved (Hadfield et al., 289:991-1002 (1999)) and the enzyme has been shown to accept the alternate substrate beta-3-methylaspartyl phosphate (Shames et al., 259:15331-15339 (1984)). The Haemophilus influenzae enzyme has been the subject of enzyme engineering studies to alter substrate binding affinities at the active site (Blanco et al., Acta Crystallogr. D. Biol. Crystallogr. 60:1388-1395 (2004); Blanco et al., Acta Crystallogr. D. Biol. Crystallogr. 60:1808-1815 (2004)). Other ASD candidates are found in Mycobacterium tuberculosis (Shafiani et al., J Appl Microbiol 98:832-838 (2005)), Methanococcus jannaschii (Faehnle et al., 353:1055-1068 (2005)), and the infectious microorganisms Vibrio cholera and Heliobacter pylori (Moore et al., Protein Expr. Purif. 25:189-194 (2002)). A related enzyme candidate is acetylglutamylphosphate reductase (EC 1.2.1.38), an enzyme that naturally reduces acetylglutamylphosphate to acetylglutamate-5-semialdehyde, found in S. cerevisiae (Pauwels et al., Eur. J. Biochem. 270:1014-1024 (2003)), B. subtilis (O'Reilly et al., 140 (Pt 5):1023-1025 (1994)) and other organisms. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 20.
Escherichia coli
Haemophilus influenzae
Mycobacterium
tuberculosis
Vibrio cholera
Heliobacter pylori
Saccharomyces cerevisiae
Bacillus subtilis
Other exemplary enzymes in this class include glyceraldehyde 3-phosphate dehydrogenase which converts glyceraldehyde-3-phosphate into D-glycerate 1,3-bisphosphate (e.g., E. coli gapA (Branlant et al., Eur. J. Biochem. 150:61-66 (1985))), N-acetyl-gamma-glutamyl-phosphate reductase which converts N-acetyl-L-glutamate-5-semialdehyde into N-acetyl-L-glutamyl-5-phosphate (e.g., E. coli argC (Parsot et al., Gene. 68:275-283 (1988))), and glutamate-5-semialdehyde dehydrogenase which converts L-glutamate-5-semialdehyde into L-glutamyl-5-phosphate (e.g., E. coli proA (Smith et al., J. Bacteriol. 157:545-551 (1984a))). Genes encoding glutamate-5-semialdehyde dehydrogenase enzymes from Salmonella typhimurium (Mahan et al., J Bacteriol. 156:1249-1262 (1983)) and Campylobacter jejuni (Louie et al., 240:29-35 (1993)) were cloned and expressed in E. coli. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 21.
Escherichia coli
Escherichia coli
Escherichia coli
Salmonella typhimurium
Campylobacter jejuni
1.2.1.e Acid Reductase
Several steps in
Nocardia iowensis
Nocardia iowensis
Additional car and npt genes can be identified based on sequence homology. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 23.
Mycobacterium bovis
Mycobacterium bovis
Nocardia farcinica IFM
Nocardia farcinica IFM
Streptomyces griseus
Streptomyces griseus
An additional enzyme candidate found in Streptomyces griseus is encoded by the griC and griD genes. This enzyme is believed to convert 3-amino-4-hydroxybenzoic acid to 3-amino-4-hydroxybenzaldehyde as deletion of either griC or griD led to accumulation of extracellular 3-acetylamino-4-hydroxybenzoic acid, a shunt product of 3-amino-4-hydroxybenzoic acid metabolism (Suzuki, et al., J. Antibiot. 60(6):380-387 (2007)). Co-expression of griC and griD with SGR—665, an enzyme similar in sequence to the Nocardia iowensis npt, may be beneficial. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 24.
Streptomyces griseus subsp.
griseus NBRC 13350
Streptomyces griseus subsp.
griseus NBRC 13350
An enzyme with similar characteristics, alpha-aminoadipate reductase (AAR, EC 1.2.1.31), participates in lysine biosynthesis pathways in some fungal species. This enzyme naturally reduces alpha-aminoadipate to alpha-aminoadipate semialdehyde. The carboxyl group is first activated through the ATP-dependent formation of an adenylate that is then reduced by NAD(P)H to yield the aldehyde and AMP. Like CAR, this enzyme utilizes magnesium and requires activation by a PPTase. Enzyme candidates for AAR and its corresponding PPTase are found in Saccharomyces cerevisiae (Morris et al., Gene 98:141-145 (1991)), Candida albicans (Guo et al., Mol. Genet. Genomics 269:271-279 (2003)), and Schizosaccharomyces pombe (Ford et al., Curr. Genet. 28:131-137 (1995)). The AAR from S. pombe exhibited significant activity when expressed in E. coli (Guo et al., Yeast 21:1279-1288 (2004)). The AAR from Penicillium chrysogenum accepts S-carboxymethyl-L-cysteine as an alternate substrate, but did not react with adipate, L-glutamate or diaminopimelate (Hijarrubia et al., J. Biol. Chem. 278:8250-8256 (2003)). The gene encoding the P. chrysogenum PPTase has not been identified to date and no high-confidence hits were identified by sequence comparison homology searching. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 25.
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Candida albicans
Candida albicans
Schizosaccharomyces pombe
Schizosaccharomyces pombe
Penicillium chrysogenum
1.4.1.a Oxidoreductase (Aminating)
Glutamate dehydrogenase (Step J,
Escherichia coli
Thermotoga maritima
Halobacterium salinarum
Bacillus cereus
Thermotoga maritima
Additional glutamate dehydrogenase gene candidates are found in Bacillus subtilis (Khan et al., Biosci. Biotechnol Biochem. 69:1861-1870 (2005)), Nicotiana tabacum (Purnell et al., Planta 222:167-180 (2005)), Oryza sativa (Abiko et al., Plant Cell Physiol 46:1724-1734 (2005)), Haloferax mediterranei (Diaz et al., Extremophiles. 10:105-115 (2006)) and Halobactreium salinarum (Hayden et al., FEMS Microbiol Lett. 211:37-41 (2002)). The Nicotiana tabacum enzyme is composed of alpha and beta subunits encoded by gdh1 and gdh2 (Purnell et al., Planta 222:167-180 (2005)). Overexpression of the NADH-dependent glutamate dehydrogenase was found to improve ethanol production in engineered strains of S. cerevisiae (Roca et al., Appl Environ. Microbiol 69:4732-4736 (2003)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 27.
Bacillus subtilis
Nicotiana tabacum
Nicotiana tabacum
Oryza sativa
Haloferax mediterranei
Halobactreium salinarum
Saccharomyces cerevisiae
An exemplary enzyme for catalyzing the conversion of aldehydes to their corresponding primary amines is lysine 6-dehydrogenase (EC 1.4.1.18), encoded by the lysDH genes. The lysine 6-dehydrogenase (deaminating), encoded by lysDH gene, catalyze the oxidative deamination of the ε-amino group of L-lysine to form 2-aminoadipate-6-semialdehyde, which in turn nonenzymatically cyclizes to form Δ1-piperidine-6-carboxylate (Misono and Nagasaki J. Bacteriol. 150:398-401 (1982)). The lysDH gene from Geobacillus stearothermophilus encodes a thermophilic NAD-dependent lysine 6-dehydrogenase (Heydari et al. Appl Environ. Microbiol 70:937-942 (2004)). The lysDH gene from Aeropyrum pernix K1 is identified through homology from genome projects. Additional enzymes can be found in Agrobacterium tumefaciens (Hashimoto et al., J. Biochem. 106:76-80 (1989); Misono et al., J. Bacteriol. 150:398-401 (1982)) and Achromobacter denitrificans (Ruldeekulthamrong et al., BMB. Rep. 41:790-795 (2008)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 28.
Geobacillus stearothermophilus
Aeropyrum pernix K1
Agrobacterium tumefaciens
Achromobacter denitrificans
An enzyme that converts 3-oxoacids to 3-amino acids is 3,5-diaminohexanoate dehydrogenase (EC 1.4.1.11), an enzyme found in organisms that ferment lysine. The gene encoding this enzyme, kdd, was recently identified in Fusobacterium nucleatum (Kreimeyer et al., 282:7191-7197 (2007)). The enzyme has been purified and characterized in other organisms (Baker et al., 247:7724-7734 (1972); Baker et al., 13:292-299 (1974)) but the genes associated with these enzymes are not known. Candidates in Myxococcus xanthus, Porphyromonas gingivalis W83 and other sequenced organisms can be inferred by sequence homology. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 29.
Fusobacterium nucleatum
Myxococcus xanthus
Porphyromonas gingivalis
2.3.1.a Acyltransferase (Transferring Phosphate Group to CoA)
Step P of
Escherichia coli
Clostridium acetobutylicum
Bacillus megaterium
2.6.1.a Aminotransferase
Steps K and N in
Flavobacterium lutescens
Streptomyces clavuligenus
Acinetobacter baumanii
The conversion of an aldehyde to a terminal amine can also be catalyzed by gamma-aminobutyrate transaminase (GABA transaminase or 4-aminobutyrate transaminase). This enzyme naturally interconverts succinic semialdehyde and glutamate to 4-aminobutyrate and alpha-ketoglutarate and is known to have a broad substrate range (Schulz et al., 56:1-6 (1990); Liu et al., 43:10896-10905 (2004)). The two GABA transaminases in E. coli are encoded by gabT (Bartsch et al., J. Bacteriol. 172:7035-7042 (1990)) and puuE (Kurihara et al., J. Biol. Chem. 280:4602-4608 (2005)). GABA transaminases in Mus musculus, Pseudomonas fluorescens, and Sus scrofa have been shown to react with a range of alternate substrates including 6-aminocaproic acid (Cooper, 113:80-82 (1985); SCOTT et al., 234:932-936 (1959)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 32.
Escherichia coli
Escherichia coli
Mus musculus
Pseudomonas fluorescens
Sus scrofa
Additional enzyme candidates for interconverting aldehydes and primary amines are putrescine transminases or other diamine aminotransferases. The E. coli putrescine aminotransferase is encoded by the ygjG gene and the purified enzyme also was able to transaminate cadaverine and spermidine (Samsonova et al., BMC. Microbiol 3:2 (2003)). In addition, activity of this enzyme on 1,7-diaminoheptane and with amino acceptors other than 2-oxoglutarate (e.g., pyruvate, 2-oxobutanoate) has been reported (Samsonova et al., BMC. Microbiol 3:2 (2003); KIM, 239:783-786 (1964)). A putrescine aminotransferase with higher activity with pyruvate as the amino acceptor than alpha-ketoglutarate is the spuC gene of Pseudomonas aeruginosa (Lu et al., J Bacteriol. 184:3765-3773 (2002)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 33.
Escherichia coli
Pseudomonas aeruginosa
Enzymes that transaminate 3-oxoacids include GABA aminotransferase (described above), beta-alanine/alpha-ketoglutarate aminotransferase and 3-amino-2-methylpropionate aminotransferase. Beta-alanine/alpha-ketoglutarate aminotransferase (WO08027742) reacts with beta-alanine to form malonic semialdehyde, a 3-oxoacid. The gene product of SkPYD4 in Saccharomyces kluyveri was shown to preferentially use beta-alanine as the amino group donor (Andersen et al., Gene 124:105-109 (1993)). SkUGA1 encodes a homologue of Saccharomyces cerevisiae GABA aminotransferase, UGA1 (Ramos et al., Eur. J. Biochem. 149:401-404 (1985)), whereas SkPYD4 encodes an enzyme involved in both beta-alanine and GABA transamination (Andersen and Hansen, Gene 124:105-109 (1993)). 3-Amino-2-methylpropionate transaminase catalyzes the transformation from methylmalonate semialdehyde to 3-amino-2-methylpropionate. The enzyme has been characterized in Rattus norvegicus and Sus scrofa and is encoded by Abat (Tamaki et al., 324:376-389 (2000); Kakimoto et al., 156:374-380 (1968)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 34.
Lachancea kluyveri
Lachancea kluyveri
Saccharomyces cerevisiae
Rattus norvegicus
Sus scrofa
Several aminotransferases transaminate the amino groups of amino acids to form 2-oxoacids. Aspartate aminotransferase is an enzyme that naturally transfers an oxo group from oxaloacetate to glutamate, forming alpha-ketoglutarate and aspartate. Aspartate is similar in structure to OHED and 2-AHD. Aspartate aminotransferase activity is catalyzed by, for example, the gene products of aspC from Escherichia coli (Yagi et al., 100:81-84 (1979); Yagi et al., 113:83-89 (1985)), AAT2 from Saccharomyces cerevisiae (Yagi et al., 92:35-43 (1982)) and ASP5 from Arabidopsis thaliana (Kwok et al., 55:595-604 (2004); de la et al., 46:414-425 (2006); Wilkie et al., Protein Expr. Purif. 12:381-389 (1998)). The enzyme from Rattus norvegicus has been shown to transaminate alternate substrates such as 2-aminohexanedioic acid and 2,4-diaminobutyric acid (Recasens et al., 19:4583-4589 (1980)). Aminotransferases that work on other amino-acid substrates may also be able to catalyze this transformation. Valine aminotransferase catalyzes the conversion of valine and pyruvate to 2-ketoisovalerate and alanine. The E. coli gene, avtA, encodes one such enzyme (Whalen et al., J. Bacteriol. 150:739-746 (1982)). This gene product also catalyzes the transamination of alpha-ketobutyrate to generate α-aminobutyrate, although the amine donor in this reaction has not been identified (Whalen et al., J. Bacteriol. 158:571-574 (1984)). The gene product of the E. coli serC catalyzes two reactions, phosphoserine aminotransferase and phosphohydroxythreonine aminotransferase (Lam et al., J. Bacteriol. 172:6518-6528 (1990)), and activity on non-phosphorylated substrates could not be detected (Drewke et al., FEBS. Lett. 390:179-182 (1996)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 35.
Escherichia coli
Saccharomyces cerevisiae
Arabidopsis thaliana
Rattus norvegicus
Escherichia coli
Escherichia coli
Another enzyme candidate is alpha-aminoadipate aminotransferase (EC 2.6.1.39), an enzyme that participates in lysine biosynthesis and degradation in some organisms. This enzyme interconverts 2-aminoadipate and 2-oxoadipate, using alpha-ketoglutarate as the amino acceptor. Gene candidates are found in Homo sapiens (Okuno et al., Enzyme Protein 47:136-148 (1993)) and Thermus thermophilus (Miyazaki et al., 150:2327-2334 (2004)). The Thermus thermophilus enzyme, encoded by lysN, is active with several alternate substrates including oxaloacetate, 2-oxoisocaproate, 2-oxoisovalerate, and 2-oxo-3-methylvalerate. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 36.
Thermus thermophilus
Homo sapiens
2.7.2.a Phosphotransferase (Carboxy Acceptor)
Step O of
Clostridium acetobutylicum
Clostridium acetobutylicum
Thermotoga maritima
Escherichia coli
Escherichia coli
Escherichia coli
Acetylglutamate kinase phosphorylates acetylated glutamate during arginine biosynthesis. This enzyme is not known to accept alternate substrates; however, several residues of the E. coli enzyme involved in substrate binding and phosphorylation have been elucidated by site-directed mutagenesis (Marco-Marin et al., 334:459-476 (2003); Ramon-Maiques et al., Structure. 10:329-342 (2002)). The enzyme is encoded by argB in Bacillus subtilis and E. coli (Parsot et al., Gene 68:275-283 (1988)), and ARG5,6 in S. cerevisiae (Pauwels et al., Eur. J Biochem. 270:1014-1024 (2003)). The ARG5,6 gene of S. cerevisiae encodes a polyprotein precursor that is matured in the mitochondrial matrix to become acetylglutamate kinase and acetylglutamylphosphate reductase. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 38.
Escherichia coli
Bacillus subtilis
Saccharomyces cerevisiae
2.8.3.a CoA Transferase
Steps G and T in
Clostridium kluyveri
Clostridium kluyveri
Clostridium kluyveri
Trichomonas
vaginalis G3
Trypanosoma brucei
An additionally useful enzyme for this type of transformation is acyl-CoA:acetate-CoA transferase, also known as acetate-CoA transferase (EC 2.8.3.8), which has been shown to transfer the CoA moiety to acetate from a variety of branched and linear acyl-CoA substrates, including isobutyrate (Matthies and Schink Appl Environ Microbiol 58:1435-1439 (1992)), valerate (Vanderwinkel et al. Biochem. Biophys. Res Commun. 33:902-908 (1968)) and butanoate (Vanderwinkel, supra (1968)). This enzyme is encoded by atoA (alpha subunit) and atoD (beta subunit) in E. coli sp. K12 (Korolev et al. Acta Crystallogr. D Biol Crystallogr. 58:2116-2121 (2002); Vanderwinkel, supra (1968)). Similar enzymes exist in Corynebacterium glutamicum ATCC 13032 (Duncan et al., 68:5186-5190 (2002)), Clostridium saccharoperbutylacetonicum (Kosaka et al., Biosci. Biotechnol Biochem. 71:58-68 (2007)), and Clostridium acetobutylicum (Cary et al., 56:1576-1583 (1990); Wiesenborn et al., 55:323-329 (1989)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 40.
Escherichia coli K12
Escherichia coli K12
Corynebacterium glutamicum
Corynebacterium glutamicum
Clostridium acetobutylicum
Clostridium acetobutylicum
Clostridium
saccharoperbutylacetonicum
Clostridium
saccharoperbutylacetonicum
The glutaconate-CoA-transferase (EC 2.8.3.12) enzyme from anaerobic bacterium Acidaminococcus fermentans reacts with diacid glutaconyl-CoA and 3-butenoyl-CoA (Mack and Buckel FEBS Lett. 405:209-212 (1997)). The genes encoding this enzyme are gctA and gctB. This enzyme has reduced but detectable activity with other CoA derivatives including glutaryl-CoA, 2-hydroxyglutaryl-CoA, adipyl-CoA and acrylyl-CoA (Buckel et al. Eur. J. Biochem. 118:315-321 (1981)). The enzyme has been cloned and expressed in E. coli (Mac et al. Eur. J. Biochem. 226:41-51 (1994)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 41.
Acidaminococcus fermentans
Acidaminococcus fermentans
3.1.1.a Hydroxyacylhydrolase
Step AB in
Xanthomonas
campestris
Aspergillus niger
Fusarium oxysporum
Additionally, it has been reported that lipases such as Candida antarctica lipase B can catalyze the lactonization of 4-hydroxybutyrate to GBL (Efe et al., Biotechnol Bioeng 99:1392-1406 (2008)). Therefore, the following genes coding for lipases can also be utilized for Step AB in
Candida antarctica
Pseudomonas fluorescens
Bacillus subtilis
3.1.2.a CoA Hydrolase
Steps H and U in
Rattus norvegicus
Saccharomyces cerevisiae
Another candidate hydrolase is the human dicarboxylic acid thioesterase, acot8, which exhibits activity on glutaryl-CoA, adipyl-CoA, suberyl-CoA, sebacyl-CoA, and dodecanedioyl-CoA (Westin et al., 280:38125-38132 (2005)) and the closest E. coli homolog, tesB, which can also hydrolyze a broad range of CoA thioesters (Naggert et al., 266:11044-11050 (1991)). A similar enzyme has also been characterized in the rat liver (Deana, Biochem. Int. 26:767-773 (1992)). Other potential E. coli thioester hydrolases include the gene products of tesA (Bonner et al., 247:3123-3133 (1972)), ybgC (Kuznetsova et al., FEMS Microbiol Rev 29:263-279 (2005); Zhuang et al., 516:161-163 (2002)), paaI (Song et al., 281:11028-11038 (2006)), and ybdB (Leduc et al., J. Bacteriol. 189:7112-7126 (2007)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 45.
Homo sapiens
Escherichia coli
Rattus norvegicus
Escherichia coli
Escherichia coli
Escherichia coli
Escherichia coli
Yet another candidate hydrolase is the glutaconate CoA-transferase from Acidaminococcus fermentans. This enzyme was transformed by site-directed mutagenesis into an acyl-CoA hydrolase with activity on glutaryl-CoA, acetyl-CoA and 3-butenoyl-CoA (Mack et al., FEBS. Lett. 405:209-212 (1997)). This suggests that the enzymes encoding succinyl-CoA:3-ketoacid-CoA transferases and acetoacetyl-CoA:acetyl-CoA transferases may also serve as candidates for this reaction step but would require certain mutations to change their function. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 46.
Acidaminococcus fermentans
Acidaminococcus fermentans
Additional hydrolase enzymes include 3-hydroxyisobutyryl-CoA hydrolase which has been described to efficiently catalyze the conversion of 3-hydroxyisobutyryl-CoA to 3-hydroxyisobutyrate during valine degradation (Shimomura et al., J Biol. Chem. 269:14248-14253 (1994)). Genes encoding this enzyme include hibch of Rattus norvegicus (Shimomura et al., supra; Shimomura et al., Methods Enzymol. 324:229-240 (2000)) and Homo sapiens (Shimomura et al., supra). Candidate genes by sequence homology include hibch of Saccharomyces cerevisiae and BC—2292 of Bacillus cereus. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 47.
Rattus norvegicus
Homo sapiens
Saccharomyces cerevisiae
Bacillus cereus
4.1.1.a Carboxy-Lyase
Alpha-ketoglutarate decarboxylase (Step B), glutamate decarboxylase (Step L), and 5-hydroxy-2-oxopentanoic acid decarboxylase (Step Z) in
Pyruvate decarboxylase (PDC), also termed keto-acid decarboxylase, is a key enzyme in alcoholic fermentation, catalyzing the decarboxylation of pyruvate to acetaldehyde. The enzyme from Saccharomyces cerevisiae has a broad substrate range for aliphatic 2-keto acids including 2-ketobutyrate, 2-ketovalerate, 3-hydroxypyruvate and 2-phenylpyruvate (22). This enzyme has been extensively studied, engineered for altered activity, and functionally expressed in E. coli (Killenberg-Jabs et al., 268:1698-1704 (2001); Li et al., Biochemistry. 38:10004-10012 (1999); ter Schure et al., Appl. Environ. Microbiol. 64:1303-1307 (1998)). The PDC from Zymomonas mobilus, encoded by pdc, also has a broad substrate range and has been a subject of directed engineering studies to alter the affinity for different substrates (Siegert et al., 18:345-357 (2005)). The crystal structure of this enzyme is available (Killenberg-Jabs et al., 268:1698-1704 (2001)). Other well-characterized PDC candidates include the enzymes from Acetobacter pasteurians (Chandra et al., 176:443-451 (2001)) and Kluyveromyces lactis (Krieger et al., 269:3256-3263 (2002)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 48.
Zymomonas mobilus
Saccharomyces cerevisiae
Acetobacter pasteurians
Kluyveromyces lactis
Like PDC, benzoylformate decarboxylase (EC 4.1.1.7) has a broad substrate range and has been the target of enzyme engineering studies. The enzyme from Pseudomonas putida has been extensively studied and crystal structures of this enzyme are available (Polovnikova et al., 42:1820-1830 (2003); Hasson et al., 37:9918-9930 (1998)). Site-directed mutagenesis of two residues in the active site of the Pseudomonas putida enzyme altered the affinity (Km) of naturally and non-naturally occurring substrates (Siegert et al., 18:345-357 (2005)). The properties of this enzyme have been further modified by directed engineering (Lingen et al., Chembiochem. 4:721-726 (2003); Lingen et al., Protein Eng 15:585-593 (2002)). The enzyme from Pseudomonas aeruginosa, encoded by mdlC, has also been characterized experimentally (Barrowman et al., 34:57-60 (1986)). Additional gene candidates from Pseudomonas stutzeri, Pseudomonas fluorescens and other organisms can be inferred by sequence homology or identified using a growth selection system developed in Pseudomonas putida (Henning et al., Appl. Environ. Microbiol. 72:7510-7517 (2006)). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 49.
Pseudomonas putida
Pseudomonas aeruginosa
Pseudomonas stutzeri
Pseudomonas fluorescens
A third enzyme capable of decarboxylating 2-oxoacids is alpha-ketoglutarate decarboxylase (KGD). The substrate range of this class of enzymes has not been studied to date. The KDC from Mycobacterium tuberculosis (Tian et al., 102:10670-10675 (2005)) has been cloned and functionally expressed in other internal projects at Genomatica. However, it is not an ideal candidate for strain engineering because it is large (˜130 kDa) and GC-rich. KDC enzyme activity has been detected in several species of rhizobia including Bradyrhizobium japonicum and Mesorhizobium loti (Green et al., 182:2838-2844 (2000)). Although the KDC-encoding gene(s) have not been isolated in these organisms, the genome sequences are available and several genes in each genome are annotated as putative KDCs. A KDC from Euglena gracilis has also been characterized but the gene associated with this activity has not been identified to date (Shigeoka et al., 288:22-28 (1991)). The first twenty amino acids starting from the N-terminus were sequenced MTYKAPVKDVKFLLDKVFKV (SEQ ID NO: 3) (Shigeoka and Nakano, 288:22-28 (1991)). The gene could be identified by testing candidate genes containing this N-terminal sequence for KDC activity. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 50.
Mycobacterium tuberculosis
Bradyrhizobium japonicum
Mesorhizobium loti
A fourth candidate enzyme for catalyzing this reaction is branched chain alpha-ketoacid decarboxylase (BCKA). This class of enzyme has been shown to act on a variety of compounds varying in chain length from 3 to 6 carbons (Oku et al., 263:18386-18396 (1988); Smit et al., 71:303-311 (2005)). The enzyme in Lactococcus lactis has been characterized on a variety of branched and linear substrates including 2-oxobutanoate, 2-oxohexanoate, 2-oxopentanoate, 3-methyl-2-oxobutanoate, 4-methyl-2-oxobutanoate and isocaproate (Smit et al., 71:303-311 (2005)). The enzyme has been structurally characterized (Berg et al., 318:1782-1786 (2007)). Sequence alignments between the Lactococcus lactis enzyme and the pyruvate decarboxylase of Zymomonas mobilus indicate that the catalytic and substrate recognition residues are nearly identical (Siegert et al., 18:345-357 (2005)), so this enzyme would be a promising candidate for directed engineering. Decarboxylation of alpha-ketoglutarate by a BCKA was detected in Bacillus subtilis; however, this activity was low (5%) relative to activity on other branched-chain substrates (Oku and Kaneda, 263:18386-18396 (1988)) and the gene encoding this enzyme has not been identified to date. Additional BCKA gene candidates can be identified by homology to the Lactococcus lactis protein sequence. Many of the high-scoring BLASTp hits to this enzyme are annotated as indolepyruvate decarboxylases (EC 4.1.1.74). Indolepyruvate decarboxylase (IPDA) is an enzyme that catalyzes the decarboxylation of indolepyruvate to indoleacetaldehyde in plants and plant bacteria. The protein sequence for the exemplary gene product, if available, can be found using the following GenBank accession numbers shown in Table 51.
Lactococcus lactis
Recombinant branched chain alpha-keto acid decarboxylase enzymes derived from the E1 subunits of the mitochondrial branched-chain keto acid dehydrogenase complex from Homo sapiens and Bos taurus have been cloned and functionally expressed in E. coli (Davie et al., 267:16601-16606 (1992); Wynn et al., 267:12400-12403 (1992); Wynn et al., 267:1881-1887 (1992)). In these studies, the authors found that co-expression of chaperonins GroEL and GroES enhanced the specific activity of the decarboxylase by 500-fold (Wynn et al., 267:12400-12403 (1992)). These enzymes are composed of two alpha and two beta subunits. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 52.
Homo sapiens
Homo sapiens
Bos taurus
Bos taurus
6.2.1.a CoA Synthetase
Step I of
Escherichia coli
Escherichia coli
Additional exemplary CoA-ligases include the rat dicarboxylate-CoA ligase for which the sequence is yet uncharacterized (Vamecq et al., Biochemical Journal 230:683-693 (1985)), either of the two characterized phenylacetate-CoA ligases from P. chrysogenum (Lamas-Maceiras et al., Biochem. J. 395:147-155 (2005); Wang et al., Biochem Biophy Res Commun 360(2):453-458 (2007)), the phenylacetate-CoA ligase from Pseudomonas putida (Martinez-Blanco et al., J. Biol. Chem. 265:7084-7090 (1990)), and the 6-carboxyhexanoate-CoA ligase from Bacillus subtilis (Bower et al., J. Bacteriol. 178(14):4122-4130 (1996)). Additional candidate enzymes are acetoacetyl-CoA synthetases from Mus musculus (Hasegawa et al., Biochim Biophys Acta 1779:414-419 (2008)) and Homo sapiens (Ohgami et al., Biochem Pharmacol 65:989-994 (2003)) which naturally catalyze the ATP-dependant conversion of acetoacetate into acetoacetyl-CoA. 4-hydroxybutyryl-CoA synthetase activity has been demonstrated in Metallosphaera sedula (Berg et al., Science 318:1782-1786 (2007)). This function has been tentatively assigned to the Msed—1422 gene. The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 54.
Penicillium chrysogenum
Penicillium chrysogenum
Pseudomonas putida
Bacillus subtilis
Mus musculus
Homo sapiens
Metallosphaera sedula
ADP-forming acetyl-CoA synthetase (ACD, EC 6.2.1.13) is another candidate enzyme that couples the conversion of acyl-CoA esters to their corresponding acids with the concurrent synthesis of ATP. Several enzymes with broad substrate specificities have been described in the literature. ACD I from Archaeoglobus fulgidus, encoded by AF1211, was shown to operate on a variety of linear and branched-chain substrates including acetyl-CoA, propionyl-CoA, butyryl-CoA, acetate, propionate, butyrate, isobutyrate, isovalerate, succinate, fumarate, phenylacetate, indoleacetate (Musfeldt et al., J Bacteriol 184:636-644 (2002)). The enzyme from Haloarcula marismortui (annotated as a succinyl-CoA synthetase) accepts propionate, butyrate, and branched-chain acids (isovalerate and isobutyrate) as substrates, and was shown to operate in the forward and reverse directions (Brasen et al., Arch Microbiol 182:277-287 (2004)). The ACD encoded by PAE3250 from hyperthermophilic crenarchaeon Pyrobaculum aerophilum showed the broadest substrate range of all characterized ACDs, reacting with acetyl-CoA, isobutyryl-CoA (preferred substrate) and phenylacetyl-CoA (Brasen et al., supra). The enzymes from A. fulgidus, H. marismortui and P. aerophilum have all been cloned, functionally expressed, and characterized in E. coli (Musfeldt et al., supra; Brasen et al., supra). The protein sequences for each of these exemplary gene products, if available, can be found using the following GenBank accession numbers shown in Table 55.
Archaeoglobus fulgidus
Haloarcula marismortui
Pyrobaculum aerophilum
This example describes exemplary biochemical pathways for 4-HB production. 4-HB is the common intermediate for both 14-BDO and GBL productions.
Previous reports of 4-HB synthesis in microbes have focused on this compound as an intermediate in production of the biodegradable plastic poly-hydroxyalkanoate (PHA) (U.S. Pat. No. 6,117,658). The use of 4-HB/3-hydroxybutyrate (3-HB) copolymers over poly-3-hydroxybutyrate polymer (PHB) can result in plastic that is less brittle (Saito and Doi, Intl. J. Biol. Macromol. 16:99-104 (1994)). The production of monomeric 4-HB described herein is a fundamentally distinct process for several reasons: (1) the product is secreted, as opposed to PHA which is produced intracellularly and remains in the cell; (2) for organisms that produce hydroxybutanoate polymers, free 4-HB is not produced, but rather the Coenzyme A derivative is used by the polyhydroxyalkanoate synthase; (3) in the case of the polymer, formation of the granular product changes thermodynamics; and (4) extracellular pH is not an issue for production of the polymer, whereas it will affect whether 4-HB is present in the free acid or conjugate base state, and also the equilibrium between 4-HB and GBL.
4-HB can be produced in two enzymatic reduction steps from succinate, a central metabolite of the TCA cycle, with succinic semialdehyde as the intermediate (
The second enzyme of the pathway, 4-hydroxybutanoate dehydrogenase, is not native to E. coli or yeast but is found in various bacteria such as C. kluyveri and Ralstonia eutropha (Lutke-Eversloh et al., FEMS Microbiol Lett. 181:63-71 (1999); Sohling et al., J. Bacteriol. 178:871-880 (1996); Wolff et al., Protein Expr. Purif. 6:206-212 (1995); Valentin et al., Eur. J. Biochem. 227:43-60 (1995)). These enzymes are known to be NADH-dependent, though NADPH-dependent forms also exist. An additional pathway to 4-HB from alpha-ketoglutarate was demonstrated in E. coli resulting in the accumulation of poly(4-HB) (Song et al., Wei Sheng Wu Xue. Bao. 45:382-386 (2005)). The recombinant strain required the overexpression of three heterologous genes, PHA synthase (R. eutropha), 4-hydroxybutyrate dehydrogenase (R. eutropha) and 4-hydroxybutyrate:CoA transferase (C. kluyveri), along with two native E. coli genes: glutamate: succinic semialdehyde transaminase and glutamate decarboxylase. Alpha-ketoglutarate can be directly converted to succinic semialdehyde by an alpha-ketoglutarate decarboxylase such as the one identified in Euglena gracilis (Shigeoka et al., Arch. Biochem. Biophys. 288:22-28 (1991); Shigeoka et al., Biochem. J. 282 (Pt 2):319-323 (1992); Shigeoka et al., Biochem. J. 292 (Pt 2):463-467 (1993)). However, this enzyme has not previously been applied to impact the production of 4-HB or related polymers in any organism.
The microbial production capabilities of 4-HB were explored in two microbes, E. coli and S. cerevisiae, using in silico metabolic models of each organism. Potential pathways to 4-HB proceed via a succinate, succinyl-CoA, or alpha-ketoglutarate intermediate as shown in
A first step in the 4-HB production pathway from succinate involves the conversion of succinate to succinic semialdehyde via an NADH- or NADPH-dependant succinic semialdehyde dehydrogenase. In E. coli, gabD is an NADP-dependant succinic semialdehyde dehydrogenase and is part of a gene cluster involved in 4-aminobutyrate uptake and degradation (Schneider et al., J. Bacteriol. 184:6976-6986 (2002); Niegemann et al., Arch. Microbiol 160:454-460 (1993)). sad is believed to encode the enzyme for NAD-dependant succinic semialdehyde dehydrogenase activity (Marek et al., J. Bacteriol. 170:991-994 (1988)). S. cerevisiae contains only the NADPH-dependant succinic semialdehyde dehydrogenase, putatively assigned to UGA2, which localizes to the cytosol (Huh et al., 425:686-691 (2003)). The maximum yield calculations assuming the succinate pathway to 4-HB in both E. coli and S. cerevisiae require only the assumption that a non-native 4-HB dehydrogenase has been added to their metabolic networks.
The pathway from succinyl-CoA to 4-hydroxybutyrate was described in U.S. Pat. No. 6,117,658 as part of a process for making polyhydroxyalkanoates comprising 4-hydroxybutyrate monomer units. Clostridium kluyveri is one example organism known to possess CoA-dependant succinic semialdehyde dehydrogenase activity (Sohling et al., Eur. J. Biochem. 212:121-127 (1993); Sohling and Gottschalk, J Bacteriol. 178:871-880 (1996)). In this study, it is assumed that this enzyme, from C. kluyveri or another organism, is expressed in E. coli or S. cerevisiae along with a non-native or heterologous 4-HB dehydrogenase to complete the pathway from succinyl-CoA to 4-HB. The pathway from alpha-ketoglutarate to 4-HB was demonstrated in E. coli resulting in the accumulation of poly(4-hydroxybutyric acid) to 30% of dry cell weight (Song et al., Wei Sheng Wu Xue. Bao. 45:382-386 (2005)). As E. coli and S. cerevisiae natively or endogenously possess both glutamate:succinic semialdehyde transaminase and glutamate decarboxylase (Coleman et al., J Biol. Chem. 276:244-250 (2001)), the pathway from alpha-ketoglutarate to 4-HB can be completed in both organisms by assuming only that a non-native 4-HB dehydrogenase is present.
This example illustrates the construction and biosynthetic production of 4-HB and 14-BDO from microbial organisms. Pathways for 4-HB and 14-BDO are disclosed herein.
There are several alternative enzymes that can be utilized in the pathway described above. The native or endogenous enzyme for conversion of succinate to succinyl-CoA can be replaced by a CoA transferase such as that encoded by the cat1 gene C. kluyveri (Sohling and Gottschalk, Eur. J Biochem. 212:121-127 (1993)), which functions in a similar manner to the conversion of 4-HB to 4-hydroxybutyryl-CoA. However, the production of acetate by this enzyme may not be optimal, as it might be secreted rather than being converted back to acetyl-CoA. In this respect, it also can be beneficial to eliminate acetate formation. As one alternative to this CoA transferase, a mechanism can be employed in which the 4-HB is first phosphorylated by ATP and then converted to the CoA derivative, similar to the acetate kinase/phosphotransacetylase pathway in E. coli for the conversion of acetate to acetyl-CoA. The net cost of this route is one ATP, which is the same as is required to regenerate acetyl-CoA from acetate. The enzymes phosphotransbutyrylase (ptb) and butyrate kinase (bk) are known to carry out these steps on the non-hydroxylated molecules for butyrate production in C. acetobutylicum (Cary et al., Appl Environ Microbiol 56:1576-1583 (1990); Valentine, R. C. and R. S. Wolfe, J Biol Chem. 235:1948-1952 (1960)). These enzymes are reversible, allowing synthesis to proceed in the direction of 4-HB.
14-BDO also can be produced via alpha-ketoglutarate in addition to or instead of through succinate. As described herein, one pathway to accomplish product biosynthesis is with the production of succinic semialdehyde via alpha-ketoglutarate using the endogenous enzymes. An alternative is to use an alpha-ketoglutarate decarboxylase that can perform this conversion in one step (Tian et al., Proc Natl Acad Sci US.A 102:10670-10675 (2005)).
For the construction of different strains of 14-BDO-producing microbial organisms, a list of applicable genes was assembled for corroboration. Briefly, one or more genes within the 4-HB and/or 14-BDO biosynthetic pathways were identified for each step of the complete 14-BDO-producing pathway shown in
Clostridium
kluyveri
Clostridium
acetobutylicum
Clostridium
acetobutylicum
Clostridium
kluyveri
Clostridium
kluyveri
Ralstonia
eutropha H16
Clostridium
kluyveri
E. coli
E. coli
Clostridium
acetobutylicum
Clostridium
acetobutylicum
Clostridium
acetobutylicum
Clostridium
acetobutylicum
Clostridium
thermocellum
Clostridium
beijerinckii
Clostridium
acetobutylicum
Clostridium
saccharoperbutylacetonicum
Clostridium
saccharoperbutylacetonicum
Clostridium
tetani
Clostridium
perfringens
Clostridium
difficile
Mycobacterium bovis
Clostridium
aminobutyricum
Porphyromonas
gingivalis W83
Porphyromonas
gingivalis W83
Porphyromonas
gingivalis W83
E. coli
Expression Vector Construction for 14-BDO Pathway.
Vector backbones and some strains were obtained from Dr. Rolf Lutz of Expressys. The vectors and strains are based on the pZ Expression System developed by Dr. Rolf Lutz and Prof. Hermann Bujard (Lutz, R. and H. Bujard, Nucleic Acids Res 25:1203-1210 (1997)). Vectors obtained were pZE13luc, pZA33luc, pZS*13luc and pZE22luc and contained the luciferase gene as a stuffer fragment. To replace the luciferase stuffer fragment with a lacZ-alpha fragment flanked by appropriate restriction enzyme sites, the luciferase stuffer fragment was first removed from each vector by digestion with EcoRI and XbaI. The lacZ-alpha fragment was PCR amplified from pUC19 with the following primers:
This generated a fragment with a 5′ end of EcoRI site, NheI site, a Ribosomal Binding Site, a SalI site and the start codon. On the 3′ end of the fragment contained the stop codon, XbaI, HindIII, and AvrII sites. The PCR product was digested with EcoRI and AvrII and ligated into the base vectors digested with EcoRI and XbaI (XbaI and AvrII have compatible ends and generate a non-site). Because NheI and XbaI restriction enzyme sites generate compatible ends that can be ligated together (but generate a NheI/XbaI non-site that is not digested by either enzyme), the genes cloned into the vectors could be “Biobricked” together. Briefly, this method allows joining an unlimited number of genes into the vector using the same 2 restriction sites (as long as the sites do not appear internal to the genes), because the sites between the genes are destroyed after each addition.
All vectors have the pZ designation followed by letters and numbers indication the origin of replication, antibiotic resistance marker and promoter/regulatory unit. The origin of replication is the second letter and is denoted by E for ColE1, A for p15A and S for pSC101-based origins. The first number represents the antibiotic resistance marker (1 for Ampicillin, 2 for Kanamycin, 3 for Chloramphenicol, 4 for Spectinomycin and 5 for Tetracycline). The final number defines the promoter that regulated the gene of interest (1 for PLtetO-1, 2 for PLlacO-1, 3 for PA1lacO-1, and 4 for Plac/ara-1). The MCS and the gene of interest follows immediately after. For the work discussed here we employed two base vectors, pZA33 and pZE13, modified for the biobricks insertions as discussed above. Once the gene(s) of interest have been cloned into them, resulting plasmids are indicated using the four digit gene codes given in Table 56; e.g., pZA33-XXXX-YYYY- . . . .
Host Strain Construction.
The parent strain in all studies described here is E. coli K-12 strain MG1655. Markerless deletion strains in adhE, gabD, and aldA were constructed under service contract by a third party using the redET method (Datsenko, K. A. and B. L. Wanner, Proc Natl Acad Sci US.A 97:6640-6645 (2000)). Subsequent strains were constructed via bacteriophage P1 mediated transduction (Miller, J. Experiments in Molecular Genetics, Cold Spring Harbor Laboratories, New York (1973)). Strain C600Z1 (laciq, PN25-tetR, SpR, lacY1, leuB6, mcrB+, supE44, thi-1, thr-1, tonA21) was obtained from Expressys and was used as a source of a lacIq allele for P1 transduction. Bacteriophage P1vir was grown on the C600Z1 E. coli strain, which has the spectinomycin resistance gene linked to the lacIq. The P1 lysate grown on C600Z1 was used to infect MG1655 with selection for spectinomycin resistance. The spectinomycin resistant colonies were then screened for the linked lacIq by determining the ability of the transductants to repress expression of a gene linked to a PA1lacO-1 promoter. The resulting strain was designated MG1655 lacIq. A similar procedure was used to introduce lacIQ into the deletion strains.
Production of 4-HB from Succinate.
For construction of a 4-HB producer from succinate, genes encoding steps from succinate to 4-HB and 4-HB-CoA (Steps G, A, C, O in
Activity of the heterologous enzymes were first tested in in vitro assays, using strain MG1655 lacIQ as the host for the plasmid constructs containing the pathway genes. Cells were grown aerobically in LB media (Difco) containing the appropriate antibiotics for each construct, and induced by addition of IPTG at 1 mM when the optical density (OD600) reached approximately 0.5. Cells were harvested after 6 hours, and enzyme assays conducted as discussed below.
In Vitro Enzyme Assays.
To obtain crude extracts for activity assays, cells were harvested by centrifugation at 4,500 rpm (Beckman-Coulter, Allegera X-15R) for 10 min. The pellets were resuspended in 0.3 mL BugBuster (Novagen) reagent with benzonase and lysozyme, and lysis proceeded for 15 minutes at room temperature with gentle shaking. Cell-free lysate was obtained by centrifugation at 14,000 rpm (Eppendorf centrifuge 5402) for 30 min at 4° C. Cell protein in the sample was determined using the method of Bradford et al., Anal. Biochem. 72:248-254 (1976), and specific enzyme assays conducted as described below. Activities are reported in Units/mg protein, where a unit of activity is defined as the amount of enzyme required to convert 1 μmol of substrate in 1 min. at room temperature. In general, reported values are averages of at least 3 replicate assays.
Succinyl-CoA transferase (Cat1) activity was determined by monitoring the formation of acetyl-CoA from succinyl-CoA and acetate, following a previously described procedure Sohling and Gottschalk, J. Bacteriol. 178:871-880 (1996). Succinyl-CoA synthetase (SucCD) activity was determined by following the formation of succinyl-CoA from succinate and CoA in the presence of ATP. The experiment followed a procedure described by Cha and Parks, J. Biol. Chem. 239:1961-1967 (1964). CoA-dependent succinate semialdehyde dehydrogenase (SucD) activity was determined by following the conversion of NAD to NADH at 340 nm in the presence of succinate semialdehyde and CoA (Sohling and Gottschalk, Eur. J. Biochem. 212:121-127 (1993)). 4-HB dehydrogenase (4-HBd) enzyme activity was determined by monitoring the oxidation of NADH to NAD at 340 nm in the presence of succinate semialdehyde. The experiment followed a published procedure Gerhardt et al. Arch. Microbiol. 174:189-199 (2000). 4-HB CoA transferase (Cat2) activity was determined using a modified procedure from Scherf and Buckel, Appl. Environ. Microbiol. 57:2699-2702 (1991). The formation of 4-HB-CoA or butyryl-CoA formation from acetyl-CoA and 4-HB or butyrate was determined using HPLC.
Alcohol (ADH) and aldehyde (ALD) dehydrogenase was assayed in the reductive direction using a procedure adapted from several literature sources (Dune et al., FEMS Microbiol. Rev. 17:251-262 (1995); Palosaari and Rogers, J. Bacteriol. 170:2971-2976 (1988) and Welch et al., Arch. Biochem. Biophys. 273:309-318 (1989)). The oxidation of NADH is followed by reading absorbance at 340 nM every four seconds for a total of 240 seconds at room temperature. The reductive assays were performed in 100 mM MOPS (adjusted to pH 7.5 with KOH), 0.4 mM NADH, and from 1 to 50 μl of cell extract. The reaction is started by adding the following reagents: 100 μl of 100 mM acetaldehyde or butyraldehyde for ADH, or 100 μl of 1 mM acetyl-CoA or butyryl-CoA for ALD. The Spectrophotometer is quickly blanked and then the kinetic read is started. The resulting slope of the reduction in absorbance at 340 nM per minute, along with the molar extinction coefficient of NAD(P)H at 340 nM (6000) and the protein concentration of the extract, can be used to determine the specific activity.
The enzyme activity of PTB is measured in the direction of butyryl-CoA to butyryl-phosphate as described in Cary et al. J. Bacteriol. 170:4613-4618 (1988). It provides inorganic phosphate for the conversion, and follows the increase in free CoA with the reagent 5,5′-dithiobis-(2-nitrobenzoic acid), or DTNB. DTNB rapidly reacts with thiol groups such as free CoA to release the yellow-colored 2-nitro-5-mercaptobenzoic acid (TNB), which absorbs at 412 nm with a molar extinction coefficient of 14,140 M cm−1. The assay buffer contained 150 mM potassium phosphate at pH 7.4, 0.1 mM DTNB, and 0.2 mM butyryl-CoA, and the reaction was started by addition of 2 to 50 μL cell extract. The enzyme activity of BK is measured in the direction of butyrate to butyryl-phosphate formation at the expense of ATP. The procedure is similar to the assay for acetate kinase previously described Rose et al., J. Biol. Chem. 211:737-756 (1954). However we have found another acetate kinase enzyme assay protocol provided by Sigma to be more useful and sensitive. This assay links conversion of ATP to ADP by acetate kinase to the linked conversion of ADP and phosphoenol pyruvate (PEP) to ATP and pyruvate by pyruvate kinase, followed by the conversion of pyruvate and NADH to lactate and NAD by lactate dehydrogenase. Substituting butyrate for acetate is the only major modification to allow the assay to follow BK enzyme activity. The assay mixture contained 80 mM triethanolamine buffer at pH 7.6, 200 mM sodium butyrate, 10 mM MgCl2, 0.1 mM NADH, 6.6 mM ATP, 1.8 mM phosphoenolpyruvate. Pyruvate kinase, lactate dehydrogenase, and myokinase were added according to the manufacturer's instructions. The reaction was started by adding 2 to 50 μL cell extract, and the reaction was monitored based on the decrease in absorbance at 340 nm indicating NADH oxidation.
Analysis of CoA Derivatives by HPLC.
An HPLC based assay was developed to monitor enzymatic reactions involving coenzyme A (CoA) transfer. The developed method allowed enzyme activity characterization by quantitative determination of CoA, acetyl CoA (AcCoA), butyryl CoA (BuCoA) and 4-hydroxybutyrate CoA (4-HBCoA) present in in-vitro reaction mixtures. Sensitivity down to low μM was achieved, as well as excellent resolution of all the CoA derivatives of interest.
Chemical and sample preparation was performed as follows. Briefly, CoA, AcCoA, BuCoA and all other chemicals, were obtained from Sigma-Aldrich. The solvents, methanol and acetonitrile, were of HPLC grade. Standard calibration curves exhibited excellent linearity in the 0.01-1 mg/mL concentration range. Enzymatic reaction mixtures contained 100 mM Tris HCl buffer (pH 7), aliquots were taken at different time points, quenched with formic acid (0.04% final concentration) and directly analyzed by HPLC.
HPLC analysis was performed using an Agilent 1100 HPLC system equipped with a binary pump, degasser, thermostated autosampler and column compartment, and diode array detector (DAD), was used for the analysis. A reversed phase column, Kromasil 100 5 um C18, 4.6×150 mm (Peeke Scientific), was employed. 25 mM potassium phosphate (pH 7) and methanol or acetonitrile, were used as aqueous and organic solvents at 1 mL/min flow rate. Two methods were developed: a short one with a faster gradient for the analysis of well-resolved CoA, AcCoA and BuCoA, and a longer method for distinguishing between closely eluting AcCoA and 4-HBCoA. Short method employed acetonitrile gradient (0 min-5%, 6 min-30%, 6.5 min-5%, 10 min-5%) and resulted in the retention times 2.7, 4.1 and 5.5 min for CoA, AcCoA and BuCoA, respectively. In the long method methanol was used with the following linear gradient: 0 min-5%, 20 min-35%, 20.5 min-5%, 25 min-5%. The retention times for CoA, AcCoA, 4-HBCoA and BuCoA were 5.8, 8.4, 9.2 and 16.0 min, respectively. The injection volume was 5 μL, column temperature 30° C., and UV absorbance was monitored at 260 nm.
The results demonstrated activity of each of the four pathway steps (Table 57), though activity is clearly dependent on the gene source, position of the gene in the vector, and the context of other genes with which it is expressed. For example, gene 0035 encodes a succinic semialdehyde dehydrogenase that is more active than that encoded by 0008, and 0036 and 0010n are more active 4-HB dehydrogenase genes than 0009. There also seems to be better 4-HB dehydrogenase activity when there is another gene preceding it on the same operon.
Recombinant strains containing genes in the 4-HB pathway were then evaluated for the ability to produce 4-HB in vivo from central metabolic intermediates. Cells were grown anaerobically in LB medium to OD600 of approximately 0.4, then induced with 1 mM IPTG. One hour later, sodium succinate was added to 10 mM, and samples taken for analysis following an additional 24 and 48 hours. 4-HB in the culture broth was analyzed by GC-MS as described below. The results indicate that the recombinant strain can produce over 2 mM 4-HB after 24 hours, compared to essentially zero in the control strain (Table 58).
An alternate to using a CoA transferase (cat1) to produce succinyl-CoA from succinate is to use the native E. coli sucCD genes, encoding succinyl-CoA synthetase. This gene cluster was cloned onto pZE13 along with candidate genes for the remaining steps to 4-HB to create pZE13-0038-0035-0036.
Production of 4-HB from Glucose.
Although the above experiments demonstrate a functional pathway to 4-HB from a central metabolic intermediate (succinate), an industrial process would require the production of chemicals from low-cost carbohydrate feedstocks such as glucose or sucrose. Thus, the next set of experiments was aimed to determine whether endogenous succinate produced by the cells during growth on glucose could fuel the 4-HB pathway. Cells were grown anaerobically in M9 minimal medium (6.78 g/L Na2HPO4, 3.0 g/L KH2PO4, 0.5 g/L NaCl, 1.0 g/L NH4Cl, 1 mM MgSO4, 0.1 mM CaCl2) supplemented with 20 g/L glucose, 100 mM 3-(N-morpholino)propanesulfonic acid (MOPS) to improve the buffering capacity, 10 μg/mL thiamine, and the appropriate antibiotics. 0.25 mM IPTG was added when OD600 reached approximately 0.2, and samples taken for 4-HB analysis every 24 hours following induction. In all cases 4-HB plateaued after 24 hours, with a maximum of about 1 mM in the best strains (
An alternate pathway for the production of 4-HB from glucose is via alpha-ketoglutarate. We explored the use of an alpha-ketoglutarate decarboxylase from Mycobacterium tuberculosis (Tian et al., Proc. Natl. Acad. Sci. USA 102:10670-10675 (2005)) to produce succinic semialdehyde directly from alpha-ketoglutarate (Step B in
Production of 14-BDO from 4-HB.
The production of 14-14-BDO from 4-HB required two reduction steps, catalyzed by dehydrogenases. Alcohol and aldehyde dehydrogenases (ADH and ALD, respectively) are NAD+/H and/or NADP+/H-dependent enzymes that together can reduce a carboxylic acid group on a molecule to an alcohol group, or in reverse, can perform the oxidation of an alcohol to a carboxylic acid. This biotransformation has been demonstrated in wild-type Clostridium acetobutylicum (Jewell et al., Current Microbiology, 13:215-19 (1986)), but neither the enzymes responsible nor the genes responsible were identified. In addition, it is not known whether activation to 4-HB-CoA is first required (Step T in
Gene candidates for the 4-HB to 14-BDO conversion pathway were next tested for activity when expressed in the E. coli host MG1655 lacIQ. Recombinant strains containing each gene candidate expressed on pZA33 were grown in the presence of 0.25 mM IPTG for four hours at 37° C. to fully induce expression of the enzyme. Four hours after induction, cells were harvested and assayed for ADH and ALD activity as described above. Since 4-HB-CoA and 4-hydroxybutyraldehyde are not available commercially, assays were performed using the non-hydroxylated substrates (Table 59). The ratio in activity between 4-carbon and 2-carbon substrates for C. acetobutylicum adhE2 (0002) and E. coli adhE (0011) were similar to those previously reported in the literature (Atsumi et al., Biochim. Biophys. Acta. 1207:1-11 (1994)).
For the 14-BDO production experiments, cat2 from Porphyromonas gingivalis W83 (gene 0034) was included on pZA33 for the conversion of 4-HB to 4-HB-CoA, while the candidate dehydrogenase genes were expressed on pZE13. The host strain was MG1655 lacIQ. Along with the alcohol and aldehyde dehydrogenase candidates, we also tested the ability of CoA-dependent succinic semialdehyde dehydrogenases (sucD) to function in this step, due to the similarity of the substrates. Cells were grown to an OD of about 0.5 in LB medium supplemented with 10 mM 4-HB, induced with 1 mM IPTG, and culture broth samples taken after 24 hours and analyzed for 14-BDO as described below. The best 14-BDO production occurred using adhE2 from C. acetobutylicum, sucD from C. kluyveri, or sucD from P. gingivalis (
As discussed above, it may be advantageous to use a route for converting 4-HB to 4-HB-CoA that does not generate acetate as a byproduct. To this aim, we tested the use of phosphotransbutyrylase (ptb) and butyrate kinase (bk) from C. acetobutylicum to carry out this conversion via Steps O and P in
Production of 14-BDO from Glucose.
The final step of pathway corroboration is to express both the 4-HB and 14-BDO segments of the pathway in E. coli and demonstrate production of 14-BDO in glucose minimal medium. New plasmids were constructed so that all the required genes fit on two plamids. In general, cat1, adhE, and sucD genes were expressed from pZE13, and cat2 and 4-HBd were expressed from pZA33. Various combinations of gene source and gene order were tested in the MG1655 lacIQ background. Cells were grown anaerobically in M9 minimal medium (6.78 g/L Na2HPO4, 3.0 g/L KH2PO4, 0.5 g/L NaCl, 1.0 g/L NH4Cl, 1 mM MgSO4, 0.1 mM CaCl2) supplemented with 20 g/L glucose, 100 mM 3-(N-morpholino)propanesulfonic acid (MOPS) to improve the buffering capacity, 10 μg/mL thiamine, and the appropriate antibiotics. 0.25 mM IPTG was added approximately 15 hours following inoculation, and culture supernatant samples taken for 14-BDO, 4-HB, and succinate analysis 24 and 48 hours following induction. The production of 14-BDO appeared to show a dependency on gene order (Table 62). The highest 14-BDO production, over 0.5 mM, was obtained with cat2 expressed first, followed by 4-HBd on pZA33, and cat1 followed by P. gingivalis sucD on pZE13. The addition of C. acetobutylicum adhE2 in the last position on pZE13 resulted in slight improvement. 4-HB and succinate were also produced at higher concentrations.
Analysis of 14-BDO, 4-HB and Succinate by GCMS.
14-BDO, 4-HB and succinate in fermentation and cell culture samples were derivatized by silylation and quantitatively analyzed by GCMS using methods adapted from literature reports (Song et al., Wei Sheng Wu Xue. Bao. 45:382-386 (2005)). The developed method demonstrated good sensitivity down to 1 μM, linearity up to at least 25 mM, as well as excellent selectivity and reproducibility.
Sample preparation was performed as follows: 100 μL filtered (0.2 μm or 0.45 μm syringe filters) samples, e.g. fermentation broth, cell culture or standard solutions, were dried down in a Speed Vac Concentrator (Savant SVC-100H) for approximately 1 hour at ambient temperature, followed by the addition of 20 μL 10 mM cyclohexanol solution, as an internal standard, in dimethylformamide. The mixtures were vortexed and sonicated in a water bath (Branson 3510) for 15 min to ensure homogeneity. 1000 μL silylation derivatization reagent, N,O-bis(trimethylsilyl)trifluoro-acetimide (BSTFA) with 1% trimethylchlorosilane, was added, and the mixture was incubated at 70° C. for 30 min. The derivatized samples were centrifuged for 5 min, and the clear solutions were directly injected into GCMS. All the chemicals and reagents were from Sigma-Aldrich, with the exception of 14-BDO which was purchased from J. T. Baker.
GCMS was performed on an Agilent gas chromatograph 6890N, interfaced to a mass-selective detector (MSD) 5973N operated in electron impact ionization (E1) mode has been used for the analysis. A DB-5MS capillary column (J&W Scientific, Agilent Technologies), 30 m×0.25 mm i.d.×0.25 μm film thickness, was used. The GC was operated in a split injection mode introducing 1 μL of sample at 20:1 split ratio. The injection port temperature was 250° C. Helium was used as a carrier gas, and the flow rate was maintained at 1.0 mL/min. A temperature gradient program was optimized to ensure good resolution of the analytes of interest and minimum matrix interference. The oven was initially held at 80° C. for 1 min, then ramped to 120° C. at 2° C./min, followed by fast ramping to 320° C. at 100° C./min and final hold for 6 min at 320° C. The MS interface transfer line was maintained at 280° C. The data were acquired using ‘lowmass’ MS tune settings and 30-400 m/z mass-range scan. The total analysis time was 29 min including 3 min solvent delay. The retention times corresponded to 5.2, 10.5, 14.0 and 18.2 min for BS TFA-derivatized cyclohexanol, 14-BDO, 4-HB and succinate, respectively. For quantitative analysis, the following specific mass fragments were selected (extracted ion chromatograms): m/z 157 for internal standard cyclohexanol, 116 for 14-BDO, and 147 for both 4-HB and succinate. Standard calibration curves were constructed using analyte solutions in the corresponding cell culture or fermentation medium to match sample matrix as close as possible. GCMS data were processed using Environmental Data Analysis ChemStation software (Agilent Technologies).
The results indicated that most of the 4-HB and 14-BDO produced were labeled with 13C (
Production of 14-BDO from 4-HB Using Alternate Pathways.
The various alternate pathways were also tested for 14-BDO production. This includes use of the native E. coli SucCD enzyme to convert succinate to succinyl-CoA (Table 63, rows 2-3), use of alpha-ketoglutarate decarboxylase in the alpha-ketoglutarate pathway (Table 63, row 4), and use of PTB/BK as an alternate means to generate the CoA-derivative of 4-HB (Table 63, row 1). Strains were constructed containing plasmids expressing the genes indicated in Table 63, which encompass these variants. The results show that in all cases, production of 4-HB and 14-BDO occurred (Table 63).
E. coli strains genes for different 14-BDO pathway variants,
This example describes exemplary biochemical pathways for GBL production.
As shown in
Previous studies have demonstrated the transformation from 4-HB to GBL. The conversion from 4-HB to GBL can be catalyzed by either the 1,4-lacton hydroxyacylhydrolase (EC 3.1.1.25) or the lipases (Step AB in
The transformation from 4-hydroxybutyryl-phosphate to GBL can be a non-enzymatic step (Step AC in
Clostridium
acetobutylicum
The transformation from 4-hydroxybutyryl-CoA to GBL through a non-enzymatic lactonization reaction (Step AD in
Clostridium
acetobutylicum
Porphyromonas
gingivalis ATCC 33277
One important aspect of coproduction of 14-BDO and GBL is to control the ratio between the two coproducts to match the market needs. Depending on different region, the local market needs for 14-BDO and GBL can be different, thus it is important to coproduce 14-BDO and GBL with tailored ratio to satisfy the market needs. In this example, we demonstrate a method to coproduce 14-BDO and GBL at different ratios.
To adjust the ratio of 14-BDO and GBL, several different methods can be employed. First, 4-hydroxybutyryl-CoA can be converted to GBL by the non-enzymatic lactonization reaction (Step AD in
As described above, the activities of the acyl-CoA reductase (aldehyde forming) can be utilized to adjust the ratio of 14-BDO to GBL in coproduction. Different acyl-CoA reductases (aldehyde forming, also known as aldehyde dehydrogenase) were tested for their aldehyde dehydrogenase activities by in vivo transformation measurements. The host strain used in the experiments was strain 761 (ΔadhE ΔldhA ΔpflB Δsad ΔgabD ΔlpdA::K.p.lpdA322 Δmdh ΔarcA gltAR163L fimD:: E. coli sucCD, P. gingivalis sucD, P. gingivalis 4hbd fimD:: M. bovis sucA, C. kluyveri 4hbd). This strain contained the components of the BDO pathway leading to 4HB integrated into the chromosome of E. coli at thefimD locus. It also contained additional genetic modifications to direct metabolic flux into the 4-HB pathway. The 4-hydroxybutyryl-CoA transferase (034) was expressed from the F′ plamid and allowed the engineered strains to convert 4-HB to 4-hydroxybutyryl-CoA. Genes encoding different aldehyde dehydrogenase were expressed from pZs* plasmid. Cells were grown in fermentor with M9 minimal medium (6.78 g/L Na2HPO4, 3.0 g/L KH2PO4, 0.5 g/L NaCl, 1.0 g/L NH4Cl, 1 mM MgSO4, 0.1 mM CaCl2) supplemented with glucose under batch fermentation conditions. Gene expression of aldehyde dehydrogenases was induced by 0.25 mM IPTG and culture supernatant samples were taken for 14-BDO, GBL, and other products analysis. As shown in Table 66, aldehyde dehydrogenases from different organism results in different 14-BDO and GBL titers in the fermentation broth and different ratios between the 14-BDO and GBL coproducts. Among the aldehyde dehydrogenase tested, gene 704 encoding the Salmonella enterica Typhimurium aldehyde dehydrogenase resulted in the lowest 14-BDO to GBL ratio at 0.5, allowing two moles of GBL produced for every mole of 14-BDO produced. On the other hand, gene 025B encoding the Clostridium beijerinckii NCIMB 8052 aldehyde dehydrogenase resulted in the highest 14-BDO to GBL ratio at 7.2. Several aldehyde dehydrogenases from different source organisms produced 14-BDO and GBL at ratios between 0.5 and 7.2 (Table 66). These genes can be utilized to generate coproduction strains with different 14-BDO to GBL ratio to meet the needs of different regional markets.
Salmonella enterica
Typhimurium
Clostridium
methylpentosum DSM 5476
Lactobacillus brevis
Bacillus selenitireducens
Clostridium beijerinckii
This Example describes the biosynthetic coproduction of 14-BDO and GBLusing fermentation and other bioprocesses.
Methods for the integration of the 4-HB fermentation step into a complete process for the coproduction of purified 14-BDO and GBL are described below. Since 4-HB and GBL are in equilibrium, the fermentation broth will contain both compounds. At low pH this equilibrium is shifted to favor GBL. Therefore, the fermentation can operate at pH 7.5 or less, generally pH 5.5 or less. After removal of biomass, the product stream enters into a separation step in which 14-BDO and GBL are removed and the remaining stream enriched in 4-HB is recycled. Finally, 14-BDO and GBL are distilled to remove any impurities. The process operates in one of three ways: 1) fed-batch fermentation and batch separation; 2) fed-batch fermentation and continuous separation; 3) continuous fermentation and continuous separation.
Fermentation Protocol to Coproduce 14-BDO and GBL (Batch):
The production organism is grown in a 10 L bioreactor sparged with an N2/CO2 mixture, using 5 L broth containing 5 g/L potassium phosphate, 2.5 g/L ammonium chloride, 0.5 g/L magnesium sulfate, and 30 g/L corn steep liquor, and an initial glucose concentration of 20 g/L. As the cells grow and utilize the glucose, additional 70% glucose is fed into the bioreactor at a rate approximately balancing glucose consumption. The temperature of the bioreactor is maintained at 30 degrees C. Growth continues for approximately 24 hours, until the total concentration of 14-BDO, GBL, and 4-HB reaches a concentration of between 20-200 g/L with a preferred ratio among the three coproducts, with the cell density being between 5 and 10 g/L. The pH is not controlled, and will typically decrease to pH 3-6 by the end of the run. Upon completion of the cultivation period, the fermenter contents are passed through a cell separation unit (e.g., centrifuge) to remove cells and cell debris, and the fermentation broth is transferred to a product separations unit. Isolation of 14-BDO and GBL is done by standard separations procedures employed in the art to separate organic products from dilute aqueous solutions, such as liquid-liquid extraction using a water immiscible organic solvent (e.g., toluene) to provide an organic solution of 14-BDO and GBL. The resulting solution is then subjected to standard distillation methods to remove and recycle the organic solvent and to provide GBL (boiling point 204° C.) and 14-BDO (boiling point 230° C.) which are distilled and isolated as purified liquids.
Fermentation Protocol to Coproduce 14-BDO/GBL (Fully Continuous):
The production organism is first grown up in batch mode using the apparatus and medium composition described above, except that the initial glucose concentration is 30-50 g/L. When glucose is exhausted, feed medium of the same composition is supplied continuously at a rate between 0.5 L/hr and 1 L/hr, and liquid is withdrawn at the same rate. The total concentration of 14-BDO, GBL, and 4-HB in the bioreactor remains constant at 30-40 g/L, with a preferred ratio among the three coproducts, and the cell density remains constant between 3-5 g/L. Temperature is maintained at 30 degrees C., and the pH is maintained at 4.5 using concentrated NaOH and HCl, as required. The bioreactor is operated continuously for one month, with samples taken every day to assure consistency of coproducts concentrations. In continuous mode, fermenter contents are constantly removed as new feed medium is supplied. The exit stream, containing cells, medium, and coproducts 14-BDO, GBL, and 4-HB, is then subjected to a continuous product separations procedure, with or without removing cells and cell debris, and is done by standard continuous separations methods employed in the art to separate organic products from dilute aqueous solutions, such as continuous liquid-liquid extraction using a water immiscible organic solvent (e.g., toluene) to provide an organic solution of 14-BDO and GBL. The resulting solution is subsequently subjected to standard continuous distillation methods to remove and recycle the organic solvent and to provide GBL (boiling point 204° C.) and 14-BDO (boiling point 230° C.) which are distilled and isolated as purified liquids.
This example describes the expression of various non-native pathway enzymes to provide improved production of 14-BDO.
4-Hydroxybutanal Reductase.
4-hydroxybutanal reductase activity of adh1 from Geobacillus thermoglucosidasius (M10EXG) was utilized. This led to improved 14-BDO production by increasing 4-hydroxybutanal reductase activity over endogenous levels.
Multiple alcohol dehydrogenases were screened for their ability to catalyze the reduction of 4-hydroxybutanal to 14-BDO. Most alcohol dehydrogenases with high activity on butyraldehyde exhibited far lower activity on 4-hydroxybutyraldehyde. One notable exception is the adh1 gene from Geobacillus thermoglucosidasius M10EXG (Jeon et al., J. Biotechnol. 135:127-133 (2008)) (GNM0084), which exhibits high activity on both 4-hydroxybutanal and butanal.
The native gene sequence and encoded protein sequence if the adh1 gene from Geobacillus thermoglucosidasius are shown in
The Adh1 enzyme (084) expressed very well from its native gene in E. coli (see
The 084 enzyme was tested for its ability to boost 14-BDO production when coupled with the C. beijerinckii ald. The 084 gene was inserted behind the C. beijerinckii ald variant 025B gene to create a synthetic operon that results in coupled expression of both genes. Similar constructs linked 025B with other ADH candidate genes, and the effect of including each ADH with 025B on 14-BDO production was tested. The host strain used was ECKh-459 (ΔadhE ldhA ΔpflB ΔlpdA::fnr-pflB6-K.p.lpdA322 Δmdh ΔarcA gltAR163L fimD:: E. coli sucCD, P. gingivalis sucD, P. gingivalis 4hbd fimD:: M. bovis sucA, C. kluyveri 4hbd fimD:: C. acetobutylicum buk1, C. acetobutylicum ptb), which contains the remainder of the 14-BDO pathway on the chromosome. The 084 ADH expressed in conjunction with 025B showed the highest amount of 14-BDO (right arrow in
Throughout this application various publications have been referenced. The disclosures of these publications in their entireties, including GenBank and GI number publications, are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains. Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention.
This application claims the benefit of priority of U.S. Provisional Application No. 61/264,598, filed Nov. 25, 2009, the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4048196 | Broecker et al. | Sep 1977 | A |
4228949 | Jackson | Oct 1980 | A |
4240578 | Jackson | Dec 1980 | A |
4301077 | Pesa et al. | Nov 1981 | A |
4430430 | Momose et al. | Feb 1984 | A |
4652685 | Cawse et al. | Mar 1987 | A |
4876331 | Doi | Oct 1989 | A |
5164309 | Gottschalk et al. | Nov 1992 | A |
5245023 | Peoples et al. | Sep 1993 | A |
5250430 | Peoples et al. | Oct 1993 | A |
5286842 | Kimura | Feb 1994 | A |
5292860 | Shiotani et al. | Mar 1994 | A |
5378616 | Tujimoto et al. | Jan 1995 | A |
5413922 | Matsuyama et al. | May 1995 | A |
5461139 | Gonda et al. | Oct 1995 | A |
5475086 | Tobin et al. | Dec 1995 | A |
5478952 | Schwartz | Dec 1995 | A |
5502273 | Bright et al. | Mar 1996 | A |
5516883 | Hori et al. | May 1996 | A |
5534432 | Peoples et al. | Jul 1996 | A |
5563239 | Hubbs et al. | Oct 1996 | A |
5602321 | John | Feb 1997 | A |
5610041 | Somerville et al. | Mar 1997 | A |
5650555 | Somerville et al. | Jul 1997 | A |
5663063 | Peoples et al. | Sep 1997 | A |
5674978 | Tobin et al. | Oct 1997 | A |
5705626 | Tobin et al. | Jan 1998 | A |
5747311 | Jewell | May 1998 | A |
5750848 | Krüger et al. | May 1998 | A |
5770435 | Donnelly et al. | Jun 1998 | A |
5830716 | Kojima et al. | Nov 1998 | A |
5846740 | Tobin et al. | Dec 1998 | A |
5849894 | Clemente et al. | Dec 1998 | A |
5869301 | Nghiem et al. | Feb 1999 | A |
5908924 | Burdette et al. | Jun 1999 | A |
5942660 | Gruys et al. | Aug 1999 | A |
5958745 | Gruys et al. | Sep 1999 | A |
5994478 | Asrar et al. | Nov 1999 | A |
5998366 | Tobin et al. | Dec 1999 | A |
6010870 | Pelzer et al. | Jan 2000 | A |
6011139 | Tobin et al. | Jan 2000 | A |
6011144 | Steinbuchel et al. | Jan 2000 | A |
6022729 | Steinbuchel et al. | Feb 2000 | A |
6080562 | Byrom et al. | Jun 2000 | A |
6091002 | Asrar et al. | Jul 2000 | A |
6111658 | Tabata | Aug 2000 | A |
6117658 | Dennis et al. | Sep 2000 | A |
6156852 | Asrar et al. | Dec 2000 | A |
6159738 | Donnelly et al. | Dec 2000 | A |
6204341 | Asrar et al. | Mar 2001 | B1 |
6228623 | Asrar et al. | May 2001 | B1 |
6248862 | Asrar et al. | Jun 2001 | B1 |
6277586 | Tobin et al. | Aug 2001 | B1 |
6280986 | Hespell et al. | Aug 2001 | B1 |
6316262 | Huisman et al. | Nov 2001 | B1 |
6329183 | Skraly et al. | Dec 2001 | B1 |
RE37543 | Krüger et al. | Feb 2002 | E |
6361983 | Ames | Mar 2002 | B1 |
6448061 | Pan et al. | Sep 2002 | B1 |
6448473 | Mitsky et al. | Sep 2002 | B1 |
6455267 | Tobin et al. | Sep 2002 | B1 |
6495152 | Steinbuchel et al. | Dec 2002 | B2 |
6515205 | Liebergesell et al. | Feb 2003 | B1 |
6576450 | Skraly et al. | Jun 2003 | B2 |
6593116 | Huisman et al. | Jul 2003 | B1 |
6596521 | Chang et al. | Jul 2003 | B1 |
6623946 | Möckel et al. | Sep 2003 | B1 |
6682906 | Tobin et al. | Jan 2004 | B1 |
6686310 | Kourtakis et al. | Feb 2004 | B1 |
6689589 | Huisman et al. | Feb 2004 | B2 |
6730503 | Asakura et al. | May 2004 | B1 |
6759219 | Hein et al. | Jul 2004 | B2 |
6770464 | Steinbuchel et al. | Aug 2004 | B2 |
6835820 | Cannon et al. | Dec 2004 | B2 |
6838276 | Falco et al. | Jan 2005 | B2 |
6897055 | Möckel et al. | May 2005 | B2 |
6913911 | Huisman et al. | Jul 2005 | B2 |
6916637 | Rieping et al. | Jul 2005 | B2 |
7052883 | Rieping et al. | May 2006 | B2 |
7067300 | Emptage et al. | Jun 2006 | B2 |
7081357 | Huisman et al. | Jul 2006 | B2 |
7125693 | Davis et al. | Oct 2006 | B2 |
7127379 | Palsson et al. | Oct 2006 | B2 |
7132267 | Davis et al. | Nov 2006 | B2 |
7135315 | Hoshino et al. | Nov 2006 | B2 |
7186541 | Gokarn et al. | Mar 2007 | B2 |
7223567 | Ka-Yiu et al. | May 2007 | B2 |
7229804 | Huisman et al. | Jun 2007 | B2 |
7256021 | Hermann | Aug 2007 | B2 |
7309597 | Liao et al. | Dec 2007 | B2 |
7314974 | Cao et al. | Jan 2008 | B2 |
7393676 | Gokarn et al. | Jul 2008 | B2 |
7504250 | Emptage et al. | Mar 2009 | B2 |
7858350 | Burk et al. | Dec 2010 | B2 |
7947483 | Burgard et al. | May 2011 | B2 |
20020012939 | Palsson | Jan 2002 | A1 |
20020164729 | Skraly et al. | Nov 2002 | A1 |
20020168654 | Maranas et al. | Nov 2002 | A1 |
20030059792 | Palsson et al. | Mar 2003 | A1 |
20030224363 | Park et al. | Dec 2003 | A1 |
20030233218 | Schilling | Dec 2003 | A1 |
20030233675 | Cao et al. | Dec 2003 | A1 |
20040009466 | Maranas et al. | Jan 2004 | A1 |
20040023347 | Skraly | Feb 2004 | A1 |
20040029149 | Palsson et al. | Feb 2004 | A1 |
20040072723 | Palsson et al. | Apr 2004 | A1 |
20040096946 | Kealey et al. | May 2004 | A1 |
20040106176 | Skraly | Jun 2004 | A1 |
20040152159 | Causey et al. | Aug 2004 | A1 |
20040152166 | Mockel | Aug 2004 | A1 |
20050042736 | San et al. | Feb 2005 | A1 |
20050090645 | Asakura | Apr 2005 | A1 |
20050164342 | Tobin | Jul 2005 | A1 |
20050170480 | Huisman | Aug 2005 | A1 |
20050239179 | Skraly et al. | Oct 2005 | A1 |
20050287655 | Tabata et al. | Dec 2005 | A1 |
20060041152 | Cantrell et al. | Feb 2006 | A1 |
20060046288 | Ka-Yiu et al. | Mar 2006 | A1 |
20060084155 | Huisman et al. | Apr 2006 | A1 |
20060134760 | Rieping | Jun 2006 | A1 |
20060141594 | San et al. | Jun 2006 | A1 |
20070072279 | Meynial-Salles et al. | Mar 2007 | A1 |
20070087425 | Ohto | Apr 2007 | A1 |
20070184539 | San et al. | Aug 2007 | A1 |
20070190605 | Bessler et al. | Aug 2007 | A1 |
20070259410 | Donaldson et al. | Nov 2007 | A1 |
20070292927 | Donaldson et al. | Dec 2007 | A1 |
20080120732 | Elliot | May 2008 | A1 |
20080138870 | Bramucci et al. | Jun 2008 | A1 |
20080171371 | Yukawa et al. | Jul 2008 | A1 |
20080182308 | Donaldson et al. | Jul 2008 | A1 |
20080229451 | Cao et al. | Sep 2008 | A1 |
20080261230 | Liao et al. | Oct 2008 | A1 |
20080274524 | Bramucci et al. | Nov 2008 | A1 |
20080274525 | Bramucci et al. | Nov 2008 | A1 |
20080274526 | Bramucci et al. | Nov 2008 | A1 |
20080293125 | Subbian et al. | Nov 2008 | A1 |
20090023182 | Schilling | Jan 2009 | A1 |
20090075351 | Burk et al. | Mar 2009 | A1 |
20090100536 | Adams et al. | Apr 2009 | A1 |
20090158452 | Johnson et al. | Jun 2009 | A1 |
20090246842 | Hawkins et al. | Oct 2009 | A1 |
20090253192 | Emptage et al. | Oct 2009 | A1 |
20100099925 | Kharas | Apr 2010 | A1 |
20100184171 | Jantama et al. | Jul 2010 | A1 |
20100304453 | Trawick et al. | Dec 2010 | A1 |
20110045575 | Van Dien et al. | Feb 2011 | A1 |
20110129904 | Burgard et al. | Jun 2011 | A1 |
20110190513 | Lynch | Aug 2011 | A1 |
Number | Date | Country |
---|---|---|
1230276 | Apr 1971 | GB |
1314126 | Apr 1973 | GB |
1344557 | Jan 1974 | GB |
1512751 | Jun 1978 | GB |
62285779 | Dec 1987 | JP |
10-2004-0060149 | Jul 2004 | KR |
10-2005-0076301 | Aug 2005 | KR |
10-2005-0076317 | Aug 2005 | KR |
10-2005-0076348 | Aug 2005 | KR |
10-2006-0026599 | Mar 2006 | KR |
10-2009-0025902 | Mar 2009 | KR |
WO 8203854 | Nov 1982 | WO |
WO 9100917 | Jan 1991 | WO |
WO 9219747 | Nov 1992 | WO |
WO 9302187 | Feb 1993 | WO |
WO 9302194 | Apr 1993 | WO |
WO 9306225 | Apr 1993 | WO |
WO 9411519 | May 1994 | WO |
WO 9412014 | Jun 1994 | WO |
WO 9420614 | Sep 1994 | WO |
WO 9420615 | Sep 1994 | WO |
WO 9511985 | May 1995 | WO |
WO 9906532 | Feb 1999 | WO |
WO 9914313 | Mar 1999 | WO |
WO 0061763 | Oct 2000 | WO |
WO 02055995 | Jul 2002 | WO |
WO 02061115 | Aug 2002 | WO |
WO 03008603 | Jan 2003 | WO |
WO 03106998 | Dec 2003 | WO |
WO 2004018621 | Mar 2004 | WO |
WO 2004029235 | Apr 2004 | WO |
WO 2005026338 | Mar 2005 | WO |
WO 2005052135 | Jun 2005 | WO |
WO 2007030830 | Mar 2007 | WO |
WO 2007141208 | Dec 2007 | WO |
WO 2008018930 | Feb 2008 | WO |
WO 2008027742 | Jun 2008 | WO |
WO 2008115840 | Sep 2008 | WO |
WO 2008115840 | Sep 2008 | WO |
WO 2008131286 | Oct 2008 | WO |
WO 2008144626 | Nov 2008 | WO |
WO 2009011974 | Jan 2009 | WO |
WO 2009023493 | Feb 2009 | WO |
WO 2009031766 | Mar 2009 | WO |
WO 2009049274 | Apr 2009 | WO |
WO 2009094485 | Jul 2009 | WO |
WO 2009103026 | Aug 2009 | WO |
WO 2009111513 | Sep 2009 | WO |
WO 2009111513 | Sep 2009 | WO |
WO 2009131040 | Oct 2009 | WO |
WO 2010085731 | Jul 2010 | WO |
Entry |
---|
U.S. Appl. No. 12/049,256, filed Mar. 14, 2008, Mahatan, C., Compositions and Methods for the Biosynthesis of 1,4-Butanediol and its Precursors, Allowed. |
U.S. Appl. No. 12/830,238, filed Jul. 2, 2010, Unassigned, Compositions and Methods for the Biosynthesis of 1,4-Butanediol and its Precursors, Abandoned. |
U.S. Appl. No. 11/891,602, filed Aug. 10, 2007, Joike, M., Methods and Organisms for the Growth-Coupled Production of 1,4-Butanediol, Granted. |
U.S. Appl. No. 13/065,303, filed Mar. 18, 2011, Joike, M., Methods and Organisms for the Growth-Coupled Production of 1,4-Butanediol, Published. |
U.S. Appl. No. 12/556,550, filed Sep. 9, 2009, Kam, C. M., Microorganisms for the Production of 1,4-Butanediol, Granted. |
U.S. Appl. No. 12/947,790, filed Nov. 16, 2010, Kam, C. M., Microorganisms for the Production of 1,4-Butanediol, Published. |
U.S. Appl. No. 13/009,813, filed Nov. 19, 2011, Kam, C. M., Microorganisms for the Production of 1,4-Butanediol, Pending. |
U.S. Appl. No. 12/793,623, filed Jun. 3, 2010, Martin, P. C., Process of Separating Components of a Fermentation Broth, Published. |
U.S. Appl. No. 12/794,700, filed Jun. 4, 2010, Gangle, B., Microorganisms for the Production of 1,4-Butanediol and Related Methods, Published. |
U.S. Appl. No. 12/878,980, filed Sep. 9, 2010, Unassigned, Microorganisms and Methods for the Co-Production of Isopropanol with Primary Alcohols, Diols and Acids, Published. |
U.S. Appl. No. 12/904,130, filed Oct. 13, 2010, Unassigned, Microorganisms for the Production of 1,4-Butanediol, 4-Hydroxybutanal, 4-Hydroxybutyryl-Coa, Putrescine and Related Compounds, and Methods Related Thereto, Published. |
U.S. Appl. No. 13/109,732, filed May 17, 2011, Ramirez, D. M., Microorganisms for the Production of 1,4-Butanediol, 4-Hydroxybutanal, 4-Hydroxybutyryl-Coa, Putrescine and Related Compounds, and Methods Related Thereto, Pending. |
U.S. Appl. No. 13/011,796, filed Jan. 21, 2011, Carlson, K., Methods for Increasing Product Yields, Allowed. |
U.S. Appl. No. 13/011,788, filed Jan. 21, 2011, Unassigned, Methods for Increasing Product Yields, Published. |
U.S. Appl. No. 13/011,818, filed Jan. 21, 2011, Desai, A., Methods for Increasing Product Yields, Published. |
U.S. Appl. No. 12/940,021, filed Nov. 4, 2010, Kosson, R., Microorganisms and Methods for the Coproduction 1,4-Butanediol and Gamma-Butyrolactone, Published. |
Abe et al., “Biosynthesis from gluconate of a random copolyester consisting of 3-hydroxybutyrate and medium-chain-length 3-hydroxyalkanoates by Pseudomonas sp. 61-3,” Int. J. Biol. Macromol. 16(3):115-119 (1994). |
Aberhart and Hsu, “Stereospecific hydrogen loss in the conversion of [2H7]isobutyrate to beta-hydroxyisobutyrate in Pseudomonas putida. The stereochemistry of beta-hydroxyisobutyrate dehydrogenase,” J. Chem. Soc. Perkin1. 6:1404-1406 (1979). |
Abiko et al., “Localization of NAD-isocitrate dehydrogenase and glutamate dehydrogenase in rice roots: candidates for providing carbon skeletons to NADH-glutamate synthase,” Plant Cell Physiol. 46(10):1724-1734 (2005). |
Adams and Kletzin, “Oxidoreductase-type enzymes and redox proteins involved in fermentative metabolisms of hyperthermophilic Archaea,” Adv. Protein Chem. 48:101-180 (1996). |
Aevarsson et al., “Crystal structure of2-oxoisovalerate and dehydrogenase and the architecture of 2-oxo acid dehydrogenase multienzyme complexes,” Nat. Struct. Biol. 6:785-792 (1999). |
Ahmed and Lewis, “Fermentation of biomass-generated synthesis gas: effects of nitric oxide,” Biotechnol. Bioeng. 97:1080-1086 (2007). |
Aidoo et al., “Cloning, sequencing and disruption of a gene from Streptomyces clavuligerus Involved in clavulanic acid biosynthesis,” Gene 147(1):41-46 (1994). |
Akhtar and Jones, “Construction of a synthetic YdbK-dependent pyruvate:H2 pathway in Escherichia coli BL21(DE3),” Metabolic Eng. 11:139-147 (2009). |
Alber et al., “Malonyl-coenzyme A reductase in the modified 3-hydroxypropionate cycle for autotrophic carbon fixation in archaeal Metallosphaera and Sulfolobus spp.,” J. Bacteriol. 188:8551-8559 (2006). |
Alberty, “Biochemical thermodynamics,” Biochem. Biophys. Acta. 1207:1-11 (1994). |
Alhapel et al., “Molecular and functional analysis of nicotinate catabolism in Eubacterium barkeri,” Proc. Natl. Acad. Sci. USA 103(33)12341-12346 (2006). |
Allen et al., “DNA sequence of the putA gene from Salmonella typhimurium: a bifunctional membrane-associated dehydrogenase that binds DNA,” Nucleic Acids Res. 21:1676 (1993). |
Amarasingham and Davis, “Regulation of alpha-ketoglutarate dehydrogenase formation in Escherichia coli,” J. Biol. Chem. 240: 3664-3668 1965. |
Amos and McInerey, “Composition of poly-.beta.-hydroxyalkanoate from Syntrophomonas wottei grown on unsaturated fatty acid substrates,” Arch. Microbiol. 155:103-106 (1991). |
Amuro et al., “Isolation and characterization of the two distinct genes for human glutamate dehydrogenase,” Biochem. Biophys. Acta. 1049:216-218 1990. |
Andersen and Hansen, “Cloning of the lysA gene from Mycobacterium tuberculosis,” Gene 124:105-109 1993. |
Andersen et al., “A gene duplication led to specialized gamma-aminobutyrate and beta-alaine aminotransferase in yeast,” FEBS J. 274(7):1804-1817 (2007). |
Andre and Jauniaux, “Nucleotide sequence of the yeast UGA1 gene encoding GABA transaminase,” Nucleic Acids Res. 18:3049 (1990). |
Andreesen and Ljungdahl, “Formate dehydrogenase of Clostridium thermoaceticum: incorporation of selenium-75, and the effects of selenite, molybdate, and tungstate on the enzyme,” J. Bacteriol. 116:867-873 (1973). |
Aneja and Charles, “Poly-3-hydroxybutyrate degradation in Rhizobium (Sinorhizobium) meliloti: isolation and characterization of a gene encoding 3-hydroxybutryate dehydrogenase,” J. Bacteriol. 181(3):849-857 (1999). |
Angrand et al., “Simplified generation of targeting constructs using ET recombination,” Nucleic Acids Res. 27:e16. (1999). |
Ansorge and Kula, “Production of Recombinant L-Leucine Dehydrogenase from Bacillus cereus in Pilot Scale Using the Runaway Replication System E. coli[pIET98],” Biotechnol. Bioeng. 68-557-562 (2000). |
Aoshima and Igarashi, “A novel biotin protein required for reductive carboxylation of 2-oxoglutarate by isocitrate dehydrogenase in Hydrogenobacter thermophilus TK-6,” Mol. Microbiol. 51(3):791-798 (2004). |
Aoshima and Igarshi, “Nondecarboxylating and decarboxylating isocitrate dehydrogenases: oxalosuccinate reductas as an ancestral form of isocitrate dehydrogenase,” J. Bacteriol. 190(6):2050-2055 (2008). |
Aoshima et al., “A novel enzyme, citryl-CoA lyase, catalysing the second step of the citrate cleavage reaction in Hydrogenobacter thermophilus TK-6,” Mol. Microbiol. 52(3):763-770 (2004). |
Aoshima et al., “A novel enzyme, citryl-CoA synthetase, catalysing the first step of the citrate cleavage reaction in Hydrogenobacter thermophilus TK-6,” Mol. Microbiol. 52(3):751-756 (2004). |
Aoshima et al., “A novel oxalosuccinate-forming enzyme involved in the reductive carboxylation of 2-oxoglutarate in Hydrogenobacter thermophilus TK-6,” Mol. Microbiol. 62(3):748-759 (2006). |
Aoshima, “Novel enzyme reactions related to the tricarboxylic acid cycle: phylogenetic/functional implications and biotechnological applications,” Appl. Microbiol. Biotechnol. 75(2):249-255 (2007). |
Aragon and Lowenstein, “A survey of enzymes which generate or use acetoacetyl thioesters in rat liver,” J. Biol. Chem. 258(8):4725-4733 (1983). |
Arikawa et al., “Soluble fumarate reductase isoenzymes from Saccharomyces cerevisiae are required for anaerobic growth,” FEMS Microbiol. Lett. 165:111-116 (1998). |
Arps et al., “Genetics of Serine Pathway Enzymes in Methylobacterium extorquens AM1: Phosphoenolpyruvate Carboxylase and Malyl Coenzyme A Lyase,” J. Bacteriol. 175(12):3776-3783 (1993). |
Asano and Kato, “Crystalline 3-methylaspartase from a facultative anaerobe, Escherichia coli strain YG1002,” FEMS Microbiol. Lett. 118(3):255-258 (1994). |
Asano et al., “Alteration of substrate specificity of aspartase by directed evolution,” Biomol. Eng. 22:95-101 (2005). |
Asuncion et al., “Overexpression, purification, crystallization and data collection of 3-methylaspartase from Clostridium tetanomorphum,” Acta Crystallogr.D. Biol. Crystallogr. 57:731-733 (2001). |
Asuncion et al., “The Structure of 3-Methylaspartase from Clostridium tetanomorphum Functions via the Common Enolase Chemical Step,” J. Biol. Chem. 277(10):8306-8311 (2002). |
Atsumi et al., “Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels,” Nature 451(7174):86-89 (2008). |
Baba et al., “Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection,” Mol. Syst. Biol. 2:2006.0008 (2006). |
Baker and van der Drift, “Purification and properties of L-erythro-3,5-diaminohexanoate dehydrogenase from Clostridium sticklandii,” Biochemistry 13(2):292-299 (1974). |
Baker et al., “Purification and properties of L-erythro-3,5-diaminohexanoate dehydrogenase from a lysine-fermenting Clostirdium,” J. Biol. Chem. 247(23):7724-7734 (1972). |
Barker et al., “Butyryl-CoA:acetoacetate CoA-transferase from a lysine-fermenting Clostridium,” J. Biol. Chem. 253(4):1219-1225 (1978). |
Barker et al., “Pathway of Lysine Degradation in Fusobacterium nucleatum,” J. Bacteriol. 152(1):201-207 (1982). |
Barrick et al., “Quantitative analysis of ribosome binding sites in E.coli,” Nucleic Acids Res. 22:1287-1295 (1994). |
Barrowman et al., “Immunological comparison of microbial TPP-dependent non-oxidative alpha-keto acid decarboxylase,” FEMS Microbiology Lett. 34:57-60 (1986). |
Barthelmebs et al., “Expression of Escherichia coli of Native and Chimeric Phenolic Acid Decarboxylases with Modified Enzymatic activites and Method for Scrreening recombinant E. coli Strains Expressing These Enzymes,” Appl. Environ. Microbiol. 67:1063-1069 (2001). |
Bartsch et al., “Molecular analysis of two genes of the Escherichia coli gab cluster: nucleotide sequence of the glutamate:succinic semialdehyde transaminase gene (gabT) and characterization of the succinic semialdehyde dehydrogenase gene (gabD),” J. Bacteriol. 172:7035-7042 (1990). |
Baum et al., “A plant glutamate decarboxylase containing a calmodulin binding domain, Cloning, sequence, and functional analysis,” J. Biol. Chem. 268:19610-19617 (1993). |
Benachenhou-Lahfa et al., “PCR-mediated cloning and sequencing of the gene encoding glutamate dehydrogenase from the archaeon Sulfolobus shiibatae: Identification of putative amino-acid signatures for extremophilic adaptation,” Gene 140:17-24 (1994). |
Berg et al., “A 3-Hydroxypropionate/4-Hydroxybutyrate Autotrophic Carbon Dioxide Assimilation Pathway in Archaea,” Science 318:1782-1786 (2007). |
Bergquist and Gibbs, “Degenerate oligonucleotide gene shuffling,” Methods Mol. Biol. 352:191-204 (2007). |
Bergquist et al., “Degenerate oligonucleotide gene shuffling (DOGS) and random drift mutagenesis (RNDN): two complementary techniques for enzyme evolution,” Biomol. Eng. 22:63-72 (2005). |
Berkovitch et al., “A locking mechanism preventing radical damage in the absence of substrate, as revealed by the x-ray structure of lysine 5,6-aminomutase,” Proc. Natl. Acad. Sci. USA 101:15870-15875 (2004). |
Bermejo et al., “Expression of Clostridium acetobutylicum ATCC 824 Genes in Escherichia coli for Acetone Production and Acetate Detoxification,” Appl. Environ. Microbiol. 64(3):1079-1085 (1998). |
Biellmann et al., “Aspartate-beta-semialdehyde dehydrogenase from Escherichia coli. Purification and general properties,” Eur. J. Biochem. 104(1):53-58 (1980). |
Binstock and Shulz, “Fatty acid oxidation complex from Escherichia coli,” Methods Enzymo. 71 Pt C:403-411 (1981). |
Birrer et al., “Electro-transformation of Clostridium beijerinckii NRRL B-592 with shuttle plasmid pHR106 and recombinant derivatives,” Appl. Microbiol. Biotechnol41(1):32-38 (1994). |
Bisswanger, “Substrate Specificity of the Pyruvate Dehydrogenase Complex from Escherichi coli,” J. Biol. Chem. 256(2):815-822 (1981). |
Blanco et al., “Critical catalytic functional groups in the mechanims of aspartate-β-semialdehyde dehydrogenase,” Acta Crystallogr. D. Biol. Crystallogr. 60:1808-1815 (2004). |
Blanco et al., “The role of substrate-binding roups in the mechanism of asparte-β-semialdehyde dehydrogenase,” Acta Crystallogr. D. Biol. Crystallog. 60:1388-1395 (2004). |
Blaschkowski et al., “Routes of flavodoxin and ferredoxin reduction in Escherichia coli. CoA-acylating pyruvate: flavodoxin and NADPH: flavodoxin oxidoreductases participating in the activation of pyruvate formate-lyase,” Eur.J Biochem. 123:563-569 (1982). |
Blattner et al., “The complete genome sequence of Escherichia coli K-12,” Science277:1453-1462 (1997). |
Boles et al., “Characterization of a glucose-repressed pyruvate kinase (Pyk2p) in Saccharomyces cerevisiae that is catalytically insensitive to fructose-1,6-bisphosphate,” J. Bacteriol. 179:2987-2993 (1997). |
Bonnarme et al., “Itaconate biosynthesis in Aspergillus terreus,” J. Bacteriol. 177(12):3573-3578 (1995). |
Bonner and Bloch, “Purification and Properties of Fatty Acyl Thiesterase I from Escherichia coli,” J. Biol. Chem. 247(10) 3123-3133 (1972). |
Bose et al., “Genetic analysis of the methanol- and methylamine-specific methyltransferase 2 genes of Methanosarcina acetivorans C2A,” J. Bacteriol. 190:4017-4026 (2008). |
Botsford et al., “Accumulation of glutamate by Salmonella typhimurium in response to osmotic stress,” Appl. Environ. Microbiol. 60:2568-2574 (1994). |
Botting et al., “Substrate Specificity of the 3-Methylaspartate Ammonia-Lyase Reaction: Observation of Differential Relative Reaction rates for Substrate-Product Pairs,” Biochemistry 27:2953-2955 (1988). |
Bower et al., “Cloning, Sequencing, and Characterization of the Bacillus subtilis Biotin Biosynthetic Operon,” J. Bacteriol. 178(14):4122-4130 (1996). |
Boynton et al., “Cloning, sequencing, and expression of clustered genes encoding beta-hydroxybutyryl-coenzyme A (CoA) dehydrogenase, crotonase, and butyryl-CoA dehydrogenase from Clostridium acetobutylicum ATCC 824,” J. Bateriol. 178(11):3015-3024 (1996). |
Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Anal. Biochem. 72:248-254 (1976). |
Brandl et al., “Ability of the phototrophic bacterium Rhodospirillum rubrum to produce various poly (beta-hydroxyalkanoates): potential sources for biodegradable polyesters,” Int. J. Biol. Macromol. 11:49-55 (1989). |
Branlant and Branlant, “Nucleotide sequence of the Escherichia coli gap gene. Differente evolutionay behaviour of the Nad+-binding domain and of the catalytic domain of D-glyceraldehyde-3-phosphate dehydrogenase,” Eur. J. Biochem. 150(1):61-66 (1985). |
Brasen and Schonheit, “Unusual ADP-forming acetyl-coenzyme a synthetases from the mesophilic halophilic eurarchaeon Haloarcula marismortui and from the hyperthermophilic crenarchaeon Pyrobaculum aerophilum,” Arch. Microbiol. 182:277-287 (2004). |
Bravo et al., “Reliable, sensitive, rapid and quantitative enzyme-based assay for gamma-hydroxybutyric acid (GHB),” J. Forensic Sci. 49:379-387 (2004). |
Bredwell et al., “Reactor Design Issues for Synthesis-Gas Fermentations,” Biotechnol Prog. 15:834-844 (1999). |
Breitkreuz et al., “A novel gamma-hydroxybutyrate dehydrogenase: identification and expression of an Arabidopsis cDNA and potential role under oxygen deficiency,” J. Biol. Chem. 278:41552-41556 (2003). |
Bremer, “Pyruvate Dehydrogenase, Substrate Specificity and Product Inhibition,” Eur. J. Biochem. 8:535-540 (1969). |
Bridger et al., “The subunits of succinyl-coenzyme. A synthetase—function and assembly,” In Krebs' Citric Acid Cycle—Half a Century and Still Turning, Biochem. Soc. Symp. 54:103-111 (1987). |
Brosch et al., “Genome plasticity of BCG and impact on vaccine efficacy,” Proc. Natl. Acad. Sci. U.S.A. 104(13):5596-5601 (2007). |
Bu et al., “Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene,” Proc. Natl. Acad. Sci. U.S.A. 89(6):2115-2119 (1992). |
Bu, et al., “The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD,” Genomics 21:222-228 (1994). |
Buck and Guest, “Overexpression and site-directed mutagenesis of the succinyl-CoA synthetase of Escherichia coli and nucleotide sequence of a gene (g30) that is adjacent to the suc operon,” Biochem. J. 260(3):737-747 (1989). |
Buck et al., “Primary Structure of the Succinyl-CoA Synthetase of Escherichia coli,” Biochemistry 24:6245-6252 1985. |
Buck et al., “Cloning and expression of the succinyl-CoA synthetase genes of Escherichia coli K12,” J. Gen. Microbiol. 132(6):1753-1762 (1986). |
Buckel et al., “Glutaconate CoA-Transferase from Acidaminococcus fermentans,” Eur. J. Biochem. 118:315-321 (1981). |
Bult et al., “Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii,” Science 273:1058-1073 (1996). |
Burgard and Maranas, “Probing the Performance Limits of the Escherichia coli Metabolic Network Subject to Gene Additions or Deletions,” Biotechnol. Bioeng. 74(5):364-375 (2001). |
Burgard et al., “Minimal reaction sets for Escherichia coli metabolism under different growth re quirements and uptake environments,” Biotechnol. Prog. 17(5):791-797 (2001). |
Burgard et al., “Optknock: a bilevel programming framework for identifying gene knockout strategies for microbial strain optimization,” Biotechnol. Bioeng. 84(6):647-657 (2003). |
Burke et al, “The Isolation, Characterization, and Sequence of the Pyruvate Kinase Gene of Saccharomyces cerevisiae,” J. Biol. Chem. 258(4):2193-2201 (1983). |
Buu et al., “Functional Characterization and Localization of Acetyl-CoA Hydrolase, Ach1p, in Saccharomyces cerevisiae,” J. Biol. Chem. 278(19):17203-17209 (2003). |
Campbell et al., “A new Escherichia coli metabolic competency: growth on fatty acids by a novel anaerobic β-oxidation pathway,” Mol. Microbiol. 47(3):793-805 (2003). |
Cary et al., “Cloning and expression of Clostridium acetobutylicum ATCC 824 acetoacetyl-coenzyme A:acetate/butyrate:coenzyme A-transferase in Escherichia coli,” Appl. Environ. Microbiol. 56(6):1576-1583 (1990). |
Cary et al., “Cloning and expression of Clostridium acetobutylicum phosphotransbutyrylase and butyrate kinase genes in Escherichia coli,” J. Bacteriol. 170(10):4613-4618 (1988). |
Caspi et al., “MetaCyc: a multiorganism database of metabolic pathways and enzymes,” Nucleic Acids Res. 34(Database issue):D511-D516 (2006). |
Causey et al., “Engineering Escherichia coli for efficient conversion of glucose to pyruvate,” Proc. Natl. Acad. Sci. U.S.A. 101:2235-2240 (2004). |
Cha and Parks, Jr., “Succinic Thiokinase. I. Purification of the Enzyme from Pig Heart,” J. Biol. Chem. 239:1961-1967 (1964). |
Chandra Raj et al., “Pyruvate decarboxylase: a key enzyme for the oxidative metabolism of lactic acid by Acetobacter pasteruianus,” Arch. Microbiol. 176:443-451 (2001). |
Chavez et al., “The NADP-glutamate dehydrogenase of the cyanobacterium Synechocystis 6803: cloning, transcriptional analysis and disruption of the gdhA gene,” Plant Mol. Biol. 28:173-188 (1995). |
Chen and Hiu, “Acetone-Butanol-Isopropanol Production by Clostridium beijerinckii (Synonym, Clostridium butylicum),” Biotechnology Letters 8(5):371-376 (1986). |
Chen and Lin, “Regulation of the adhE gene, which encodes ethanol dehydrogenase in Escherichia coli,” J. Bacteriol. 173(24):8009-8013 (1991). |
Chen et al., “A novel lysine 2,3-aminomutase encoded by the yodO gene of Bacillus subtilis: characterization and the observation of organic radical intermediates,” Biochem. J. 348:539-549 (2000). |
Chen et al., “Cloning, Sequencing, Heterologous Expression, Purification, and Characterization of Adenosylcobalamin-dependent D-Ornithine Aminomutase from Clostridium sticklandii,” J. Biol. Chem. 276:44744-44750 (2001). |
Chicco et al., “Regulation of Gene Expression of Branched-chain Keto Acid Dehydrogenase Complex in Primary Cultured Hepatocytes by Dexamethasone and cAMP Analog,” J. Biol. Chem. 269(30):19427-19434 (1994). |
Chirpich et al., “Lysine 2,3-Aminomutase. Purification and properties of a pyridoxal phosphate and S-adenosylmethionine-activated enzyme,” J. Biol. Chem. 245(7):1778-1789 (1970). |
Cho et al., “Critical residues for the coenzyme specificity of NAD+-deptendent 15-hydroxyprtaglandin dehydrogenase,” Arch. Biochem. Biophys. 419(2): 139-146 (2003). |
Chowdhury et al., “Cloning and Overexpression of the 3-Hydroxyisobutyrate Dehydrogenase Gene from Pseudomonas putida E23,” Biosci. Biotechnol. Biochem. 67(2):438-441 (2003). |
Chowdhury et al., “3-Hydroxyisobutyrate dehydrogenase from Pseudomonas putida E23: purification and characterization,” Biosci. Biotechnol. Biochem. 60(12):2043-2047 (1996). |
Christenson et al., “Kinetic analysis of the 4-methylideneimidazole-5-one-containing tyrosine aminomutase in enediyne antitumor antibiotic C-1027 biosynthesis,” Biochemistry 42(43):12708-12718 (2003). |
Chu et al., “Enzymatically active truncated cat brain glutamate decarboxylase: expression, purification, and absorption spectrum,” Arch. Biochem. Biophys. 313:287-295 (1994). |
Clark and Ljungdahl, “Purification and properties of 5,10-methylenetetrahydrofolate reductase from Clostridium formicoaceticum,” Methods Enzymol. 122:392-399 (1986). |
Clark and Ljungdahl, “Purification and properties of 5,10-methylenetetrahydrofolate reductase, an iron-sulfur flavoprotein from Clostridium formicoaceticum,” J. Biol. Chem. 259:10845-10849 (1984). |
Clark, Progress Report for Department of Energy Grant DE-FG02-88ER13941, “Regulation of Alcohol Fermentation in Escherichia coli,” pp. 1-7 for the period: Jul. 1991-Jun. 1994. |
Clarke et al., “Rational construction of a 2-hydroxyacid dehydrogenase with new substrate specificity,” Biochem. Biophys. Res. Commun. 148:15-23 (1987). |
Clausen et al., “PAD1 encodes phenylacrylic acid decarboxylase which confers resistance to cinnamic acid in Saccharomyces cerevisiae,” Gene 142:107-112 (1994). |
Cock et al., “A nuclear gene with many introns encoding ammonium-inductible chloroplastic NADP-specific glutamate dehydrogenase(s) in Chlorella sorokiniana,” Plant Mol. Biol. 17:1023-1044 (1991). |
Coco et al., “DNA shuffling method for generating highly recombined genes and evolved enzymes,” Nat. Biotechnol. 19(4):354-359 (2001). |
Cogoni et al., “Saccharomyces cerevisiae has a single glutamate synthase gene coding for a plant-like high-molecular-weight polypeptide,” J. Bacteriol. 177:792-798 (1995). |
Colby and Chen, “Purification and properties of 3-Hydroxybutyryl-Coenzyme A Dehydrogenase from Clostridium beijerinckii (Clostridium butylicum:) NRRL 8593,” Appl. Environ. Microbiol. 58:3297-3302 (1992). |
Cole et al., “Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence,” Nature 393:537-544 (1998). |
Coleman et al., “Expression of a glutamate decarboxylase homologue is required for normal oxidative stress tolerance in Saccharomyces cerevisiae,” J. Biol. Chem. 276:244-250 (2001). |
Cooper, “Glutamate-γ-aminobutyrate transaminase,” Methods Enzymol. 113:80-82 (1985). |
Corthesy-Theulaz et al., “Cloning and characterization of Helicobacter pylori succinyl CoA:acetoacetate CoA-transferase, a novel prokaryotic member of the CoA-transferase family,” J. Biol. Chem. 272(41):25659-25667 (1997). |
Creaghan and Guest, “Succinate dehydrogenase-dependent nutritional requirement for succinate in mutants of Escherichia coli K12 ” J. Gen. Microbiol. 107(1):1-13 (1978). |
Cukalovic et al., “Feasibility of production method for succinic acid derivatives: a marriage of renewable resources and chemical technology,” Biofuels Bioprod. Bioref. 2:505-529 (2008). |
Cunningham and Guest, “Transcription and transcript processing in the sdhCDAB-sucABCD operon of Escherichia coli,” Microbiology 144:2113-2123 (1998). |
Cunningham et al., “Transcriptional regulation of the aconitase genes (acnA and acnB) of Escherichia coli,” Microbiology 143:3795-3805 (1997). |
D'Ari and Rabinowitz, “Purification, characterization, cloning, and amino acid sequence of the bifunctional enzyme 5,10-methylenetetrahydrofolate dehydrogenase/5,10-methenyltetrahydrofolate cyclohydrolase from Escherichia coli,” J. Biol. Chem. 266:23953-23958 (1991). |
Darlison et al., “Nucleotide sequence of the sucA gene encoding the 2-oxoglutarate dehydrogenase of Escherichia coli K12,” Eur. J. Biochem. 141(2):351-359 (1984). |
Das et al, “Characterization of a corrinoid protein involved in the C1 metabolism of strict anaerobic bacterium Moorella thermoacetica,” Proteins 67:167-176 (2007). |
Database WPI Week 198804 Thomson Scientific, London, GB; AN 1988-025175. |
Datar et al., “Fermentation of biomass-generated producer gas to ethanol,” Biotechnol. Bioeng. 86:587-594 (2004). |
Datsenko and Wanner, “One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products,” Proc. Natl. Acad. Sci. U.S.A. 97(12):6640-6645 (2000). |
Davie et al., “Expression and Assembly of a Functional E1 Component (α2β2) of Mammalian Branched-Chain α-Ketoacid Dehydrogenase Complex in Escherichia coli,” J. Biol. Chem. 267:16601-16606 (1992). |
De Biase et al., “Isolation, overexpression, and biochemical characterization of the two isoforms of glutamic acid decarboxylase from Escherichia coli,” Protein Expr. Purif. 8:430-438 (1996). |
de Bok et al., “Two W-containing formate dehydrogenases (CO2-reductases) involved in syntrophic propionate oxidation by Syntrophobacter fumaroxidans,” Eur. J. Biochem. 270:2476-2485 (2003). |
de la Torre et al., “Identification and functional analysis of prokaryotic-type aspartate aminotransferase: implications for plant amino acid metabolism,” Plant J. 46(3):414-425 (2006). |
de Mata and Rabinowitz, “Formyl-methenyl-methylenetetrahydrofolate synthetase(combined) from yeast. Biochemical characterization of the protein from an ade3 mutant lacking the formyltetrahydrofolate synthetase function,” J. Biol. Chem. 255:2569-2577 (1980). |
Deana, “Substrate specificity of a dicarboxyl-CoA: dicarboxylic acid coenzyme A transferase from rat liver mitochondria,” Biochem. Int. 26(4):767-773 (1992). |
Deckert et al., “The complete genome of the hyperthermophilic bacterium Aquifex aeolicus,” Nature 392:353-358 1998. |
Diao et al., “Crystal Structure of Butyrate Kinase 2 from Thermotoga maritima, a Member of the ASKHA Superfamily of Phosphotransferases,” J. Bacteriol. 191(8):2521-2529 (2009). |
Diao et al., “Crystallization of butyrate kinase 2 from Thermotoga maritima medicated by varpor diffusion of acetic acid ” Acta Crystallogr. D. Crystallogr. 59:1100-1102 (2003). |
Diaz et al., “Gene cloning, heterologous overexpression and optimized refolding of the NAD-glutamate dehydrogenase from haloferax mediterranei,” Extremophiles. 10(2):105-115 (2006). |
Diderichsen et al., “Cloning of aldB, which encodes alpha-acetolactate decarboxylase, an exoenzyme from Bacillus brevis,” J. Bacterial. 172(8):4315-4321 (1990). |
Diruggiero et al., “Expression and in vitro assembly of recombinant glutamate dehydrogenase from the hyperthermophilic archaeon Pyrococcus turiosus,” Appl. Environ. Microbiol. 61:159-164 (1995). |
Do et al., “Engineering Escherichia coli for fermentative dihydrogen production: potential role of NADH-ferredoxin oxidoreductase from the hydrogenosome of anaerobic protozoa,” Appl. Biochem. Biotechnol. 153:21-33 (2009). |
Dobbek et al., “Crystal structure of a carbon monoxide dehydrogenase reveals a [Ni-4Fe-5S] cluster,” Science 293:1281-1285 (2001). |
Doi et al., “Biosynthesis and characterization of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in Alcaligenes eutrophus,” Int. J. Biol. Macromol. 12:106-111 (1990). |
Doi et al., “Nuclear Magnetic Resonance Studies on Unusual Bacterial Copolyesters of 3-Hydroxybutyrate and 4-Hydroxybutyrate,” Macromolecules 21:2722-2727 (1988). |
Doi, “Microbial Synthesis, Physical Properties, and Biodegradability of Polyhydroxyalkanoates,” Macromol. Symp. 98:585-599 (1995). |
Dombek and Ingram, “Ethanol production during batch fermentation with Saccharomyces cerevisiae: changes in glycolytic enzymes and internal pH,” Appl. Environ. Mircobiol. 53:1286-1291 (1987). |
Donnelly and Cooper, “Succinic semialdehyde dehydrogenases of Escherichia coli: their role in the degradation of p-hydroxyphenylacetate and gamma-aminobutyrate,” Eur. J. Biochem. 113(3):555-561 (1981). |
Donnelly and Cooper, “Two succinic semialdehyde dehydrogenases are induced when Escherichia coli K-12 is grown on gamma-aminobutyrate,” J. Bacteriol. 145:1425-1427 (1981). |
Dover et al., “Genetic analysis of the gamma-aminobutyrate utilization pathway in Escherichia coli K-12,” J. Bacteriol. 117(2):494-501 (1974). |
Doyle et al., “Structural basis for a change in substrate specificity: crystal structure of S113E isocitrate dehydrogenase in a complex with isopropylmalate, Mg2+, and NADP,” Biochemistry 40(14):4234-4241 (2001). |
Drake and Daniel, “Physiology of the thermophilic acetogen Moorella thermoacetica,” Res. Microbiol. 155:869-883 (2004). |
Drake, “Demonstration of hydrogenase in extracts of the homoacetate-fermenting bacterium Clostridium thermoaceticum,” J. Bacteriol. 150:702-709 (1982). |
Drake, “Acetogenesis, acetogenic bacteria, and the acetyl-CoA “Wood/Ljungdahl” pathway: past and current perspectives,” in H.L. Drake (ed.), Acetogenesis pp. 3-60 Chapman and Hall, New York (1994). |
Drewke et al., “4-O-Phosphoryl-L-threonine, a substrate of the pdxC(serC) gene product involved in vitamin B6 biosynthesis,” FEBS Lett. 390:179-182 (1996). |
Duncan et al., “Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine,” Appl. Environ. Microbiol. 68(10):5186-5190 (2002). |
Duncan et al., “Purification and properties of NADP-dependent glutamate dehydrogenase from Ruminococcus flavefaciens FD-1,” Appl. Environ. Microbiol. 58:4032-4037 (1992). |
Durre and Bahl, “Microbial Production of Acetone/Butanol/Isopropanol,” In Biotechnology vol. 6: “Products of Primary Metabolism”, Second edition pp. 229-268, M. Roehr, ed. Published jointly by: VCH Verlagsgesellschaft mbH, Weinheim, Federal Republic of Germany and VCH Publishers Inc., New York, NY (1996). |
Dürre et al., “Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation,” FEMS Microbiol. Rev. 17(3):251-262 (1995). |
Dürre, “New insights and novel developments in clostridial acetone/butanol/isopropanol fermentation,” Appl. Microbiol. Biotechnol. 49:639-648 (1998). |
Edwards and Palsson, “Systems properties of the Haemophilus influenzae Rd metabolic genotype,” J. Biol. Chem. 274(25):17410-17416 (1999). |
Edwards and Palsson, “The Escherichia coli MG1655 in silico Metabolic Genotype: Its Definition, Characteristics, and Capabilities,” Proc. Natl. Acad. Sci. U.S.A. 97(10):5528-5533 (2000). |
Edwards et al., “In Silico Predictions of Escherichia coli metabolic capabilities are Consistent with Experimental Data,” Nat. Biotechnol. 19(2):125-130 (2001). |
Efe et al., “Options for biochemical production of 4-hydroxybutyrate and its lactone as a substitute for petrochemical production,” Biotechnol. Bioeng. 99:1392-1406 (2008). |
Eggen et al., “The glutamate dehydrogenase-encoding gene of the hyperthermophilic archaeon Pyrococcus furiosus: sequence, transcription and analysis of the deduced amino acid sequence,” Gene 132:143-148 (1993). |
Eikmanns et al., “The phosphoenolpyruvate carboxylase gene of Corynebacterium glutamicum: Molecular cloning, nucleotide sequence, and expression,” Mol. Gen. Genet. 218:330-339 (1989). |
Ekiel et al., “Acetate and CO2 assimilation by Methanothrix concilii,” J. Bacteriol. 162(3):905-908 (1985). |
Enomoto et al., “Cloning and sequencing of the gene encoding the soluble fumarate reductase from Saccharomyces cerevisiae,” DNA Res. 3:263-267 (1996). |
Estevez et al., “X-ray crystallographic and kinetic correlation of a clinically observed human fumarase mutation,” Protein Sci. 11:1552-1557 (2002). |
Evans et al., “A new ferredoxin-dependent carbon reduction cycle in a photosynthetic bacterium,” Proc. Natl. Acad. Sci. U.S.A. 55 4 :928-934 1966. |
Faehnle et al., “A New Branch in the Family: Structure of Aspartate-β-semialdehyde dehydrogenase from Methanococcus jannaschii,” J. Mol. Biol. 353:1055-1068 (2005). |
Feist et al., “The growing scope of applications of genome-scale metabolic reconstructions using Escherichia coli,” Nat. Biotechnol. 26(6):659-667 (2008). |
Fell and Small, “Fat Synthesis in Adipose Tissue. An Examination of Stoichiometric Constraints,” Biochem. J. 238(3):781-786 (1986). |
Fernandez-Valverde et al., “Purification of Pseudomonas putida Acyl coenzyme a Ligase Active with a Range of Aliphatic and Aromatic Substrates,” Appl. Environ. Microbiol. 59:1149-1154 (1993). |
Filetici et al., “Sequence of the GLT1 gene from Saccharomyces cerevisiae reveals the domain structure of yeast glutamate synthase,” Yeast 12:1359-1366 (1996). |
Fischer and Sauer, “Metabolic flux profiling of Escherichi coli mutants in central carbon metabolism using GC-MS,” Eur. J. Biochem. 270(5) 880-891 (2003). |
Fishbein and Bessman, “Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of gamma-lactones. I. Tissue localization, stoichiometry, specificity, distinction from esterase,” J. Biol. Chem. 241(21):4835-4841 (1966). |
Föllner et al., “Analysis of the PHA granule-associatc proteins GA20 and GA11 in Methylobacterium extorquens and Methylobacterium rhodesianum,” J. Basic. Microbiol. 37(1):11-21 (1997). |
Fong and Palsson, “Metabolic gene-deletion strains of Escherichia coli evolve to computationally predicted growth phenotypes,” Nat. Genet. 36(10):1056-1058 (2004). |
Fong et al., “Description and interpretation of adaptive evolution of Escherichia coli K-12 MG1655 by using a genome-scale in silico metabolic model,” J. Bacteriol. 185(21):6400-6408 (2003). |
Fontaine et al., “A New Type of Glucose Fermentation by Clostridium thermoaceticum N.Sp.,” J. Bacteriol. 43:701-715 (1942). |
Fontaine et al., “Molecular characterization and transcriptional analysis of adhE2, the gene encoding the NADH-dependent aldehyde/alcohol dehydrogenase responsible for butanol production in alcohologenic cultures of Clostridium acetobutylicum ATCC 824,” J. Bacteriol. 184(3):821-830 (2002). |
Ford, et al., “Molecular properties of the lys1+ gene and the regulation of alpha-aminoadipate reductase in Schizosaccharomyces pombe,” Curr. Genet. 28(2):131-137 (1995). |
Forster et al., “Genome-scale reconstruction of the Saccharomyces cerevisiae metabolic network,” Genome Res. 13:244-253 (2003). |
Fox et al, “Characterization of the region encoding the CO-induced hydrogenase of Rhodospirillum rubrum,” J. Bacteriol. 178:6200-6208 (1996). |
Friedrich et al., “The complete stereochemistry of the enzymatic dehydration of 4hydroxybutyryl coenzyme A to crotonyl coenzyme A ” Angew. Chem. Int. Ed. Engl. 47:3254-3257 (2008). |
Fries et al., “Reaction Mechanism of the Heteroameric (α2β2) E1 Component of 2-Oxo Acid Dehydrogenase Multienzyme Complexes,” Biochemistry 42:6996-7002 (2003). |
Fuhrer, et al., “Computational prediction and experimental verification of the gene encoding the NAD+/NADP+-dependent succinate semialdehyde dehydrogenase in Escherichia coli,” J. Bacteriol. 189:8073-8078 (2007). |
Fujii et al., “Characterization of L-lysine 6-aminotransferase and its structural gene from Favobacterium lutescens IFO3084,” J. Biochem. 128(3):391-397 (2000). |
Fujii et al., “Error-prone rolling circle amplification: the simplest random mutagenesis protocol,” Nat. Protoc. 1(5):2493-2497 (2006). |
Fujii et al., “One-step random mutagenesis by error-prone rolling circle amplification,” Nucleic Acids Res. 32(19):e145 (2004). |
Fujita et al., “Novel Substrate Specificity of designer3-Isopropylmalate Dehydrogenase Derived from Thermus thermophilus HBI,” Biosci. Biotechnol. Biochem. 65(12):2695-2700 (2001). |
Fukao et al., “Succinyl-coA:3-Ketoacid CoA Transferase (SCOT): Cloning of the Human SCOT Gene, Tertiary Structural Modeling of the Human SCOT Monomer, and Characterization of Three Pathogenic Mutations,” Genomics 68:144-151 (2000). |
Fukuda and Wakagi, “Substrate recognition by 2-oxoacid:ferredoxin oxidoreductase from Sulfolobus sp. Strain 7,” Biochim. Biophys. Acta 1597:74-80 (2002). |
Fukuda et al., “Role of a highly conserved YPITP motif in 2-oxoacid:ferredoxin oxidoreductase,” Eur. J. Biochem. 268:5639-5646 (2001). |
Furdui and Ragsdale, “The role of pyruvate ferredoxin oxidoreductase in pyruvate synthesis during autotrophic growth by the Wood-Ljungdahl pathway,” J. Biol. Chem. 275:28494-28499 (2000). |
Galagan et al., “The genome of M. acetivorans reveals extensive metabolic and physiological diversity,” Genome Res. 12:532-542 (2002). |
Gallego et al., “A role for glutamate decarboxylase during tomato ripening: the characterisation of a cDNA encoding a putative glutamate decarboxylase with a calmodulin-binding site,” Plant Mol Biol. 27:1143-1151 (1995). |
Gangloff et al., “Molecular cloning of the Yeast Mitochondrial Aconitase Gene (ACO1) and Evidence of a Synergistic Regulation of Expression by Glucose plus Glutamate,” Mol. Cell. Biol. 10(7):3551-3561 (1990). |
Gay et al., “Cloning Structural Gene sacB, Which codes for Exoenzyme Levansucrase of Bacillus subtilis: Epxresion of the Gene in Escherichia coli,” J. Bacteriol. 153:1424-1431 (1983). |
Gerhardt et al., “Fermentation of 4-aminobutyrate by Clostridium aminobutyricum: cloning of two genes involved in the formation and dehydration of 4-hydroxybutyryl-CoA,” Arch. Microbiol. 174:189-199 (2000). |
Gerischer and Dürre, “mRNA Analysis of the adc Gene Region of Clostridium acetobutylicum during the Shift to Solventogenesis,” J. Bacteriol.174(2):426-433 (1992). |
Gerngross and Martin, “Enzyme-catalyzed synthesis of poly((R)-(−)-3-hydroxybutyrate): formation of macroscopic granules in vitro,” Proc. Natl. Acad. Sci. U.S.A. 92:6279-6783 (1995). |
Gerngross, et al., “Overexpression and purification of the soluble polyhydroxyalkanoate synthase from Alcalligenes eutrophus: evidence for a required posttranslational modification for catalytic activity,” Biochemistry 33:9311-9320 (1994). |
Gibbs et al., “Degenerate oligonucleotide gene shuffling (DOGS): a method for enhancing the frequency of recombination with family shuffling,” Gene. 271:13-20 (2001). |
Gibson and McAlister-Henn, “Physical and Genetic Interactions of Cytosolic Malate Dehydrogenase with Other Gluconeogenic Enzymes,” J. Biol. Chem. 278(28):25628-25636 (2003). |
Giesel and Simon, “On the occurrence of enoate reductase and 2-oxo-carboxylate reductase in clostridia and some observations on the amino acid fermentation by Peptostreptococcus anaerobius,” Arch. Microbiol. 135(1):51-57 (1983). |
Girbal, et al., “Regulation of metabolic shifts in Clostridium acetobutylicum ATCC 824,” FEMS Microbiol. Rev. 17:287-297 1995. |
Goda et al., “Cloning, Sequencing, and Expression in Escherichia coli of the Clostridium tetanomorphum Gene Encoding β-Methylaspartase and Characterization of the Recombinant Protein,” Biochemistry 31:10747-10756 (1992). |
Gong et al., “Effects of transport properites of ion-exchange membranes on desalination of 1,3-propanediol fermentation broth by electrodialysis,” Desalination 191:193-199 (2006). |
Gong et al., “Specificity Determinants for the Pyruvate Dehydrogenase Component Reaction Mapped with Mutated and Prosthetic Group Modified Lipoyl Domains,” J. Biol. Chem. 275(18):13645-13653 (2000). |
Gonzalez and Robb, “Genetic analysis of Carboxydothermus hydrogenoformans carbon monoxide dehydrogenase genes cooF and cooS,” FEMS Microbiol. Lett. 191:243-247 (2000). |
Gonzalez, et al., “Cloning of a yeast gene coding for the glutamate synthase small subunit (GUS2) by complementation of Saccharomyces cerevisiae and Escherichia coli glutamate auxotrophs,” Mol. Microbiol. 6:301-308 (1992). |
Gonzalez-Pajuelo et al., “Metabolic engineering of Clostridium acetobutylicum for the industrial production of 1,3-propanediol from glycerol,” Met. Eng. 7:329-336 (2005). |
Goupil et al., “Imbalance of leucine flux in Lactoccus lactis and its use for the isolation of diacetyl-overproducing strains,” Appl. Environ. Microbiol. 62(7):2636-2640 (1996). |
Goupil-Feuillerat et al., “Transcriptional and translational regulation of alpha-acetolactate decarboxylase of Lactococcus lactis subsp. Lactis,” J. Bacteriol. 182(19):5399-5408 (2000). |
Green et al., “Catabolism of α-Ketoglutarate by a sucA Mutant of Bradyrhizobium japonicum: Evidence for an Alternative Tricarboxylic Acid Cycle,” J. Bacteriol. 182(10):2838-2844 (2000). |
Gregerson, et al., “Molecular characterization of NADH-dependent glutamate synthase from alfalfa nodules,” Plant Cell 5:215-226 (1993). |
Grubbs, “Olefin Metathesis,” Tetrahedron 60:7117-7140 (2004). |
Guest et al., “The fumarase genes of Escherichia coli: location of the fumB gene and discovery of a new gene (fumC),” J. Gen. Microbiol. 131:2971-2984 (1985). |
Guirard and Snell, “Purification and properties of ornithine decarboxylase from Lactobacillus sp. 30a,” J. Biol. Chem. 255(12):5960-5964 (1980). |
Guo et al., “Posttranslational activation, site-directed mutation and phylogenetic analyses of lysine biosynthesis enzymes alpha-aminoadipate reductase Lys1P (AARO and the phosphopantetheinyl transferase Lys7p (PPTase) from Schizosaccharomyces pombe,” Yeast 21(15):1279-1288 (2004). |
Guo et al., “Site-directed mutational analysis of the novel catalytic domains of alpha-aminoadipate reductase (Lys2p) from Candida albicans,” Mol. Genet. Genomics 269(2):271-279 (2003). |
Guzman, et al., “Tight regulation, modulation and high-level expression by vectors containing the arabinose PBAD promoter,” J. Bacteriol. 177(14):4121-4130 (1995). |
Hadfield et al., “Active site analysis of the potential antimicrobial target aspartate semialdehyde dehydrogenase,” Biochemistry 40(48):14475-14483 (2001). |
Hadfield et al., “Structure of aspartate-beta-semialdehyde dehydrogenase from Escherichia coli, a key enzyme in the aspartate family of amino acid biosynthesis,” J. Mol. Biol. 289(4):991-1002 (1999). |
Hagemeier et al., “Insight into the mechanism of biological methanol activation based on the crystal structure of the methanol-cobalamin methyltransferase complex,” Proc. Natl. Acad. Sci. U.S.A. 103:18917-18922 (2006). |
Hammer and Bode, “Purification and characterization of an inducible L-lysine:2-oxoglutarate 6-aminostransferase from Dandida utilis,” J. Basic Microbiol. 32:21-27 (1992). |
Hanai et al., “Engineered synthetic pathway for isopropanol production in Escherichia coli,” Appl. Environ. Microbiol. 73:7814-7818 (2007). |
Hansford, “Control of mitochondrial substrate oxidation,” Curr. Top. Bioenerg. 10:217-278 (1980). |
Harms and Thauer, “Methylcobalamin: coenzyme M methyltransferase isoenzymes MtaA and MtbA from Methanosarcina barkeri. Cloning, sequencing and differential transcription of the encoding genes, and functional overexpression of the mtaA gene in Escherichia coli,” Eur. J. Biochem. 235:653-659 (1996). |
Hasegawa et al., “Transcriptional regulation of ketone body-utilizing enzyme, acetoacetyl-CoA synthetase, by C/EBPα during adipocyte differentiation,” Biochim. Biophys. Acta 1779:414-419 (2008). |
Haselbeck and McAlister-Henn, “Isolation, nucleotide sequence, and disruption of the Saccharomyces cerevisiae gene encoding mitochondrial NADP(H)-specific isocitrate dehydrogenase,” J. Biol. Chem. 266(4):2339-2345 (1991). |
Hashidoko et al., “Cloning of a DNA Fragment Carrying the 4-Hydroxycinnamate Decarboxylase (pofK) Gene from Klebsiella oxtoca, and its Constitutive Expression in Escherichia coli JM109 Cells,” Biosci. Biotech. Biochem. 217-218 (1994). |
Hashimoto et al., “Activation of L-Lysine ε-Dehydrogenase from Agrobacterium tumefaciens by Several Amino Acids and Monocarboxylates,” J. Biochem. 106:76-80 (1989). |
Hasson et al., “The Crystal Structure of Benzoylformate Decarboxylase at 1.6 Å Resolution: Diversity of Catalytic Residues in thiamin Diphosphate-Dependent Enzymes,” Biochemistry 37:9918-9930 (1998). |
Hawes et al., “Mammalian 3-hydroxyisobutyrate dehydrogenase,” Methods Enzymol. 324:218-228 (2000). |
Hayden et al., “Glutamate dehydrogenase of Halobacterium salinarum: evidence that the gene sequence currently assigned to the NADP+-dependent enzyme is in fact that of the NAD+-dependent glutamate dehydrogenase,” FEMS Microbiol. Lett. 211:37-41 (2002). |
Hayes et al., “Combining computational and experimental screening for rapid optimization of protein properties,” Proc. Natl. Acad. Sci. U.S.A. 99(25):15926-15931 (2002). |
Hein, et al., “Biosynthesis of poly(4-hydroxybutyric acid) by recombinant strains of Escherichia coli,” FEMS Microbiol. Lett. 153(2):411-418 (1997). |
Henne, et al., “Construction of environmental DNA libraries in Escherichia coli and screening for the presence of genes conferring utilization of 4-hydroxybutyrate,” Appl. Environ. Microbiol. 65(9):3901-3907 (1999). |
Hennessy, et al., “The reactivity of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic solutions,” J. Forensic. Sci. 49(6):1220-1229 (2004). (provided electronically by publisher as pp. 1-10). |
Henning et al., “Identification of Novel enzoylformate Decarboxlyases by Growth Selection,” Appl. Environ. Microbiol. 72(12)7510-7517 (2006). |
Hermes et al., “Searching sequence space by definably random mutagenesis: Improving the catalytic potency of an enzyme,” Proc. Natl. Acad. Sci. U.S.A. 87:696-700 (1990). |
Herrmann et al., “Energy conservation via electron-transferring flavoprotein in anaerobic bacteria,” J. Bacteriol. 190(3):784-791 (2007). |
Herrmann et al., “Two beta-alanyl-CoA:ammonia lyases in Clostridium propionicum ” FEBS J. 272:813-821 (2005). |
Hesslinger et al., “Novel keto acid formate-lyase and propionate kinase enzymes are components of an anaerobic pathway in Escherichia coli that degrades L-threonine to propionate,” Mol. Microbiol 27:477-492 (1998). |
Hester et al., “Purification of active E1 alpha 2 beta 2 of Pseudomonas putida branched-chain-oxoacid dehydrogenase,” Eur. J. Biochem. 233(3):828-836 (1995). |
Heydari et al., “Highly Stable L-Lysine 6-Dehydrogenase from the Thermophile Geobacillus stearothemophilus Isolated from a Japanese Hot Spring: Characterization, gene Cloning and Sequencing, and Expression,” Appl. Environ. Microbiol. 70:937-942 (2004). |
Hezayen et al., “Biochemical and enzymological properties of the polyhydroxybutyrate synthase from the extremely halophilic archaeon strain 56,” Arch. Biochem. Biophys. 403(2):284-291 (2002). |
Hibbert et al. “Directed evolution of biocatalytic processes,” Biomol. Eng. 22:11-19 (2005). |
Hijarrubia et al., “Domain Structure characterization of the Multifunctional α-Aminoadipate Reductase from Penicillium chrysogenum by Limited Proteolysis,” J. Biol. Chem. 278:8250-8256 (2003). |
Hillmer and Gottschalk, “Solubilization and partial characterization of particulate dehydrogenases from Clostridium kluyveri,” Biochim. Biophys. Acta 334:12-23 (1974). |
Hiramitsu, et al., “Production of Poly(3-hydroxybutyrate-co-4-hydroxybutyrate) by Alcallgenes latus,” Biotechnol Lett. 15:461-464 (1993). |
Hirano et al., “Purification and Characterization of the alcohol dehydrogenase with a broad substrate specificity originated from 2-phenylethanol-assimilating Brevibacterium sp. KU 1390,” J. Biosci. Bioeng. 100(3):318-322 (2005). |
Hiser et al., “ERG10 from Saccharomyces cerevisiae encodes acetoacetyl-CoA thiolase,” J. Biol. Chem. 269:31383-31389 (1994). |
Hoffmeister et al., “Mitochondrial trans-2-enoyl-CoA reductase of wax ester fermentation from Euglena gracilis defines a new family of enzymes involved in lipid synthesis,” J. Biol. Chem. 280:4329-4338 (2005). |
Hogan et al., “Improved specificity toward substrates with ositively charged side chains by site-directed mutagenesis of the L-lactate dehydrogenase of Bacillus stearothermophilus,” Biochemistry 34(13):4225-4230 (1995). |
Hong and Lee, “Enhanced Production of Succinic Acid by Metabolically Engineered Escherichia coli with Amplified Activities of Malic Enzyme and Fumarase,” Biotechnol. Bioprocess Eng. 9:252-255 (2004). |
Hong, et al., “The genome sequence of the capnophilic rumen bacterium Mannheimia succiniciproducens,” Nat. Biotechnol. 22(10):1275-1281 (2004). |
Horswill and Escalante-Semerena, “In vitro conversion of propionate to pyruvate by Salmonella enterica enzymes: 2-methylcitrate dehydratase (PrpD) and aconitas Enzymes catalyze the conversion of 2-methylcitrate to 2-methylisocitrate,” Biochemistry 40(15):4703-4713 (2001). |
Huang et al., “Identification and Characterization of a Second Butyrate Kinase from Clostridium acetobutylicum ATCC 824,” J. Mol. Microbiol. Biotechnol. 2(1):33-38 (2000). |
Huang et al., “Purification and Characterization of a Ferulic Acid Decarboxylase from Pseudomonas fluorescens,” J. Bacteriol. 176(19):5912-5918 (1994). |
Hughes et al., “Evidence for Isofunctional Enzymes in the Degradation of Phenol, m- and p-Toulate, and p-Cresol via Catechol meta-Cleavage Pathways in Alcaligenes eutrophus,” J. Bacteriol. 158:79-83 (1984). |
Hugler et al., “Autotrophic CO2 fixation via the reductive tricarboxylic acid cycle in different lineages within the phylum Aquificae: evidence for two ways of citrate cleavage,” Environ. Microbiol. 9:81-92 (2007). |
Hugler et al., “Evidence for autotrophic Co2 fixation via the reductive tricarboxylic acid cycle by members of the epsilon subedivision of proteobacteria,” J. Bacteriol. 187(9):3020-3027 (2005). |
Hugler et al., “Malonyl-coenzyme a reductase from Chloroflexus aurantiacus, a key enzyme of the 3-hydroxypropionate cycle for autotrophic CO(2) fixation,” J.Bacteriol. 184:2404-2410 (2002). |
Huh et al., “Global analysis of protein localization in budding yeast,” Nature425:686-691 (2003). |
Huisman and Lalonde, “Ch. 30: Enzyme Evolution for Chemical Process Applications,” In R N. Patel (ed.), Biocatalysis in the pharmaceutical and biotechnology industries, CRC Press, Boca Raton, FL, p. 717-742 (2007). |
Huo and Viola, “Substrate specificity and identification of functional groups of homoserine kinase from Escherichia col,” Biochemistry 35(50):16180-16185 (1996). |
Ibarra et al., “Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth,” Nature 420(6912):186-189 (2002). |
Ichikawa et al. “Catalytic reaction of 1,3-butanediol over solid acids,” J. Mol. Catalysis A Chem. 256:106-112 (2006). |
Ichikawa et al., “PIO study on 1,3-butanediol dehydration over CeO2 (1 1 1) surface,” J. Mol. Catalysis A Chem. 231:181-189 (2005). |
Iffiand et al., “Directed molecular evolution of cytochrome c peroxidase,” Biochemistry 39(25):10790-10798 (2000). |
lkai and Yamamoto, “Identification and Analysis of a Gene Encoding L-2,4-Diaminobutyrate:2-Ketoglutarate 4-Aminotransferase Invloved in the 1,3-Diaminopropane Production Pathway in Acinetobacter baumanni,” J. Bacteriol. 179(16):5118-5125 (1997). |
Imai and Ohno, “Measurement of yeast intracellular pH by image processing and the change it undergoes during growth phase,” J. Biotechnol. 38:165-172 (1995). |
Ingoldsby et al., “The discovery of four distinct glutamate dehydrogenase genes ina strain of Halobacterium salinarum,” Gene 349:237-244 (2005). |
Ishida et al., “Efficient production of L-Lactic acid by metabolically engineered Saccharomyces cerevisiae with a genome-integrated L-lactate dehydrogenase gene,” Appl. Environ. Microbiol. 71:1964-1970 (2005). |
Ishige et al., “Wax ester production from n-alkanes by Acinetobacter sp. strain M-1: ultrastructure of cellular inclusions and role of acyl coenzyme a reductase,” Appl. Environ. Microbiol. 68(3):1192-1195 (2002). |
Ismaiel et al., “Purification and characterization of a primary-secondary alcohol dehydrogenase from two strains of Clostridium beijerinckii,” J. Bacteriol. 175(16):5097-5105 (1993). |
Ismail et al., “Functional genomics by NMR spectroscopy Phenylacetate catabolism in Escherichia coli,” Eur. J. Biochem. 270:3047-3054 (2003). |
Ito et al., “D-3-hydroxybutyrate dehydrogenase from Pseudomonas fragi: molecular cloning of the enzyme gene and crystal structure of the enzyme,” J. Mol. Biol. 355(4):722-733 (2006). |
Iverson et al., “Structure of the Escherichia coli fumarate reductase respiratory complex,” Science 284(5422):1961-1966 (1999). |
Jacobi et al., “The hyp operon gene products are required for the maturation of catalytically active hydrogenase isoenzymes in Escherichia coli,” Arch. Microbiol. 158:444-451 (1992). |
Jeon et al., “Heterologous expression of the alcohol dehydrogenase (adhl) gene from Geobacillus thermoglucosidasius strain M10EXG,” J. Biotechnol. 135:127-133 (2008). |
Jesudason and Marchessault, “Synthetic Poly[(R,S)-.beta.-hydroxyalkanoates] with Butyl and Hexyl Side Chains,” Macromolecules 27:2595-2602 (1994). |
Jewell et al., “Bioconversion of propionic, valeric and 4-hydroxybutyric acids into the corresponding alcohols by Clostridium acetobutylicum NRRL 527,” Curr. Microbiol. 13(4):215-219 (1986). |
Jiang et al., “De novo computational design of retro-aldol enzymes,” Science 319(5868):1387-1391 (2008). |
Johnson et al., “Alteration of a single amino acid changes the substrate specificity of dihydroflavonol 4-reductase,” Plant J. 25(3):325-333 (2001). |
Johnston et al., “Complete nucleotide sequence of Saccharomyces cerevisiae chromosome VIII,” Science 265:2077-2082 (1994). |
Jojima et al., “Production of isopropanol by metabolically engineered Escherichia coli,” Appl. Microbiol. Biotechnol. 77:1219-1224 (2008). |
Jones and Woods,“Acetone-butanol fermentation revisited,” Microbiol. Rev. 50(4):484-524 (1986). |
Jones et al., “Purification and characterization of D-b-hydroxybutyrate dehydrogenase expressed in Escherichia coli,” Biochem. Cell Biol. 71(7-8):406-410 (1993). |
Kai et al., “Phosphoenolpyruvate carboxylase: three-dimensional structure and molecular mechanisms,” Arch. Biochem. Biophys. 414:170-179 (2003). |
Kanao et al., “Characterization of isocitrate dehydrogenase from the green sulfur bacterium Chlorbium limicola. A carbon dioxide-fixing enzyme in the reductive tricarboxylic acid cycle,” Eur. J. Biochem. 269(7):1926-1931 (2002). |
Kanao et al., “Kinetic and biochemical analyses on the reaction mechanism of a bacterial ATP-citrate lyase,” Eur. J. Biochem. 269(14):3409-3416 (2002). |
Kaneko et al., “Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803, II. Sequence determination of the entire genome and assignment of potential protein-coding regions,” DNA Res. 3:109-136 (1996). |
Kapatral et al., “Genome Sequence and Analysis of the Oral Bacterium Fusobacterium nucleatum Strain ATCC 25586,” J. Bacteriol. 184(7):2005-2018 (2002). |
Kato et al., “Open reading frame 3 of the barotolerant bacterium strain DSS12 is complementary with cydD in Escherichia coli: cydD functions are required for cell stability at high pressure,” J. Biochem. 120:301-305 (1996). |
Kato et al., “Production of a novel copolyester of 3-hydroxybutyric acid with a medium-chain-length 3-hydroxyalkanoic acids by Pseudomonas sp. 61-3 from sugars,” Appl. Microbiol. Biotechnol. 45:363-370 (1996). |
Kazahaya et al, “Aerobic Dissimilation of Glucose by Heterolactic Bacteria,” J. Gen. Appl. Microbiol. 18(1):43-55(1972). |
Kellum and Drake, “Effects of cultivation gas phase on hydrogenase of the acetogen Clostridium thermoaceticum,” J. Bacteriol. 160:466-469 (1984). |
Keng and Viola, “Specificity of Aspartokinase III from Escherichia coli and an Examination of Important Catalytic Residues,” Arch. Biochem. Biophys. 335:73-81 (1996). |
Kessler et al., “Pyruvate-formate-lyase-deactivase and acetyl-CoA reductase activities of Escherichia coli reside on a polymeric protein particle encoded by adhE,” FEBS.Lett. 281:59-63 (1991). |
Khan et al., “Molecular properties and enhancement of thermostability by random mutagenesis of glutamate ehydrogenase from Bacillus subtilis,” Biosci. Biotechnol. Biochem. 69(10):1861-1870 (2005). |
Killenberg-Jabs et al., “Active oligomeric states of pyruvate decarboxylase and their functional characterization,” Eur. J. Biochem. 268:1698-1704 (2001). |
Kim and Tabita, “Both subunits of ATP-citrate lyase from Chlorobium tepidum contribute to catalytic activity,” J. Bacteriol. 188(18):6544-6552 (2006). |
Kim et al., “Construction of an Escherichia coli K-12 mutant for homoethanologenic fermentation of glucose or xylose without foreign genes,” Appl. Environ. Microbiol 73:1766-1771 (2007). |
Kim et al., “Dihydrolipoamide Dehydrogenase Mutation Alters the NADH Sensitivity of Pyruvate Dehydrogenase Complex of Escherichi coli K-12,” J. Bacteriol. 190:3851-3858 (2008). |
Kim et al., “Effect of overexpression of Actinobacillus succinogenes phosphoenolpyruvate carboxykinase on succinate production in Escherichia coli,” Appl. Environ. Microbiol. 70:1238-1241 (2004). |
Kim, “Purification and Propertis of a mine α-Ketoglutarate Transaminase from Escherichia coli,” J. Biol. Chem. 239:783-786 (1964). |
Kimura et al., “Production of Poly(3-hydroxybutyrate-co-4-hydroxybutyrate) by Pseudomonas acidovorans,” Biotechnol. Lett. 14(6):445-450 (1992). |
Kinnaird et al., “The complete nucleotide sequence of the Neurospora crassa am (NADP-specific glutamate dehydrogenase) gene,” Gene 26:253-260 (1983). |
Kino et al., “Synthesis of DL-tryptophan by modified broad specificity amino acid racemase from Pseudomonas putida IFO 12996,” Appl. Microbiol. Biotechnol. 73(6):1299-1305 (2007). |
Kinoshita, “Purification of two alcohol dehydrogenases from Zymomonas mobilis and their properties,” Appl. Microbiol. Biotechnol. 22:249-254 (1985). |
Kirby et al., “Purification and properties of rabbit brain and liver 4-aminobutyrate aminotransferases isolated by monoclonal-antibody Immunoadsorbent chromatography,” Biochem. J. 230:481-488 (1985). |
Klasson et al., “Biological conversion of coal and coal-derived synthesis gas,” Fuel 72:1673-1678 (1993). |
Klatt et al., “Comparative genomics provides evidence for the 3-hydroxypropionate autotrophic pathway in filamentous anoxygenic phototrophic bacteria and in hot spring microbial mats,” Environ. Microbiol. 9(8):2067-2078 (2007). |
Klenk et al., “The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus,” Nature 390:364-370 (1997). |
Knapp et al., “Crystal Structure of the Truncated Cubic Core Component of the Escherichia coli 2-Oxoglutarate Dehydrogenase Multienzyme Complex,” J. Mol. Biol. 289:655-668 (1998). |
Knappe and Sawers, A radical-chemical route to acetyl-CoA: the anaerobically induced pyruvate formate-lyase system of Escherichia coli, FEMS Microbiol. Rev. 75:383-398 (1990). |
Kobayashi et al., “Physiochemical, Catalytic, and Immunochemical Properties of Fumarases Crystallized Separately from Mitochondrial and Cytosolic Fractions of Rat Liver,” J. Biochem. 89:1923-1931 (1981). |
Koland and Gennis, “Proximity of rreactive cysteine residue and flavin in Escherichia coli pyruvate oxidase as estimated by fluorescence energy transfer,” Biochemistry 21(18):4438-4442 (1982). |
Koo et al., “Cloning and characterization of the bifunctional alcohol/acetaldehyde dehydrogenase gene (adhE) in Leuconostoc mesenteroides isolated from kimchi,” Biotechnol. Lett. 27(7):505-510 (2005). |
Korbert et al., “Crystallization of the NADP+-dependent Glutamate Dehydrogenase from Escherichia coli,” J. Mol. Biol. 234:1270-1273 (1993). |
Korolev et al., “Autotracing of Escherichia coli acetate CoA-transferase α-subunit structure using 3.4 Å MAD and 1.9 Å native data,” Acta. Cryst. D58:2116-2121 (2002). |
Kort et al., “Glutamate dehydrogenase from the Hyperthermophilic bacterium Thermotoga maritima: molecular characterization and phylogenetic implications,” Extremophiles 1:52-60 (1997). |
Kosaka et al., “Characterization of the sol operon in butanol-hyperproducing Clostridium saccharoperbutylacetonicum strain N1-4 and its degeneration mechanism,” Biosci. Biotechnol. Biochem. 71:58-68 (2007). |
Kosjek et al., “Purification and characterization of a chemotolerant alcohol dehydrogenase applicable to coupled redox reactions,” Biotechnol. Bioeng. 86(1):55-62 (2004). |
Kreimeyer et al., “Indentification of the Last Unknown Genes in the fermentation Pathway of Lysine,” J. Biol. Chem. 282:7191-7197 (2007). |
Kretz et al., “Gene site saturation mutagenesis: a comprehensive mutagenesis approach,” Methods Enzymol. 388:3-11 (2004). |
Krieger et al., “Pyruvate decarboxylase from Kluyveromyces lactis an enzyme with an extraordinary substrate activation behaviour,” Eur. J. Biochem. 269:3256-3263 (2002). |
Kumamaru et al., “Enhanced degradation of polychlorinated biphenyls by directed evolution of biphenyl dioxgenase,” Nat. Biotechnol. 16(7)663-666 (1998). |
Kumari et al., “Cloning, Characterization, and Functional Expression of acs, the Gene Which Encodes Acetyl Coenzyme A Synthetase in Escherichia coli,” J. Bacteriol. 177(10): 2878-2886 (1995). |
Kunioka et al., “New bacterial copolyesters produced in Alcaligenes eutrophus from organic acids,” Polym. Commun. 29:174-176 (1988). |
Kurihara et al., “A Novel Putrescine Utilization Pathway Involves γ-Glutamylated Intermediates of Escherichia coli K-12,” J. Biol. Chem. 280(6) 4602-4608 (2005). |
Kuznetsova et al., “Enzyme genomics: Application of general enzymatic screens to discover new enzymes,” FEMS Microbiol. Rev. 29:263-279 (2005). |
Kwok and Hanson, “GFP-labelled Rubisco and aspartate aminotransferase are present in plastid stromules and traffic between plastids,” J. Experi. Bot. 55:(397)595-604 (2004). |
Kwon et al., “Brain 4-aminobutyrate aminotransferase. Isolation and sequence of a cDNA encoding the enzyme,” J. Biol. Chem. 267:7215-7216 (1992). |
Kwon et al., “Influence of gluconeogenic phosphoenolpyruvate carboxykinase (PCK) expression on succinic acid fermentation in Escherichia coli under high bicarbonate condition,” J. Microbiol. Biotechnol. 16(9):1448-1452 (2006). |
Lageveen, et al., “Formation of Polyesters by Pseudomonas oleovorans: Effect of Substrates on Formation and Composition of Poly-(R)-3-Hydroxyalkanoates and Poly-(R)-3-Hydroxyalkenoates,” Appl. Environ. Microbiol. 54:2924-2932 (1988). |
Laivenieks et al., “Cloning sequencing, and overexpression of the Anaerobiospirillum succinicproducens phosphoenolpyruvate carboxykinase (pckA) gene,” Appl. Environ. Microbiol. 63:2273-2280 (1997). |
Lam and Winkler, “Metabolic Relationships between Pyridoxine (vitamin B6) and Serine Biosynthesis in Escherichia coli K-12,” J. Bacteriol. 172(11):6518-6528 (1990). |
Lamas-Maceiras et al., “Amplification and disruption of the phenylacetyl-CoA ligase gene of Penicillium chrysogenum encoding an aryl-capping enzyme that supplies phenylacetic acid to the isopenicillin N-acyltransferase ” Biochem. J. 395:147-155 (2006). |
Lamed and Zeikus, “Novel NAP-linked alcohol-aldehyde/ketone oxidoreductase in thermophilic ethanologenic bacteria,” Biochem. J. 195:183-190 (1981). |
Lebbink et al., “Engineering activity and stability of Thermotoga maritima Glutamate Dydrogenase. I. Introduction of a Six-residue Ion-pair Network in the Hinge Region,” J. Mol. Biol. 280:287-296 (1998). |
Lebbink et al., “Engineering activity and stability of Thermotoga maritima glutamate dehydrogenase. II: construction of a 16-residue ion-pair network at the subunit interface,” J. Mol. Biol. 289(2):357-369 (1999). |
Leduc et al., “The Hotdog Thiesterase EntH (YbdB) Plays a Role in Vivo in Optimal Enterobactin biosynthesis by Interacting with the ArCP Domain of EntB,” J. Bacteriol. 189(19):7112-7126 (2007). |
Lee and Cho, “Identification of essential active-site residues in ornithine decarboxylase of Nicotiana glutinosa decarboxylating both L-ornithine and L-lysine,” Biochem. J. 360(Pt 3):657-665 (2001). |
Lee et al., “Biosynthesis of enantiopure (s)-3-hydroxybutyric acid in metabolically engineered Escherichia coli,” Appl. Microbiol. Biotechnol. 79(4):633-641 (2008). |
Lee et al., “Cloning and Characterization of Mannheimia succiniciproducens MBEL55E Phosphoenolpyruvate Carboxykinase (pckA) Gene,” Biotechnol. Bioprocess Eng. 7:95-99 (2002). |
Lee et al., “Phylogenetic diversity and the structural basis of substrate specificity in the beta/alpha-barrel fold basic amino acid decarboxylases,” J. Biol. Chem. 282(37)27115-27125 (2007). |
Lee et al., “A new approach to directed gene evolution by recombined extension on truncated templates (RETT),” J. Molec. Catalysis 26:119-129 (2003). |
Lee et al., “Biosynthesis of copolyesters consisting of 3-hydroxybutyric acid and medium-chain-length 3-hydroxyalkanoic acids from 1,3-butanediol or from 3-hydroxybutyrate by Pseudomonas sp. A33,” Appl. Microbiol. Biotechnol. 42: 901-909 (1995). |
Lee et al., “Enhanced biosynthesis of P(3HB-3HV) and P(3HB-4HB) by amplification of the cloned PHB biosynthesis genes in Alcatigenes eutrophus,” Biotechnol. Lett. 19:771-774 (1997). |
Lemoigne and Rouklehman, “Fermentation b-Hydroxybutyrique,” Annales des Fermentations 5:527-536 (1925). |
Lemonnier and Lane, “Expression of the second lysine decarboxylase gene of Escherichia coli,” Microbiology 144(Pt 3):751-760 (1998). |
Lepore et al., “The x-ray crystal structure of lysine-2,3-aminomutase from Clostridium subterminale,” Proc. Natl. Acad. Sci. U.S.A. 102:13819-13824 (2005). |
Lessner et al., “An unconventional pathway for reduction of CO2 to methane in CO-grown Methanosarcina acetivorans revealed by proteomics,” Proc. Natl. Acad. Sci. U.S.A. 13:17921-17926 (2006). |
Li and Jordan, “Effecrts of Substitution of Tryptophan 412 in the Substrate Activation Pathway of Yeast Pyruvate Decarboxylase,” Biochemistry 38:10004-10012 (1999). |
Li et al., “Properties of Nicotinamide Adenine Dinucleotide Phosphate-Dependent Formate Dehydrogenase from Clostridium thermoaceticum,” J.Bacteriol. 92:405-412 (1966). |
Li, Guang-Shan, “Development of a reporter system for the study of gene expression for solvent production in Clostridium beijerinckii NRRL 8592 and Clostridium acetobutylicum ATCC 824,” Dissertation, Department of Biochemestry, Virginia Polytechnic Institute and State University (Sep. 1998). |
Lian and Whitman, “Sterochemical and Isotopic Labeling Studies of 4-Oxalocrotonate Decarboxylase and Vinylpyruvate Hydratase: Analysis and Mechanistic Implications,” J. Am. Chem. Soc. 116:10403-10411 (1994). |
Liebergesell and Steinbuchel, “Cloning and nucleotide sequences of genes relevant for biosynthesis of poly(3-hydroxybutyric acid) in Chromatium vinosum strain D,” Eur. J. Biochem. 209(1):135-150 (1992). |
Lin et al., “Fed-batch culture of a metabolically engineered Escherichia coli strain designed for high-level succinate production and yield under aerobic conditions,” Biotechnol. Bioeng. 90(6):775-779 (2005). |
Lin et al., “Functional expression of horseradish peroxidase in E. coli by directed evolution,” Biotechnol. Prog. 15(3):467-471 (1999). |
Lingen et al., “Alteration of the Substrate Specificity of Benzoylformate Decarboxylase from Pseudomonas putida by Directed Evolution,” Chembiochem 4:721-726 (2003). |
Lingen et al., “Improving the carboligase activity of benzoylformate decarboxylase from Pseudomonas putida by a combination of directed evolution and site-directed mutagenesis,” Protein Eng. 15:585-593 (2002). |
Link et al., “Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli: application to open reading frame characterization,” J. Bacteriol. 179:6228-6237 (1997). |
Liu and Steinbuchel, “Exploitation of butyrate kinase and phosphotransbutyrylase from Clostridium acetobutylicum for the in vitro biosynthesis of poly (hydroxyalkanoic acid),” Appl. Microbiol. Biotechnol. 53(5):545-552 (2000). |
Liu et al., “Crystal Structures of Unbound and Aminoxyacetate-Bound Eschericiha coli Y-Aminobutyrate Aminotransferase,” Biochem. 43:10896-10905 (2004). |
Liu et al., “Kinetic and crystallographic analysis of active site mutants of Escherichia coli gamma-aminobutyrate aminotransferase,” Biochemistry44:(8):2982-2992 (2005). |
Ljungdahl and Andreesen, “Formate dehydrogenase, a selenium—tungsten enzyme from Clostridium thermoaceticum,” Methods Enzymol. 53:360-372 (1978). |
Ljungdahl et al., “Tungsten, a component of active formate dehydrogenase from Clostridium thermoacetium,” FEBS Lett. 54:279-282 (1975). |
Lokanath et al., “Crystal Structure of novel NADP-dependent 3-Hydroxyisobutyrate Dehydrogenase from Thermus thermophilus HB8,” J. Mol Biol. 352:905-917 (2005). |
Louie and Chan, “Cloning and characterization of the gamma-glutamyl phosphate reductase gene of Campylobacter jejuni,” Mol. Gen. Genet. 240:29-35 (1993). |
Louis et al., “Restricted Distribution of the Butyrate Kinase Pathway among Butyrate-Producing Bacteria from the Human Colon,” J. Bacteriol. 2099-2106 (2004). |
Lovell et al., “Cloning and expression in Escherichia coli of the Clostridium thermoaceticum gene encoding thermostable formyltetrahydrofolate synthetase,” Arch. Microbiol. 149:280-285 (1988). |
Lovell et al., “Primary structure of the thermostable formyltetrahydrofolate synthetase from Clostridium thermoaceticum,” Biochemistry 29:5687-5694 (1990). |
Low et al., “Mimicking somatic hypermutation: affinity maturation of antibodies displayed on baceriophage using a bacterial mutator strain,” J. Mol. Biol. 260(3):359-368 (1996). |
Lu et al, “Functional analysis and regulation of the divergent spuABCDEFG-spul operons for polyamine uptake and utilization in Pseudomonas aeruginosa PA01,” J. Bacteriol. 184:3765-3773 (2002). |
Lu et al., “Sequence and expression of the gene encoding the corrinoid/iron-sulfur protein from Clostridium thermoaceticum and reconstitution of the recombinant protein to full activity,” J. Biol. Chem. 268:5605-5614 (1993). |
Lu et al., “Enhanced production of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) via manipulating the fatty acid beta-oxidation pathway in E. coli,” FEMS Microbiol. Lett. 221(1):97-101 (2003). |
Lu et al., “Molecular cloning of polyhydroxyalkanoate synthesis operon from Aeromonas hydrophilia and its expression in Escherichia coli,” Biotechnol. Prog. 20(5):1332-1336 (2004). |
Lutke-Eversloh and Steinbuchel, “Biochemical and molecular characterization of a succinate semialdehyde dehydrogenase involved in the catabolism of 4-hydroxybutyric acid in Ralstonia eutropha,” FEMS Microbiol. Lett. 181:63-71 (1999). |
Lutz and Bujard, “Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements,” Nucleic Acids Res. 25:1203-1210 (1997). |
Lutz et al., “Creating multiple-crossover DNA libraries independent of sequence identity,” Proc. Natl. Acad. Sci. U.S.A. 98(20):11248-11253 (2001). |
Lutz et al., “Rapid generation of incremental truncation libraries for protein engineering using α-phosphothioate nucleotides,” Nucleic Acids Res. 15:29(4):e16 (2001). |
Ma et al., “Induced Rebuilding of Aspartase Confromation,” Ann. N.Y. Acad. Sci. 672:60-65 (1992). |
Mack and Buckel, “Conversion of glutaconate CoA-transferase from Acidaminococcus fermentas into an acyl-CoA hydrolase by site-directed mutagenesis,” FEBS Lett. 405:209-212 (1997). |
Mack et al., “Location of the two genes encoding glutaconate coenzyme A-transferase at the beginning of the hydroxyglutarate operon in Acidaminococcus fermentans,” Eur. J. Biochem. 226:41-51 (1994). |
Maeder et al., “The Methanosarcina barkeri genome: comparative analysis with Methanosarcina acetivorans and Methanosarcina mazei reveals extensive rearrangement within methanosarcinal genomes,” J. Bacteriol. 188:7922-7931 (2006). |
Mahadevan and Schilling, “The effects of alternate optimal solutions in constraint-based genome-scale metabolic models,” Metab. Eng. 5(4):264-276 (2003). |
Mahadevan et al., “Application of metabolic modeling to drive bioprocess development for the production of value-added chemicals,” Biotechnol. Bioprocess. Eng. 10(5):408-417 (2005). |
Mahan and Csonka, “Genetic analysis of the proBA genes of Salmonella typhimurium: physical and genetic analyses of the cloned proB+ A+ genes of Escherichia coli and of a mutant allele that confers proline overproduction and enhanced osmotolerance,” J. Bacteriol. 156(3):1249-1262 (1983). |
Majewski and Domach, “Simple Constrained-Optimization View of Acetate Overflow in E. coli,” Biotech. Bioeng. 35:732-738 (1990). |
Majumdar et al., “Functional consequences of substitution in the active site (phosphor) histidine residue of Escherichia coli succinyl-CoA synthetase,” Biochim. Biophys. Acta. 1076:86-90 (1991). |
Mandal and Ghosh, “Isolation of a glutamate synthase (GOGAT)-negative, pleiotropically N utilization-defective mutant of Azospirillum brasilense: cloning and partial characterization of GOGAT structural gene,” J. Bacteriol. 175:8024-8029 (1993). |
Manning and Pollitt, “Tracer studies of the interconversion of R- and S-methylmalonic semialdehydes in man,” Biochem. J. 231:481-484 (1985). |
Marco-Marin et al., “Site-directed Mutagenesis of Escherichia coli Acetylglutamate Kinase and Aspartokinase III Probes the Catalytic and Substrate-binding Mechanisms of these Amino Acid Kinase Family Enzymes and Allows Three-dimensional Modelling of Aspartokinase,” J. Mol. Biol. 334:459-476 (2003). |
Marek and Henson, “Cloning and expression of the Escherichia coli K-12 sad gene,” J. Bacteriol. 170(2):991-994 (1988). |
Marks et al., “Molecular Cloning and Characterization of (R)-3-Hydroxybutyrate Dehydrogenase from Human Heart,” J. Biol. Chem. 267:15459-15463 (1992). |
Martin et al., “Engineering a mevalonate pathway in Escherichia coli for production of terpenoids,” Nat. Biotechnol. 21:796-802 (2003). |
Martinez-Blanco et al., “Purification and Biochemical Characterization of Phenylacetyl-CoA Ligase from Pseudomonas putida,” J. Biol. Chem. 265(12):7084-7090 (1990). |
Mat-Jan et al., “Anaerobic growth defects resulting from gene fusions affecting succinyl-CoA synthetase in Escherichia coli K12,” Mol. Gen. Genet. 215:276-280 (1989). |
Mattevi et al., “Atomic structure of the cubic core of the pyruvate dehydrogenase multienzyme complex,” Science 255:1544-1550 (1992). |
Matthies and Schink, “Reciprocal Isomerization of Butyrate and Isobutyrate by the Strictly Anaerobic Bacterium Strain WoG13 and Methanogenic Isobutyrate Degradation by a Devined Triculture,” Appl. Environ. Microbiol. 58(5):1435-1439 (1992). |
Mavrovouniotis, “Estimation of standard Gibbs energy changes of biotransformations,” J. Biol. Chem. 266:14440-14445 (1991). |
McKinlay et al., “Prospects for a bio-based succinate industry,” Appl. Microbiol. Biotechnol. 76(4):727-740 (2007). |
McLaggan et al., “Interdependence of K+ and glutamate accumulation during osmotic adaptation of Escherichia coli,” J. Biol. Chem. 269:1911-1917 (1994). |
McPherson and Wootton, “Complete nucleotide sequence of the Escherichia coli gdhA gene,” Nucleic Acids Res. 11(15):5257-5266 (1983). |
Melchiorsen et al., “The level of pyruvate-formate lyase controls the shift from homolactic to mixed-acid product formation in Lactoccus lactis,” Appl. Microbiol. Biotechnol. 58(3):338-344 (2002). |
Meng and Chuang, “Site-Directed Mutagenesis and functional Analysis of the Active-Site Residues of the E2 Component of Bovine Branched-Chain α-Keto Acid Dehydrogenase Complex,” Biochem. 33:12879-12885 (1994). |
Menon and Ragsdale, “Mechanism of the Clostridium thermoaceticum pyruvate:ferredoxin oxidoreductase: evidence for the common catalytic intermediacy of the hydroxyethylthiamine pyropyrosphate radical,” Biochemistry 36:8484-8494 (1997). |
Menzel et al., “Enzymatic evidence for an involvement of pyruvate dehydrogenase in the anaerobic glycerol metabolism of Klebsiella pneumoniae,” J. Biotechnol. 56:135-142 (1997). |
Menzel et al., “Kinetic, dynamic, and pathway studies of glycerol metabolism by Klebsiella pneumoniae in anaerobic continuous culsutre: IV. Enzynmes and fluxes of pyruvate metabolism,” Botechnol. Bioeng. 60(5):617-626 (1998). |
Mermelstein et al., “Metabolic Engineering of Clostridium acetobutylicum ATCC 824 for Increased Solvent Production by Enhancement of Acetone Formation Enzyme Activities Using a Synthetic Acetone Operon,” Biotechnol. Bioeng. 42(9):1053-1060 (1993). |
Metz et al., “Purification of a jojoba embryo fatty acyl-coenzyme a reductase and expression of its cDNA in high erucic acid rapeseed,” Plant Physiol. 122(3):635-644 (2000). |
Metzer and Halpern, “In vivo cloning and characterization of the gabCTDP gene cluster of Escherichia coli K-12,” J. Bacteriol. 172:3250-3256 (1990). |
Metzer et al., “Isolation and properties of Escherichia coli K-12 mutants impaired in the utilization of gamma-aminobutyrate,” J. Bacteriol. 137(3):1111-1118 (1979). |
Miles and Guest, “Molecular genetic aspects of the citric acid cycle of Escherichia coli,” Biochem. Soc. Svmp. 54:45-65 1987. |
Miller and Brenchly, “Cloning and characterization of gdhA, the structural gene for glutamate dehydrogenase of Salmonella typhimurium,” J. Bacteriol. 157:171-178 (1984). |
Minard and McAlister-Henn, “Isolation, Nucleotide Sequence Analysis, and Disruption of theMDH2 Gene from Saccharomyces cerevisiae: Evidence for Three Isozymes of Yeast Malate Dehydrogenase,” Mol. Cell. Biol. 11(1):370-380 (1991). |
Misono and Nagasaki, “Occurrence of L-Lysine ε-Dehydrogenase in Agrobacterium tumefaciens,” J. Bacteriol. 150(1):398-401 (1982). |
Miyamoto and Katsuki, “Possible physiological roles of aspartase, NAD- and NADP-requiring glutamate dehydrogenases of Pseudomonas fluorescens,” J. Biochem. 112:52-56 (1992). |
Miyazaki et al., “α-Aminoadipate aminotransferase from an extremely thermophilic bacterium, Thermus thermophilus,” Microbiology 150:2327-2334 (2004). |
Mizobata et al., “Purification and Characterization of a thermostable Class II Fumarase from Thermus thermophilus,” Arch. Biochem. Biophys. 355:49-55 (1998). |
Momany et al., “Crystallographic Structures of a PLP-Dependent Ornithine Decarboxylase from Lactobacillus 30a to 3.0 Å Resolution,” J. Mol. Biol. 242:643-655 (1995). |
Monnet et al., “Regulation of branched-chain amino acid biosynthesis by α-acetolactate decarboxylase in Streptococcus thermophilus,” Lett. Appl. Microbiol. 36:(6):399-405 (2003). |
Moore et al., “Expression and Purification of Aspartate β-Semialdehyde Dehydrogenase from Infectious Microorganisms,” Protein Expr. Purif. 25:189-194 (2002). |
Morris et al., “Nucleotide sequence of the LYS2 gene of Saccharomyces cerevisiae: homology to Bacillus brevis tyrocidine synthetase1,” Gene 98:141-145 (1991). |
Morton et al., “Cloning, sequencing, and expression of genes encoding enzymes of the autotrophic acetyl-CoA pathway in the acetogen Clostridium thermoaceticum,” In M. Sebald (ed.), Genetics and molecular biology of anaerobic bacteria. Springer Vrlag, New York, p. 389-406 (1992). |
Morton et al., “The primary structure of the subunits of carbon monoxide dehydrogenase/acetyl-CoA synthase from Clostridium thermoaceticum,” J. Biol. Chem. 266:23824-23828 (1991). |
Mountain et al., “The Klebsiella aerogenes glutamate dehydrogenase (gdnA) gene: cloning, high-level expression and hybrid enzyme formation in Escherichia coli,” Mol. Gen. Genet. 199:141-145 (1985). |
Muh et al., “4-Hydroxybutyryl-CoA dehydratase from Clostridium aminobutyricum: characterization of FAD and iron-sulfur clusters involved in an overall non-redox reaction,” Biochemistry 35:11710-11718 (1996). |
Muh et al., “Mossbauer study of 4-hydroxybutyryl-CoA dehydratase—probing the role of an iron-sulfur cluster in an overall non-redox reaction,” Eur. J. Biochem. 248:380-384 (1997). |
Mukhopadhyay and Purwantini, “Pyruvate carboxylase from Mycobacterium smegmatis: stabilization, rapid purification, moleculare and biochemical characterization and regulation of the cellular level,” Biochim. Biophys. Acta. 1475(3):191-206 (2000). |
Muller et al., “Nucleotide exchange and excision technology (NExT) DNA shuffling: a robust method for DNA fragmentation and directed evolution,” Nucleic Acids Res. 33(13):e117 (2005). |
Muller, “Energy conservation in acetogenic bacteria,” Appl. Environ. Microbiol. 69:6345-6353 (2003). |
Muratsubaki and Enomoto, “One of the fumarate reductase isoenzymes from Saccharomyces cerevisiae is encoded by the OSM1 gene,” Arch. Biochem. Biophys. 352(2):175-181 (1998). |
Musfeldt and Schonheit, “Novel Type of ADP-Forming Acetyl Coenzyme A Synthetase in Hyperthermophilic Archaea: Heterologous Expression and Characterization of Isoenzymes from the Sulfate Reducer Archaeoglobus fulgidus and the Methanogen Methanococcus jannaschii” J. Bacteriol. 184(3):636-644 (2002). |
Muyrers et al., “Rapid modification of bacterial artificial chromosomes by ET-recombination,” Nucleic Acids Res. 27:1555-1557 (1999). |
Nagasu et al., “Nucleotide Sequence of the GDH gene coding for the NADP-specific glutamate dehydrogenase of Saccharomyces cerevisiae,” Gene 37:247-253 (1985). |
Naggert et al., “Cloning, Sequencing, and Characterization of Escherichia coli thioesterasell,” J. Biol. Chem. 266(17):11044-11050 (1991). |
Nahvi et al., “Genetic control by a metabolite binding mRNA,” Chem. Biol. 9:1043-1049 (2002). |
Naidu and Ragsdale, “Characterization of a three-component vanillate O-demethylase from Moorella thermoacetica,” J. Bacteriol. 183:3276-3281 (2001). |
Najafpour and Younesi, “Ethanol and acetate synthesis from waste gas using batch culture of Clostridium ljungdahlii,” Enzyme Microb. Tech. 38:223-228 (2006). |
Najmudin et al., “Purification, crystallization and preliminary X-ray crystallographic studies on acetolactate decarboxylase,” Acta. Crystallogr. D. Biol. Crystallog. 59:1073-1075 (2003). |
Nakahigashi and Inokuchi, “Nucleotide sequence of the fadA and fadB genes from Escherichia coli,” Nucleic Acids Res. 18 16 :4937 (1990). |
Nakano et al., “Characterization of Anaerobic Fermentative Growth of Bacillus subtilis: Identification of Fermentation End Products and Genes Required for Growth,” J. Bacteriol. 179(21):6749-6755 (1997). |
Namba et al., “Coenzyme a and Nicotinamide Adenine dinucleotide-deptendent Branched Chain α-Keto Acid Dehydrogenase,” J. Biol. Chem. 244:4437-4447 (1969). |
Ness et al., “Synthetic shuffling expands functional protein diversity by allowing amino acids to recombine independently,” Nat. Biotechnol. 20(12):1251-1255. |
Nexant, “1,4-Butanediol/THF—PERP Program New Report Alert,” Nexant ChemSystems PERP Report 02/03-7, p. 1-5 (Jan. 2004). |
Niegemann et al., “Molecular organization of the Escherichia coli gab cluster: nucleotide sequence of the structural genes gabD and gabP and expression of the GABA permease gene,” Arch. Microbiol. 160:454-460 (1993). |
Nimmo, “Kinetic mechanism of Escherichia coli isocitrate dehydrogenase and its inhibition by glyoxylate and oxaloacetate,” Biochem. J. 234(2):317-323 (1986). |
Nishizawa et al., “Gene expression and characterization of two 2-oxoacid:ferredoxin oxidoreductases from Aeropyrum pernix K1,” FEBS. Lett. 579:2319-2322 (2005). |
Niu, et al., “Benzene-free synthesis of adipic acid,” Biotechnol. Prog. 18:201-211 (2002). |
Nolling et al., “Genome sequence and comparative analysis of the solvent-producing bacterium Clostridium acetobutylicum,” J. Bacteriol. 183(16):4823-4838 (2001). |
Nowicki et al., “Recombinant tyrosine aminotransferase from Trypanosoma cruzi: structural characterization and site directed mutagenesis of a broad substrate specificity enzyme,” Biochim. Biophys. Acta 1546(2):268-281 (2001). |
O'Brien and Gennis, “Studies of the thiamin pyrophosphate binding site of Escherichia coli pyruvate oxidase. Evidence for an essential tryptophan residue,” J. Biol. Chem. 255(8):3302-3307 (1980). |
O'Brien et al., “Chemical, physical and enzymatic comparisons of formyltetrahydrofolate synthetases from thermo- and mesophilic Clostridia,” Experientia. Suppl. 26:249-262 (1976). |
O'Brien et al., “Regulation by lipids of cofactor binding to a peripheral membrane enzyme: binding of thiamin pyrophosphate to pyruvate oxidase,” Biochemistry 16(14)3105-3109 (1977). |
Ohgami et al., “Expression of acetoacetyl-CoA synthetase, a novel cytosolic ketone body-utilizing enzyme, in human brain,” Biochem. Pharmacol. 65:989-994 (2003). |
Ohsugi et al., “Metabolism of L-β-Lysine by a Pseudomonas, Purification and Properties of a Deacetylase-Thiolesterase utilizing 4-Acetamidobutyrl CoA and Related Compounds,” J. Biol. Chem. 256:7642-7651 1981. |
Okino et al., “An efficient succinic acid production process in a metabolically engineered Corynebacterium glutamicum strain,” Appl. Microbiol. Biotechnol. 81(3):459-464 (2008). |
Oku and Kaneda, “Biosynthesis of Branched-chain Fatty Acids in Bacillis subtilis,” J. Biol. Chem. 263:18386-18396 (1988). |
Okuno et al., “2-Aminoadipate-2-oxoglutarate aminotransferase isoenzymes in human liver: a plausible physological role in lysine and tryptophan metabolism,” Enzyme Protein 47(3):136-148 (1993). |
Oliver et al., “Determination of the nucleotide sequence for the glutamate synthase structural genes of Escherichia coli K-12,” Gene 60:1-11 (1987). |
Olivera et al., “Molecular characterization of the phenylacetic acid catabolic pathway in Pseudomonas putida U: The phenylacetyl-CoA catabolon,” Proc. Natl. Acad. Sci. U.S.A. 95:6419-6424 (1998). |
Onuffer and Kirsch, “Redesign of the substrate specificity of Escherichia coli aspartate aminotransferase to that of Escherichia coli tyrosine aminotransferase by homology modeling and site-directed mutagenesis ” Protein Sci. 4:1750-1757 (1995). |
O'Reilly and Devine, “Sequence and analysis of the citrulline biosynthetic operon argC-F from Bacillus subtilis,” Microbiology140:1023-1025 (1994). |
Orencio-Trejo et al., “Metabolic regluation analysis of an ethanologenic Escherichia coli strain based on RT-PCR and enzymatic activities,” Biotechnol. Biofuels 1:8 (2008). |
Ostermeier et al., “A combinatorial approach to hybrid enzymes independent of DNA homology,” Nat. Biotechnol. 17(12):1205-1209 (1999). |
Ostermeier et al., “Combinatorial protein engineering by incremental truncation,” Proc. Natl. Acad. Sci. U.S.A. 96(7):3562-3567 (1999). |
O'Sullivan, et al., “Purification and characterisation of acetolactate decarboxylase from Leuconostoc lactis NCW1,” FEMS Microbiol. Lett. 194(2):245-249 (2001). |
Otten and Quax, “Directed evolution: selecting today's biocatalysts,” Biomol. Eng. (22):1-9 (2005). |
Palosaari and Rogers, “Purification and properties of the inducible coenzyme A-linked butyraldehyde dehydrogenase from Clostridium acetobutylicum,” J. Bacteriol. 170(7):2971-2976 (1988). |
Park and Lee, “Biosynthesis of poly(3-hydroxybutyrate-co-3-hydroxyalkanoates) by metabolically engineered Escherichia coli strains,” Appl. Biochem. Biotechnol. 113-116:335-346 (2004). |
Park and Lee, “Identification and Characterization of a New Enoyl coenzyme a Hydratase involved in biosynthesis of Medium-Chain-Length Polyhdroxyalkanoates in recombinant Escherichia coli,” J. Bacteriol. 185(18):5391-5397 (2003). |
Park and Lee, “New FadB homologous enzymes and their use in enhanced biosynthesis of medium-chain-length polyhydroxyalkanoates in FadB mutant Escherichia coli,” Biotechnol. Bioeng. 86:681-686 (2004). |
Park et al., “Regulation of succinate dehydrogenase (sdhCDAB) operon expression ion Escherichia coli in response to carbon supply and anaerobiosis: role of ArcA and Fnr,” Mol. Micriobiol. 15:473-482 (1995). |
Park et al., “Aerobic regulation of the sucABCD genes of Escherichia coli, which encode alpha-ketoglutarate dehydrogenase and succinyl coenzyme a synthetase: roles of ArcA, Fnr, and the upstream sdhCDAB promoter,” J. Bacteriol. 179:4138-4142 (1997). |
Park et al., “Isolation and characterization of recombinant mitochondrial 4-aminobutyrate aminotransferase,” J. Biol. Chem. 268:7636-7639 (1993). |
Parkin et al., “Rapid and efficient electrocatalytic CO2/CO interconversions by Carboxydothermus hydrogenoformans CO dehydrogenase I on an electrode,” J. Am. Chem. Soc. 129:10328-10329 (2007). |
Parsot et al., “Nucleotide sequence of Escherichia coli argB and argC genes: comparison of N-acetylglutamate kinase and N-acetylglutamate-gamma-semialdehyde dehydrogenase with homologous and analogous enzymes,” Gene. 68(2): 275-283 (1988). |
Pauwels et al., “The N-acetylglutamate synthase?N-acetylglutamate kinase metabolon of Saccharomyces cerevisiae allows cor-ordinated feedback regulation of the first two steps in arginine biosynthesis,” Eur. J. Biochem. 270:1014-1024. |
Paxton et al., “Role of branched-chain 2-oxo acid dehydrogenase and pyruvate dehydrogenase in 2-oxobutyrate metabolism,” Biochem. J. 234:295-303 (1986). |
Pelanda et al., “glutamate synthase genes of the diazotroph Azospirillum brasillense. Cloning, sequencing, and analysis of functional domains,” J. Biol. Chem. 268:3099-3109 (1993). |
Peoples and Sinskey, “Fine structural analysis of the Zoogloea ramigera phhA-phhB locus encoding beta-ketothiolase and acetoacetyl-CoA reductase: nucleotide sequence of phbB,” Mol. Microbiol. 3:349-357 (1989). |
Pereira et al., “Active site mutants of Escherichia coli citrate synthase. Effects of mutations on catalytic and allosteric properties,” J. Biol. Chem. 269:412-417 (1994). |
Peretz and Burstein, “Amino Acid Sequence of Alcohol Dehydrogenase from the Thermophilic bacterium Thermoanaerobium brockii,” Biochem. 28:6549-6555 (1989). |
Peretz et al., “Molecular cloning, nucleotide sequencing, and expression of genes encoding alcohol dehydrogenases from the thermophile Thermoanaerobacter brockii and the mesophile Clostridium beijerinckii,” Anaerobe 3:259-270 (1997). |
Perez et al., “Escherichia coli YqhD exhibits aldehyde reductase activity and protects from the harmful effect of lipid peroxidation-derived aldehydes,” J. Biol. Chem. 283(12):7346-7353 (2008). |
Petersen and Bennett, “Purification of acetoacetate decarboxylase from Clostridium acetobutylicum ATCC 824 and cloning of the acetoacetate decarboxylase gene in Escherichia coli,” Appl. Environ. Microbiol. 56:3491-3498 (1990). |
Petitdemange et al., “Regulation of the NADH and NADPH-ferredoxin oxidoreductases in Clostridia of the butyric group,” Biochim. Biophvs. Acta. 421(2):334-337 (1976). |
Phalip et al., “Purification and properties of the alpha-acetolactate decarboxylase from Lactococcus lactis subsp. Lactis NCDO 2118,” FEBS Lett. 351:95-99 1994. |
Pharkya et al., “Exploring the overproduction of amino acids using the bilevel optimization framework OptKnock,” Biotechnol. Bioeng. 84 7 :887-899 2003. |
Pierce et al.,“The complete genome sequence of Moorella thermoacetia (f. Clostridium thermoaceticum),” Environ. Microbiol. 10(10):2550-2573 (2008). |
Pieulle, “Isolation and analysis of the gene encoding the pyruvate-ferredoxin oxidoreductase of Desulfovibrio africanus, production of the recombinant enzyme in Escherichia coli, and effect of carboxy-terminal deletions on its stability,” J. Bacteriol. 179:5684-5692 (1997). |
Ploux et al., “The NADPH-linked acetoacetyl-CoA reductase from Zoogloea ramigera, Characterization and mechanistic studies of the cloned enzyme overproduced in Escherichia coli,” Eur. J. Biochem. 174:177-182 (1988). |
Pohl et al., “Remarkably broad substrate tolerance of malonyl-CoA synthetase, an enzyme capable of intracellular synthesis of polyketide precursors,” J. Am. Chem. Soc. 123(24): 5822-5823 (2001). |
Pohlmann et al., “Genome sequence of the bioplastic-producing “Knallgas” bacterium Ralstonia eutropha H16,” Nat. Biotechnol. 24(10):1257-1262 (2006). |
Poirier et al., “Polyhydroxybutyrate, a Biodegradable Thermoplastic Produced in Transgenic Plants,” Science 256:520-523 (1992). |
Polovnikova et al., “Structural and Kinetic Analysis of Catalysis by a thiamin diphosphate-Dependent Enzyme, Benzoylformate Decarboxylase,” Biochemistry 42: 1820-1830 (2003). |
Poston, “Assay of leucine 2,3-aminomutase,” Methods Enzymol. 166:130-135 (1988). |
Powlowski et al., “Purification and properties of the physically associated meta-cleavage pathway enzymes 4-hydroxy-2-ketovalerate aldolase and aldehyde dehydrogenase (acylating) from Pseudomonas sp. strain CF600,” J. Bacteriol. 175:377-385 (1993). |
Presecan et al., “The Bacillus subtillis genome from gerBC (311 degrees) to licR (334 degrees),” Microbiology 143:3313-3328 (1997). |
Price et al., “Genome-scale models of microbial cells: evaluating the consequences of constraints,” Nat. Rev. Microbiol. 2(11):886-897 (2004). |
Pritchard et al., “A general model of error-prone PCR,” J. Theor. Biol. 234:497-509 (2005). |
Pritchett and Metcalf, “Genetic, physiological and biochemical characterization of multiple methanol methyltransferase isozymes in Methanosarcina acetivorans C2A,” Mol. Microbiol. 56:1183-1194 (2005). |
Purnell et al., “Modulation of higher-plant NAD(H)-dependent glutamate dehydrogenase activity in transgenic tobacco via alteration of beta subunit levels,” Planta 222:167-180 (2005). |
Qi et al., “Functional expression of prokaryotic and eukaryotic genes in Escherichia coli for conversion of glucose to p-hydroxystyrene,” Metab. Eng. 9:268-276 (2007). |
Qian et al., “Metabolic engineering of Escherichia coli for the production of putrescine: a four carbon diamine,” Biotechnol. Bioeng. 104(4)651-662 (2009). |
Qiu et al., “Metabolic engineering for the production of copolyesters consisting of 3-hydroxybutyrate and 3-hydroxyhexanoate by Aeromonas hydrophilia,” Macromol. Biosci. 4(3):255-261 (2004). |
Radhakrishnan et al., “Applications of metabolic modeling to drive bioprocess development for the production of value-aded chemicals,” Biotechnol. Bioprocess. Eng. 10:408-417 (2005). |
Ragsdale, “Enzymology of the wood-Ljungdahl pathway of acetogenesis,” Ann. NY Acad Sci. 1125:129-136 (2008). |
Ragsdale, “Life with carbon monoxide,” Crit Rev. Biochem. Mol. Biol. 39:165-195 (2004). |
Ragsdale, “Pyruvate ferredoxin oxidoreductase and its radical intermediate,” Chem. Rev. 103:2333-2346 (2003). |
Rajpal et al., “A general method for greatly improving the affinity of antibodies by using combinatorial libraries,” Proc. Natl. Acad. Sci. U.S.A. 102(24):8466-8471 (2005). |
Ramon-Maiques et al., “Structure of Acetylglutamate Kinase, a Key Enzyme for Arginine Biosynthesis and a Prototype for the Amino Acid Kinase Enzyme Family, during Catalysis,” Structure 10:329-342 (2002). |
Ramos et al., “Mutations affecting the enzymes involved in the utilization of 4-aminobutyric acid as nitrogen source by the yeast Saccharomyces cerevisiae,” Eur. J. Biochem. 149:401-404 (1985). |
Rangarajan et al., “Structure of [NiFe] hydrogenase maturation protein HypE from Escherichia coli and its interaction with HypF,” J. Bacteriol. 190:1447-1458 (2008). |
Rathinasabapathi, “Propionate, a source of β-alanine, is an inhibitor of β-alanine methylation in Limonium latifolium, Plumbaginaceae,” J. Plant Physiol. 159:671-674 (2002). |
Raybuck et. al., “Kinetic characterization of the carbon monoxide-acetyl-CoA (carbonyl group) exchange activity of the acetyl-CoA synthesizing CO dehydrogenase from Clostridium thermoaceticum,” Biochemistry 27:7698-7702 (1988). |
Recasens et al., “Cysteine Sulfinate Aminotransferase and Aspartate Aminotransferase Isoenzymes of Rat Brain. Purification, Characterization, and Further Evidence for Identity,” Biochemistry 19:4583-4589 (1980). |
Reda et al., “Reversible interconversion of carbon dioxide and formate by an electroactive enzyme,” Proc. Natl. Acad. Sci. U.S.A. 105:10654-10658 (2008). |
Redenbach et al., “A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb Streptomyces coelicolor A3(2) chromosome,” Mol. Microbiol. 21:77-96 (1996). |
Reed et al., “An expanded genome-scale model of Escherichia coli K-12 (iJR904 GSM/GPR),” Genome Biol. 4 9 :R54 (2003). |
Reetz and Carballeria, “Iterative aturation mutagenesis (ISM) for rapid directed evolution of functional enzymes,” Nat. Protoc. 2 4 :891-903 2007. |
Reetz et al., “Creation of Enantioselective biocatalysts for Organic Chemistry by In Vitro Evolution,” Agnew. Chem. Int. Ed. Engl. 36:2830-2832 (1997). |
Reetz et al., “Directed Evolution of an Enantioselective Enzyme through Combinatorial Multiple-Cassette Mutagenesis,” Agnew. Chem. Int. Ed. Engl. 40:3589-3591 (2001). |
Reetz et al., “Expanding the Range of Substrate Acceptance of Enzymes: Combinatorial Active-site saturation test,” Agnew. Chem. Int. Ed. Engl. 44:4192-4196 (2005). |
Reetz et al., “Iterative Saturation Mutagenesis on the Basis of B Factors as a Strategy for Increasing Protein Thermostability,” Agnew. Chem. Int. Ed. Engl. 45:7745-7751 (2006). |
Regev-Rudzki et al., “Yeast Aconitase in Two Locations and Two Metabolic Pathways: Seeing Small Amounts Is Believing,” Mol. Biol. Cell 16:4163-4171 (2005). |
Reidhaar-Olson and Sauer, “Combinatorial cassette mutagenesis as a probe of the informational content of protein sequences,” Science 241(4861):53-57 (1988). |
Reidhaar-Olson et al., “Random mutagenesis of protein sequences using oligonucleotide cassettes,” Methods Enzmol. 208:564-586 (1991). |
Reiser and Somerville, “Isolation of mutants of Acinetobacter calcoaceticus deficient in wax ester synthesis and complementation of one mutation with a gene encoding a fatty acyl coenzyme a reductase,” J. Bacteriol. 179(9):2969-2975. |
Reitzer, “Ammonia Assimillation and the Biosynthesis of Glutamine, Glutamate, Aspartate, Asparagine, I-Alanine, and d-Alanine,” In Neidhardt (Ed.), Escherichia coli and Salmonella: Cellular and Molecular Biology, ASM Press: Washington, DC, p. 391-407 (1996). |
Repetto and Tzagoloff, “Structure and Regulation of KGD1, the Structural Gene for Yeast 60 -Ketoglutarate Dehydrogenase,” Mol. Cell. 9:2695-2705 (1989). |
Resnekov et al., “Organization and regulation of the Bacillus subtilis odhAB operon, which encodes two of the subenzymes of the 2-oxoglutarate dehydrogenase complex,” Mol. Gen. Genet. 234(2):285-296 (1992). |
Ribeiro et al., “Microbial reduction of α-acetyl-γ-butyrolactone,” Tetrahedron: Asymmetry. 17(6):984-988 (2006). |
Rigden et al., “A cofactor-dependent phosphoglycerate mutase homolog from Bacillus stearothermophilus is actually a broad specificity phosphatase,” Protein Sci. 10:1835-1846 (2001). |
Ringquist et al., “Translation initiation in Escherichia coli: sequences within the ribosome-binding site,” Mol. Microbiol. 6:1219-1229 (1992). |
Riondet et al., “Measurement of the intracellular pH in Escherichia coli with the internally conjugated fluorescent probe 5- (and 6) carboxyfluorescein succinimidyl ester,” Biotechnol. Tech. 11:735-738 (1997). |
Riviere et al., “Acetyl:Succinate CoA-transferase in Procyclic Trypanosoma brucei,” J. Biol Chem. 279(44):45337-45346 (2004). |
Roberts et al., “Cloning and expression of the gene cluster encoding key proteins involved in acetyl-CoA synthesis in Clostridium thermoaceticum: CO dehydrogenase, the corrinoid/Fe-S protein, and methyltransferase,” Proc. Natl. Acad. Sci. U.S.A. 86:32-36 (1989). |
Robinson et al., “Studies on Rat Brain Acyl-Coenzyme a Hydrolase (Short Chain),” Biochem. Biophys. Res. Commun. 71:959-965 (1976). |
Roca et al., “Metabolic engineering of ammonium assimilation in xylose-fermenting Saccharmyces cerevisiae improves ethanol production,” Appl. Environ. Microbiol. 69(8):4732-4736 (2003). |
Rodriguez et al., “Characterization of the p-coumaric acid decarboxylase from Lactobacillus plantarum CECT 748(T),” J. Agric. Food Chem. 56(9):3068-3072 (2008). |
Rohdich et al., “Enoate reductases of Clostridia. Cloning, sequencing, and expression,” J. Biol. Chem. 276(8):5779-5787 (2001). |
Romero et al., “Partial purification, characterization and nitrogen regulation of the lysine epsilon-aminotransferase of Streptomyces clavuligerus,” J. Ind. Microbiol. Biotechnol. 18(4):241-246 (1997). |
Rose and Weaver, “The role of the allosteric B site in the fumarase reaction,” Proc. Natl. Acad. Sci. U.S.A. 101:3393-3397 (2004). |
Rose et al., “Enzymatic phosphorylation of acetate,” J. Biol. Chem. 211(2):737-756 (1954). |
Rother and Metcalf, “Anaerobic growth of Methanosarcina acetivorans C2A on carbon monoxide: an unusual way of life for a methanogenic archaeon,” Proc. Natl. Acad. Sci. U.S.A. 101:16929-16934 (2004). |
Rother et al., “Genetic and proteomic analyses of CO utilization by Methanosarcina acetivorans,” Arch. Microbiol. 188:463-472 (2007). |
Roy and Dawes, “Cloning and Characterization of the Gene Encoding Lipamide Dehydrogenase in Saccharomyces cerevisiae” J. Gen. Microbiol. 133:925-933 (1987). |
Ruldeekulthamrong et al., “Molecular characterization of lysine 6-dehydrogenase from Achromobacter denitrificans,” BMB Rep. 41:790-795 (2008). |
Sabo et al., “Purification and Physical Properties of Inducible Escherichia coli Lysine Decarboxylase,” Biochemistry 13(4):662-670 (1974). |
Saito and Doi, “Microbial synthesis and properties of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in Comamonas acidovorans,” Int. J. Biol. Macromol. 16:99-104 (1994). |
Saito et al., “Microbial Synthesis and properties of Poly(3-hydroxybutyrate-co-4-hydroxybutyrate),” Polym. Int. 39:169-174 (1996). |
Sakai et al., “Acetate and ethanol production from H2 and CO2 by Moorella sp. using a repeated batch culture,” J. Biosci. Bioeng. 99:252-258 (2005). |
Sakakibara et al., “Isolation and characterization of a cDNA that encodes maize glutamate dehydrogenase,” Plant Cell Physiol. 36:789-797 (1995). |
Salmon et al., “Global gene expression profiling in Escherichia coli K12: effects of oxygen availability and ArcA,” J. Biol. Chem. 280(15):15084-15096 (2005). |
Samsonova et al., “Molecular cloning and characterization of Escherichia coli K12 ygjG gene,” BMC Microbiol. 3:2 (2003). |
Sanchez et al., “Properties and functions of two succinic-semialdehyde dehydrogenases from Pseudomonas putida,” Biochim. Biophvs. Acta. 953(3):249-257 (1988). |
Sanchez et al., “Purification and properties of two succinic semialdehyde dehydrogenases from Klebsiella pneumoniae,” Biochim. Biophys. Acta. 990(3):225-231 (1989). |
Sariaslani, “Development of a Combined Biological and Chemical Process for Production of Industrial Aromatics from Renewable Resources,” Annu. Rev. Microbiol. 61:51-69 (2007). |
Sass et al., “Folding of fumarase during mitochondrial import determines its dual targeting in yeast,” J. Biol. Chem. 278(46):45109-45116 (2003). |
Sato et al., “Poly[(R)-3-Hydroxybutyrate] Formation in Escherichia coli from Glucose through an Enoyl-CoA Hydratase-Mediated Pathway,” J. Biosci. Bioeng. 103(1):38-44 (2007). |
Sauer et al., “Methanol:coenzyme M methyltransferase from Methanosarcina barkeri. Purification, properties and encoding genes of the corrinoid protein MT1,” Eur. J. Biochem. 243:670-677 (1997). |
Sawers and Boxer, “Purification and properties of membrane-bound hydrogenase isoenzyme 1 from anaerobically grown Escherichia coli K12,” Eur. J. Biochem. 156:265-275 (1986). |
Sawers et al., “Characterization and physiological roles of membrane-bound hydrogenase isoenzymes from Salmonella typhimurium ” J. Bacteriol. 168:398-404 (1986). |
Sawers et al., “Differential expression of hydrogenase isoenzymes in Escherichia coli K-12: evidence for a third isoenzyme,” J. Bacteriol. 164:1324-1331 (1985). |
Sawers, “The hydrogenases and formate dehydrogenases of Escherichia coli,” Antonie Van Leeuwenhoek 66:57-88 (1994). |
Scherf and Buckel, “Purification and properties of 4-hydroxybutyrate coenzyme a transferase from Clostridium aminobutyricum,” Appl. Environ. Microbiol. 57(9):2699-2702 (1991). |
Scherf and Buckel, “Purification and properties of an iron-sulfur and FAD-containing 4-hydroxybuturyl-CoA dehydratase/vinylacetyl-CoA Δ3-Δ2-isomerase from Clostridium aminobutyricum,” Eur. J. Biochem. 215:421-429 (1993). |
Scherf et al., “Suffinate-ethanol fermentation in Clostridium kluyveri: purification and characterisation of 4-hydroxybutyryl-CoA dehydratase/vinylacetyl-CoA delta 3-delta 2-isomerase,” Arch. Microbiol. 161:239-245 (1994). |
Schilling et al., “Toward Metabolic Phenomics: Analysis of Genomic Data Using Flux Balances,” Biotechnol. Prog. 15:288-295 (1999). |
Schilling et al., “Combining Pathway Analysis with Flux Balance Analysis for the Comprehensive Study of Metabolic Systems,” Biotechnol. Bioeng. 71(4):286-306 (2000-2001). |
Schilling et al., “Theory for the Systematic Definition of Metabolic Pathways and Their Use in Interpreting Metabolic Function from a Pathway-Oriented Perspective,” J. Theor. Biol. 203(3):229-248 (2000). |
Schneider et al., “The Escherichia coli gabDTPC operon: specific gamma-aminobutyrate catabolism and nonspecific induction,” J. Bacteriol. 184:6976-6986. |
Schulz et al., “Stereopsecific Production of the Herbicide Phosphinothricin (Glufosinate) by Transamination: Isolation and Characterization of a Phosphinothricin-Specific Transaminase from Escherichia coli,” Appl. Environ. Microbiol. 56:1-6 (1990). |
Scott and Jakoby, “Soluble γ-Aminobutyric-Glutamic Transaminase from Pseudomonas fluorescens,” J. Biol. Chem. 234:932-936 (1959). |
Seedorf et al., “The genome of Clostridium kluyveri, a strict anaerobe with unique metabolic features,” Proc. Natl. Acad. Sci. U.S.A. 105(6):2128-2133 (2008). |
Selifonova et al., “Rapid evolution of novel traits in microorganisms,” Appl. Environ. Microbiol. 67(8():3645-3649 (2001). |
Sen et al., “Developments in directed evolution for improving enzyme functions,” Appl. Biochem. Biotechnol. 143(3):212-223 (2007). |
Seravalli et al., “Evidence that NiNi acetyl-CoA synthase is active and that the CuNi enzyme is not,” Biochemistry 43:3944-3955 (2004). |
Seravalli et al., “Mechanism of transfer of the methyl group from (6S)-methyltetrahydrofolate to the corrinoid/iron-sulfur protein catalyzed by the methyltransferase from Clostridium thermoaceticum: a key step in the Wood-Ljungdahl pathway of acetyl-CoA synthesis,” Biochemistry 38:5728-5735 (1999). |
Shafiani et al., “Cloning and characterization of aspartate-β-semialdehyde dehydrogenase from Mycobacterium tuberculosis H37 Rv,” J. Appl. Microbiol. 98:832-838 (2005). |
Shalel-Levanon et al., “Effect of ArcA and FNR on the expression of genes related to the oxygen rregulation and the glycolysis pathway in Eschericiha coli under microaerobic growth conditions,” Biotechnol. Bioeng. 92(2):147-159 (2005). |
Shames et al., “Interaction of aspartate and aspartate-derived antimetabolites with the enzymes of the threonine biosynthetic pathway of Escherichia ecoli,” J. Biol. Chem. 259(24):15331-15339 (1984). |
Shao et al., “Random-priming in vitro recombination: an effective tool for directed evolution,” Nucleic Acids Res. 26(2):681-683 (1998). |
Sheppard et al., “Purification and properties of NADH-dependent 5, 10-methylenetetrahydrofolate reductase (MetF) from Escherichia coli,” J. Bacteriol. 181:718-725 (1999). |
Shi et al., “The structure of L-aspartate ammonia-lyase from Escherichia coli,” Biochem. 36(30):9136-9144 (1997). |
Shigeoka and Nakano, “Characterization and molecular properties of 2-oxoglutarate decarboxylase from Euglena gracilis,” Arch. Biochem. Biophys. 288:22-28 (1991). |
Shigeoka and Nakano, “The effect of thiamin on the activation of thiamin pyrophosphate-dependent 2-oxoglutarate decarboxylase in Euglena gracilis,” Biochem. J. 292:463-467 (1993). |
Shigeoka et al., “Effect of L-glutamate on 2-oxoglutarate decarboxylase in Euglena gracilis,” Biochem. J. 282:319-323 (1992). |
Shimomura et al., “3-Hydroxyisobutyryl-CoA Hydrolase,” Meth. Enzymol. 324:229-240 (2000). |
Shimomura et al., “Purification and Partial Characterization of 3-Hydroxyisobutyryl-coenzyme A Hydrolase of Rat Liver,” J. Biol. Chem. 269:14248-14253 (1994). |
Shimoyama et al., “MmcBC in Pelotomaculum thermopropionicum represents a novel group of prokaryotic fumarases,” FEMS Microbiol Lett. 270(2):207-213 (2007). |
Shingler et al., “Nucleotide Sequence and Functional Analysis of the Complete Phenol/3,4-Dimethylphenol Catabolic Pathway of Pseudomonas sp. Strain CF600,” J. Bacteriol. 174(3):711-724 (1992). |
Shiraki et al., “Fermentative production of (R)-(−)-(3) hydroxybutyrate using 3-hydroxybutyrate dehydrogenase null mutant of Ralstonia eutropha and recombinant Escherichia coli,” J. Biosci. Bioeng. 102(6):529-534 (2006). |
Shukla et al., “Production of D(−)-lactate from sucrose and molasses,” Biotechnol. Lett. 26(9):689-693 (2004). |
Sieber et al., “Libraries of hybrid proteins from distantly related sequences,” Nat. Biotechnol. 19(5):456-460 (2001). |
Siebers et al., “Reconstruction of the central carbohydrate metabolism of Thermoproteus tenax by use of genomic and biochemical data,” J. Bacteriol186(7):2179-2194 (2004). |
Siegert et al., “Exchanging the substrate specificities of pyruvate decarboxylase from Zymomonas mobilis and benzoylase from Pseudomonas putida,” Protein Eng. Des. Sel. 18:345-357 (2005). |
Siminov et al.,“Application of Gas Chromatography and Gas Chromatography-Mass Spectrometry to the Detection of γ-Hydroxybutyric Acid and Its Precursors in Various Materials ” J. Anal. Chem. 59:965-971 (2004). |
Simpma et al., “Microbial CO Conversions with Applications in Synthesis Gas Purification and Bio-Desulfurization,” Crit. Rev. Biotech. 26:41-65 (2006). |
Sinclair et al, “Purification and characterization of the branched chain α-ketoacid dehydrogenase complex from Saccharomyces cerevisiae,” Biochem. Mol. Biol. Int. 31(5):911-922 (1993). |
Sivaraman et al., “Codon choice in genes depends on flanking sequence information—implications for theoretical reverse translation,” Nucleic Acids Res. 36(3):e16 (2008). |
Sjostrom et al., “Purfication and characterisation of a plasminogen-binding protein from Haemophilus influenzae. Sequence determination reveals identity with aspartase,” Biochim. Biophys. Acta. 1324:182-190 (1997). |
Skarstedt and Silverstein, “Escherichia coli Acetate Kinase Mechanism Studied by Net Initial Rate, Equilibriu, and Independent Isotopic Exchange Kinetics,” J. Biol. Chem. 251:6775-6783 (1976). |
Skinner and Cooper, “An Escherichia coli mutant defective in the NAD-dependent succinate semialdehyde dehydrogenase,” Arch. Microbiol. 132(3):270-275 (1982). |
Smit et al., “Identification, Cloning, and Characterization of a Lactococcus lactis Branched-Chain α-Keto Acid Decarboxylase Involved in Flavor Formation,” Appl. Environ. Microbiol. 71:303-311 (2005). |
Smith et al., “Fumarate metabolism and the microaerophily of Campylobacter species,” Int. J. Biochem. Cell Biol. 31:961-975 (1999). |
Smith et al., “Purification and characteristics of a gamma-glutamyl kinase involved in Escherichia coli proline biosynthesis,” J.Bacteriol. 157:545-551 (1984). |
Smith et al., “Complete genome sequence of Methanobacterium thermoautotrophicum deltaH: functional analysis and comparative genomics,” J. Bacteriol. 179:7135-7155 (1997). |
Snedecor et al., “Selection, expression, and nucleotide sequencing of the glutamate dehydrogenase gene of Peptostreptococcus asaccharolyticus,” J. Bacteriol. 173:6162-6167 (1991). |
Soda and Misono, “L-Lysine:alpha-ketoglutarate aminotransferase. II. Purification, crystallization, and properties,” Biochemistry 7(11):4110-4119 (1968). |
Sohling and Gottschalk, “Molecular analysis of the anaerobic succinate degradation pathway in Clostridium kluyveri.,” J. Bacteriol. 178(3):871-880 (1996). |
Sohling and Gottschalk, “Purification and characterization of a coenzyme-A-dependent succinate-semialdehyde dehydrogenase from Clostridium kluyveri,” Eur. J. Biochem. 212:121-127 (1993). |
Sokatch et al., “Purification of a Branched-Chain Keto Acid Dehydrogenase from Pseudomonas putida,” J. Bacteriol. 647-652 (1981). |
Song et al., “Structure, Function, and Mechanism of the Phenylacetate Pathway Hot Dog-fold Thioesterase Paal,” J. Biol. Chem. 281(16):11028-11038 (2006). |
Song et al., “Construction of recombinant Escherichia coli strains producing poly (4-hydroxybutyric acid) homopolyester from glucose,” Wei Shenq Wu Xue Bao, 45(3):382-386 (2005). (In Chinese, includes English abstract). |
Spencer and Guest, “Transcription analysis of the sucAB, aceEF and Ipd genes of Escherichia coli,” Mol. Gen. Genetics 200:145-154 (1985). |
Spencer et al., “Nucleotide sequence of the sucB gene encoding the dihydrolipoamide succinyltransferase of Escherichia coli K12 and homology with the corresponding acetyltransferase,” Eur. J. Biochem. 141(2):361-374 (1984). |
St Maurice et al., “Flavodoxin:quinone reductase (FqrB): a redox partner of pyruvate:ferredoxin oxidoreductase that reversibly couples pyruvate oxidation to NADPH production in Helicobacter pylori and Campylobacter jejuni,” J. Bacteriol. 189(13):4764-4773 (2007). |
Stadtman, “The enzymatic synthesis of β-alanyl coenzyme A,” J. Am. Chem. Soc. 77:5765-5766 (1955). |
Stanley et al., “Expression and Sterochemical and Isotope Effect Studies of Active 4-Oxalocrotonate Decarboxylase,” Biochem. 39:(4):718-726 (2000). |
Starai et al., “Acetate excretion during rowth of Salmonella enterica on ethanolamine requires phosphotransacetylase (EutD) activity, and acetate recapture requires acetyl-CoA synthetase (Acs) and phosphotransacetylase (Pta) activities,” Microbiology 151:3793-3801 (2005). |
Starai et al., “Residue Leu-641 of Acetyl-CoA synthetase is critical for the acetylation of residue Lys-609 by the Protein acetyltransferase enzyme of Salmonella enterica,” J. Biol. Chem. 280(28):26200-26205 (2005). |
Steffan and McAlister-Henn, “Isolation and Characterization of the Yeast Gene Encoding the MDH3 Isozyme of Malate Dehydrogenase,” J. Biol. Chem. 267(34):24708-24715 (1992). |
Steinbüchel and Schlegel, “NAD-linked L(+)-lactate dehydrogenase from the strict aerobe alcaligenes eutrophus. 2. Kinetic properties and inhibition by oxaloacetate,” Eur. J. Biochem. 130(2):329-334 (1983). |
Steinbuchel and Schlegel, “A multifunctional fermentative alcohol dehydrogenase from the strict aerobe Alcaligenes eutrophus: purification and properties,” Eur. J. Biochem. 141:555-564 (1984). |
Steinbuchel and Schlegel, “Physiology and molecular genetics of poly(beta-hydroxy-alkanoic acid) synthesis in Alcaligenes eutrophus,” Mol. Microbiol. 5(3):535-542 (1991). |
Steinbuchel and Valentin, “Diversity of bacterial polyhydroxyalkanoic acids,” FEMS Microbiol. Lett. 128:219-228 (1995). |
Steinbuchel et al., “A Pseudomonas strain accumulating polyesters of 3-hydroxybutyric acid and medium-chain-length 3-hydroxyalkanoic acids,” Appl. Microbiol. Biotechnol. 37:691-697 (1992). |
Stemmer, “DNA Shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution,” Proc. Natl. Acad. Sci. U.S.A. 91(22):10747-10751 (1994). |
Stemmer, “Rapid evolution of a protein in vitro by DNA shuffling,” Nature 370:389-391 (1994). |
Stokell et al., “Probing the roles of key residues in the unique regulatory NADH binding site of type II citrate synthase of Escherichia coli,” J. Biol. Chem. 278(37):35435-35443 (2003). |
Stols et al., “New vectors for co-expression of proteins: Structure of Bacillus subtilis ScoAB obtained by high-throughput protocols,” Protein Expr. Purif. 53:396-403 (2007). |
Stoyan et al., “Cloning, sequencing and overexpression of the leucine dehydrogenase gene from Bacillus cereus,” J. Biotechnol. 54:77-80 (1997). |
Strauss and Fuchs, “Enzymes of a novel autotrophic CO2 fixation pathway in the phototrophic bacterium Chloroflexus aurantiacus, the 3-hydroxypropionate cycle,” Eur. J. Biochem. 215:633-643 (1993). |
Suda et al., “Purification and properties of alpha-keoadipate reductase, a newly discovered enzyme from human placenta,” Arch. Biochem. Biophys. 176(2):610-620 (1976). |
Suda et al., “Subcellular Localization and tissue Distribution of α-Ketodaipate Reduction and Oxidation in the Rat,” Biochem. Biophys. Res. Commun. 77:586-591 (1977). |
Suematsu et al., “Molecular cloning and functional expression of rat liver cytosolic acetyl-CoA hydrolase,” Eur. J. Biochem. 268(9):2700-2709 (2001). |
Sulzenbacher et al., “Crystal structure of E.coli alcohol dehydrogenase YqhD: evidence of a covalently modified NADP coenzyme,” J. Mol. Biol. 342(2):489-502 (2004). |
Suthers et al., “Metabolic flux elucidation for large-scale models using 13C labeled isotopes,” Metab. Eng. 9(5-6):387-405 (2007). |
Suzuki et al., “GriC and GriD Constitute a carboxylic acid reductase involved in grixazone biosynthesis in Streptomyces griseus,” J. Antibiot. 60(6):380-387 (2007). |
Suzuki, “Phosphotransacetylase of Escherichia coli B, activation by pyruvate and inhibition by NADH and certain nucleotides,” Biochim. Biophys. Acta 191(3):559-569 (1969). |
Svetlitchnyi et al., “A functional Ni-Ni-[4Fe-4S] cluster in the monomeric acetyl-CoA synthase from Carboxydothermus hydrogenoformans,” Proc. Natl. Acad. Sci. U.S.A. 101:446-451 (2004). |
Svetlitchnyi et al., “Two membrane-associated NiFeS-carbon monoxide dehydrogenases from the anaerobic carbon-monoxide-utilizing eubacterium Carboxydothermus hydrogenoformans,” J. Bacteriol. 183:5134-5144 (2001). |
Syntichaki et al., “The amino-acid sequence similarity of plant glutamate dehydrogenase to the extremophilic archaeal enzyme conforms to its stress-related function,” Gene. 168:87-92 (1996). |
Takagi and Kisumi, “Isolation of a Versatile Serratia marcescens Mutant as a Host and Molecular Cloning of the Aspartase Gene,” J. Bacteriol. 161(1):1-6 (1985). |
Takagi et al., “Purfication, Crystallization, and Molecular Properties of Aspartase from Pseudomonas fluorescens,” J. Biochem. 96:545-552 (1984). |
Takahashi et al., “Metabolic Pathways for Cytoxic End Product Formation from Glutamate- and Aspartate-Containing Peptides by Porphyromonas gingivalis,” J. Bacteriol. 182(17):4704-4710 (2000). |
Takahashi-Abbe et al., “Biochemical and functional properties of a pyruvate formate-lyase (PFL)-activating system in Streptococcus mutans,” Oral Microbiol. Immunol. 18(5):293-297 (2003). |
Takanashi et al., “Characterization of a novel 3-hydroxybutyrate dehydrogenase from Ralstonia pickettii T1,” Antonie van Leeuwnhoek 95(3):249-262 (2009). |
Takatsuka et al., “Gene cloning and molecular characterization of lysine decarboxylase from Selenomonas ruminantium delineate its evolutionary relationship to ornithine decarboxylases from eukaryotes,” J. Bacteriol. 182(23):6732-6741 (2000). |
Takatsuka et al., “Identification of the amino acid residues conferring substrate specificity upon Selenomonas ruminantium lysine decarboxylase,” Biosci. Biotechnol. Biochem. 63(10):1843-1846 (1999). |
Takigawa et al., “Probabilistic path ranking based on adjacent pairwise coexpression for metabolic transcripts analysis,” Bioinformatics 24(2):250-257 (2008). |
Tallant and Krzycki, “Coenzyme M methylase activity of the 480-kilodalton corrinoid protein from Methanosarcina barkeri,” J. Bacteriol. 175:1295-1301 (1996). |
Tallant and Krzycki, “Methylthiol:coenzyme M methyltransferase from Methanosarcina barkeri, an enzyme of methanogenesis from dimethylsulfide and methylmercaptopropionate,” J. Bacteriol. 179:6902-6911 (1997). |
Tallant et al., “The MtsA subunit of the methylthiol:coenzyme M methyltransferase of Methanosarcina barkeri catalyses both half-reactions of corrinoid-dependent dimethylsulfide: coenzyme M methyl transfer,” J. Biol. Chem. 276:4485-4493 (2001). |
Tamaki et al., “Purification, Properties, and Sequencing of Aminisobutyrate Aminotransferases from Rat Liver,” Meth. Enzymol. 324:376-389 (2000). |
Tanaka et al., “Cloning and characterization of a human orthologue of testis-specific succinyl CoA:3-oxo acid CoA transferase (Scot-t) cDNA,” Mol. Hum. Reprod. 8:16-23 (2001.). |
Tanaka et al., “Lysine decarboxylase of Vibrio parahaemolyticus: kinetics of transcription and role in acid resistance,” J. Appl. Microbiol. 104(5):1283-1293 (2007). |
Tang et al., “Identification of a novel pyridoxal 5′-phosphaste binding site in adenosylcobalamin-dependent lysine 5,6-aminomutase from Porphyromonas gingivalis,” Biochemistry 41(27):8767-8776 (2002). |
Tani et al., “Thermostable NADP(+)-dependent medium-chain alcohol dehydrogenase from Acinetobacter sp strain M-1: Purification and characterization and gene expression in Escherichia coli,” Appl. Environ. Microbiol. 66:5231-5235 (2000). |
Teller et al., “The glutamate dehydrogenase gene of Clostridium symbiosum, Cloning by polymerase chain reaction sequence analysis and over-expression in Escherichia coli,” Eur. J. Biochem. 206:151-159 (1992). |
ter Schure et al., “Pyruvate Decarboxylase Catalyzes Decarboxylation of Branched-Chaing 2-Oxo Acids but is Not Essential for Fusel Alcohol Production by Saccharomyces cerevisiae,” Appl. Environ. Microbiol. 64(4):1303-1307 (1998). |
Thakur et al., “Changes in the Electroencephalographic and .gamma.-Aminobutyric Acid Transaminsase and Succinic Semialdehyde Dehydrogenase in the Allergen Induced Rat Brain,” Biochem. Int. 16:235-243 (1998). |
Thauer, “Microbiology. A fifth pathway of carbon fixation,” Science 318:1732-1733 (2007). |
Tian et al., “Variant tricarboxylic acid cycle in Mycobacterium tuberculosis: identification of alpha-ketoglutarate decarboxylase,” Proc. Natl. Acad. Sci. U.S.A. 102(30):10670-10675 (2005). |
Tobin et al., “Localization of the lysine epsilon-aminotransferase (lat) and delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-Valine synthetase (pcbAB) genes from Streptomyces ciavuligerus and production of lysine epsilon-aminotransferase activity in Escherichia coli,” J. Bacteriol. 173(19):6223-6229 (1991). |
Tomb et al., “The complete genome sequence of the gastric pathogen Helicobacter pylon,” Nature 388:539 (1997). |
Toth et al., “The aid gene, encoding a coenzyme A-acylating aldehyde dehydrogenase, distinguishes Clostridium beijerinckii and two other solvent-producing clostridia from Clostridium acetobutylicum,” Appl. Environ. Microbiol. 65(11):4973-4980 (1999). |
Tretter and Adam-Vizi, “Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress,” Philos. Trans. R. Soc. Lond B. Biol. Sci. 360:2335-2345 (2005). |
Tseng et al., “Metabolic engineering of Escherichia coli for enhanced production of (R)- and (S)-3-hydroxybutyrate,” Appl. Environ. Microbiol. 75(10):3137-3145 (2009). |
Tseng et al., “Oxygen- and growth rate-dependent regulation of Escherichia coli fumarase (FumA, FumB, and BumC) activity,” J. Bacteriol. 183(2):461-467 (2001). |
Tucci and Martin, “A novel prokaryotic trans-2-enoyl-CoA reductase from the spirochete Treponema denticola,” FEBS Lett. 581:1561-1566 (2007). |
Twarog and Wolfe, “Role of Buyryl Phosphate in the Energy Metabolism of Clostridium tetanomorphum,” J. Bacteriol. 86:112-117 (1963). |
Tzimagiorgis et al., “Molecular cloning, structure and expression analysis of a full-length mouse brain glutamate dehydrogenase cDNA,” Biochem. Biophys. Acta. 1089:250-253 (1991). |
Tzimagiorgis et al., “Structure and expression analysis of a member of the human glutamate dehydrogenase (GLUD) gene gamily mapped to chromosome 10p11.2,” Hum. Genet. 91:433-438 (1993). |
Uchiyama et al., “Identification of the4-Hydroxycinnamate Decarboxylase (PAD) Gene of Klebsiella oxytoca,” Biosci. Biotechnol. Biochem. 72:116-123 (2008). |
Umeda et al., “Cloning and sequence analysis of the poly(3-hydroxyalkanoic acid)-synthesis genes of Pseudomonas acidophila,” Appl. Biochem. Biotechnol. 70-72:341-352 (1998). |
Uttaro and Opperdoes, “Purification and characterisation of a novel iso-propanol dehydrogenase from Phytomonas sp,” Mol. Biochem. Parasitol. 85:213-219 (1997). |
Valdes-Hevia and Gancedo, “Isolation and characterization of the gene encoding phosphoenolpyruvate carboxykinase from Saccharomyces cerevisiae,” FEBS Lett. 258(2):313-316 (1989). |
Valentin et al., “Indentication of 4-hydroxyhexanoic acid as a new constituent of biosynthetic polyhydroxyalkanoic acids from bacteria,” Appl. Microbiol. Biotechnol. 40:710-716 (1994). |
Valentin et al., “Identification of 4-hydroxyvaleric acid as a constituent of biosynthetic polyhydroxyalkanoic acids from bacteria,” Appl. Microbiol. Biotechnol. 36:507-514 (1992). |
Valentin et al., “Identification of 5-hydroxyhexanoic acid, 4-hydroxyaheptanoic acid and 4-hydroxyoctanoic acid as new constituents of bacterial polyhydroxyalkanoic acids,” Appl. Microbiol. Biotechnol. 46:261-267 (1996). |
Valentin et al., “Metabolic pathway for biosynthesis of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) from 4-hydroxybutyrate by Alcaligenes eutrophus,” Eur. J. Biochem. 227:43-60 (1995). |
Valentin et al., “Poly(3-hydroxybutyrate-co-4-hydroxybutyrate) formation from gamma-aminobutyrate and glutamate,” Biotechnol Bioeng. 67(3):291-299 (2000). |
Valentin et al., “Production of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in recombinant Escherichia coli grown on glucose,” J. Biotechnol. 58:33-38 (1997). |
Valentine and Wolfe, “Purification and role of phosphotransbutyrylase,” J. Biol. Chem. 235:1948-1952 (1960). |
Valle et al., “Complete nucleotide sequence of the glutamate dehydrogenase gene from Escherichia coli K-12,” Gene 27:193-199 (1984). |
Valle et al., “Nucleotide sequence of the promotor and amino-terminal coding region of the glutamate dehydrogenase structural gene of Escherichia coli,” Gene. 23:199-209 (1983). |
Vamecq et al., “The microsomal dicarboxylyl-CoA synthetase,” Biochem. J. 230:683-693 (1985). |
Van der Rest et al., “Functions of the membrane-associated and cytoplasmic malate dehydrogenases in the citric acid cycle of Escherichia coli,” J. Bacteriol. 182(24):6892-6899 (2000). |
van der Voorhorst et al., “Genetic and biochemcial characterization of a short-chain alcohol dehydrogenase from the hyperthermophilic archaeon Pyrococcus furiosus,” Eur. J. Biochem. 268:3062-3068 (2001). |
Van Grinsven et al., “Acetate:Succinate CoA-transferase in the Hydrogenosomes of Trichomonas vaginalis,” J. Biol. Chem. 283:1411-1418 (2008). |
Vanderwinkel et al., “Growth of Escherichia coli on Fatty Acids: Requirement for Coenzyme a Transferase Activity,” Biochem. Biophys. Res. Commun. 33:902-908 (1968). |
Vanrolleghem et al., “Validation of a Metabolic Network for Saccharomyces cerevisiae Using Mixed Substrate Studies ” Biotechnol. Prog. 12(4):434-448 (1996). |
Varma and Palsson, “Metabolic Flux balancing: Basic concepts, Scientific and Practical Use,” Biotechnol. 12:994-998 (1994). |
Varma and Palsson, “Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type Escherichia coli W3110,” Appl. Environ. Microbiol. 60:3724-3731 (1994). |
Vazquez et al., “Phosphotransbutyrylase Expression in Bacillus megaterium,” Curr. Microbiol. 42:345-349 (2001). |
Venkitasubramanian et al. Biocatalysis in the Pharmaceutical and Biotechnology Industries, ed. R.N. Patel, Chapter 15, pp. 425-440, CRC Press LLC, Boca Raton, Fl. 2007. |
Venkitasubramanian et al., “Reduction of Carboxylic Acids by Nocardia Aldehyde Oxidoreductase Requires a Phosphopantetheinylated Enzyme,” J. Biol Chem. 282:478-485 (2007). |
Vernal et al., “Cloning and heterologous expression of a broad specificity aminotransferase of leishmania mexicana promastigotes1,” FEMS Microbiol. Lett. 229(2):217-222 (2003). |
Vernal et al., “Isolation and partial characterization of a broad specificity aminotransferase from Leishmania mexicana promastigotes,” Mol. Biochem. Parasitol. 96(1-2):83-92 (1998). |
Vey et al., “Structural basis for glycyl radical formation by pyruvate formate-lyase activating enzyme,” Proc. Natl. Acad. Sci. U.S.A. 105(42):16137-16141 (2008). |
Viola, “L-aspartase: new tricks from an old enzyme,” Adv. Enzymol. Relat. Areas. Mol. Biol. 74:295-341 (2000). |
Voets et al., “Reduced intracellular ionic strength as the initial trigger for activation of endothelial volume-regulated anion channels,” Proc. Natl. Acad. Sci. USA 96:5298-5303 (1999). |
Volkov et al., “Random chimeragenesis by heteroduplex recombination,” Methods Enzymol. 325:456-463 (2000). |
Volkov et al., “Recombination and chimeragenesis by in vitro heteroduplex formation and in vivo repair,” Nucleic Acids Res. 27(18):e18 (1999). |
Wakil et al., “Studies on the Fatty Acid Oxidizing System of Animal Tissues,” J. Biol. Chem. 207:631-638 (1954). |
Walker et al., “Yeast pyruvate carboxylase: identification of two genes encoding isoenzymes,” Biochem. Biophys. Res. Commun. 176(3):1210-1217 (2007). |
Walter et al., “Sequence and arrangement of two genes of the butyrate-synthesis pathway of Clostridium acetobutylicum ATCC 824,” Gene 134:107-111 (1993). |
Walter et al., “Molecular characterization of two Clostridium acetobutylicum ATCC 824 butanol dehydrogenase isozyme genes,” J. Bacteriol. 174(22):7149-7158 (1992). |
Wang et al., “Molecular cloning and functional identification of a novel phenylacetyl-CoA ligase gene from Penicillium chrysogenum,” Biochem. Biophys. Res. Commun. 360(2):453-458 (2007). |
Wang et al., “The primary structure of branched-chain α-oxo acid dehydrogenase from Bacillus subtilis and its similarity to other α-oxo acid dehydrogenases,” Eur. J. Biochem. 213:1091-1099 (1993). |
Wang et al., “Isolation of poly-3-hydroxybutyrate metabolism genes from complex microbial communities by phenotypic complementation of bacterial mutants,” Appl. Environ. Microbiol. 72(1):384-391 (2006). |
Wang et al., “Screening microorganisms for utilization of furfural and possible intermediates in its degradative pathway,” Biotechnol. Lett. 16(9):977-982 (1994). |
Ward et al., “Molecular analysis of the role of two aromatic aminotransferases and a broad-specificity aspartate aminotransferase in the aromatic amino acid metabolism of Pyrococcus furiosus,” Archaea 1:133-141 (2002). |
Weaver, “Structure of free fumarase C from Eschericiha coli,” Acta. Crystallog. D. Biol. Crystallogr. 61:1395-1401 (2005). |
Weidner and Sawers, “Molecular Characterization of the Genes Encoding Pyruvate Formate-Lyase and its Activating Enzyme of Clostridium pasteruianum,” J. Bacteriol. 178(8):2440-2444 (1996). |
Welch et al., “Purification and characterization of the NADH-dependent butanol dehydrogenase from Clostridium acetobutylicum (ATCC 824),” Arch. Biochem. Biophys. 273(2):309-318 (1989). |
Werpy et al., “Top Value Added Chemicals from Biomass. vol. I—Results of Screening for Potential Candidates from Sugars and Synthesis Gas,” DOE Report (2004). |
Westin et al., “The Identification of Succinyl-CoA Thioesterase Suggests a Novel Pathway for Succinate Production in Peroxisomes,” J. Biol. Chem. 280(46):38125-38132 (2005). |
Wexler et al., “A wide host-range metagenomic library from a waste water treatment plant yields a novel alcohol/aldehyde dehdrogenase,” Environ. Microbiol. 7:1917-1926 (2005). |
Whalen and Berg, “Analysis of an avtA::Mu d1(Ap lac) Mutant: Metabolic role of Transaminase C,” J. Bacteriol. 150(2):739-746 (1982). |
Whalen and Berg, “Gratuitous Repression of avtA in Escherichia coli and Salmonella typhimurium,” J. Bacteriol. 158(2):571-574 (1984). |
Whitehead and Rabinowitz, “Cloning and expression in Escherichia coli of the gene for 10-formyltetrahydrofolate synthetase from Clostridium acidiurici (“Clostridium acidi-urici”),” J. Bacteriol. 167:205-209 (1986). |
Whitehead and Rabinowitz, “Nucleotide sequence of the Clostridium acidiurici (“Clostridium acidi-urici”) gene for 10-formyltetrahydrofolate synthetase shows extensive amino acid homology with the trifunctional enzyme C1-tetrahydrofolate synthase from Saccharomyces cerevisiae,” J. Bacteriol. 170:3255-3261 (1988). |
Wiesenborn et al., “Coenzyme a Transferase from Clostridium acetobutylicum ATC 824 and its Role in the Uptake of Acids,” Appl. Environ. Microbiol. 55:323-329 (1989). |
Wilkie and Warren, “Recombinant Expression, Purification, and Characterization of Three Isoenzymes of Aspartate Aminotrannsferase from Arabidopsis thaliana,” Protein Expr. Purif. 12:381-389 (1998). |
Wilks et al., “A specific, highly active malate dehydrogenase by redesign of a lactate dehydrogenase framework,” Science 242(4885):1541-1544 (1988). |
Wilks et at, “Design for a broad substrate specificity keto acid dehydrogenase,” Biochemistry 29(37)8587-8591 (1990). |
Wilks et al., “Design of a specific phenyllactate dehydrogenase by peptide loop exchange on the Bacillus stearothermophilus lactate dehydrogenase framework,” Biochemistry 31(34):7802-7806 (1992). |
Willadsen and Buckel, “Assay of 4-hydroxybutyryl-CoA dehydrasate from Clostridium aminobutyricum,” FEMS Microbiol. Lett. 70:187-191 (1990). |
Williams et al., “Biodegradable plastics from plants,” CHEMTECH 26:38-44 (1996). |
Willke and Vorlop, “Biotechnological production of itaconic acid,” Appl. Microbiol. Biotechnol. 56:289-295 (2001). |
Winzer et al., “Differential regulation of two thiolase genes from Clostridium acetobutylicum DSM 792,” J. Mol. Microbiol. Biotechnol. 2:531-541 (2000). |
Wolff and Kenealy, “Purification and characterization of the oxygen-sensitive 4-hydroxybutanoate dehydrogenase from Clostridium kluyveri,” Protein Expr. Purif. 6:206-212 (1995). |
Wolff et al., “Dehydrogenases involved in the conversion of succinate to 4-hydroxybutanoate by Clostridium kluyven,” Appl. Environ. Microbio. 59:1876-1882 (1993). |
Wong et al., “Sequence satruation mutagenesis with tunable mutation frequencies,” Anal. Biochem. 341:187-189 (2005). |
Wong et al., “Sequence saturation mutagenesis (SeSaM): a novel method for directed evolution,” Nucleic Acids Res. 32(3):e26 (2004). |
Wong et al., “Transversion-enriched sequence saturation mutagenesis (SeSaM-Tv+): a random mutagenesis method with consecutive nucleotide exchanges that complements the bias of error-prone PCR,” Biotechnol. J. 3:74-82 (2008). |
Woods, “Two biochemically distinct classes of fumarase in Escherichia coli,” Biochim. Biophys. Acta 954(1):14-26 (1988). |
Wu et al., “Life in hot carbon monoxide: the complete genome sequence of Carboxydothermus hydrogenoformans Z-2901,” PLoS Genetics 1(5):0563-0574 (2005). |
Wynn et al., “Chaperonins GroEL and GroES Promote Assembly of Heterotramers (α2β2) of Mammalian Mitochondrial Branched-chain α-Keto Acid Decarboxylase in Escherichia coli,” J. Biol. Chem. 267(18):12400-12403 (1992). |
Wynn et al., “Cloning and Expression in Escherichia coli of a Mature E1β Subunit of Bovine Mitochondrial Branched-chain α-Keto Acid Dehydrogenase Complex,” J. Biol Chem. 267(3):1881-1887 (1992). |
Yagi et al., “Aspartate: 2-Oxoglutarate Aminotransferase from Bakers' Yeast: Crystallization and Charactierization,” J. Biochem. 92:35-43 (1982). |
Yagi et al., “Crystallization and Properties of Aspartate Aminotransferase from Escherichi coli B,” FEBS Lett. 100(1)81-84 (1979). |
Yagi et al., “Glutamate-Aspartate Transaminase from Microorganisms,” Meth. Enzymol. 113:83-89 (1985). |
Yamamoto et al., “Carboxylation reaction catalyzed by 2-oxoglutarate:ferredoxin oxidoreductases from Hydrogenobacter thermophilus,” Extremophiles 14:79-85 (2010). |
Yamamoto et al., “Purification and properties of NADP-dependent formate dehydrogenase from Clostridium thermoaceticum, a tungsten-selenium-iron protein,” J. Biol. Chem. 258:1826-1832 (1983). |
Yang et al, “Nucleotide Sequence of the fadA Gene. Primary structure of 3-ketoacyl-coenzyme A thiolase from Escherichia coli and the structural organization of the fadAB operon,” J. Biol. Chem 265(18):10424-10429 (1990) with correction in J. Biol Chem 266(24):16255 (1991). |
Yang et al., “Aspartate Dehydrogenase, a Novel Enszyme Idnetified from Structural and Functional Studies of TM16343,” J. Biol. Chem. 278:8804-8808 (2003). |
Yang et al., “Continuous cultivation of Lactobacillus rhamnosus with cell recycling using an acoustic cell settler,” Biotechnol. Bioprocess. Eng. 7(6):357-361 (2002). |
Yang et al., “Nucleotide Sequence of the fadA Gene,” J. Biol. Chem. 265(18):10424-10429 (1990). |
Yang et al., Nucleotide sequence of the promoter and fadB gene of the fadBA operon and primary structure of the multifunctional fatty acid oxidation protein from Escherichia coli, Biochemistry 30(27):6788-6795 (1991). |
Yano et al., “Directed evolution of an aspartate aminotransferase with new substrate specificities,” Proc. Natl. Acad. Sci. U.S.A. 95:5511-5515 (1998). |
Yarlett et al., “Trichomonas vaginalis: characterization of ornithine decarboxylase,” Biochem. J. 293:487-493 (1993). |
Yee et al., “Isolation and characterization of a NADP-dependent glutamate dehydrogenase gene from the primitive eucaryote Giardia lamblia,” J. Biol. Chem. 267:7539-7544 (1992). |
Yoshida et al., “The structures of L-rhamnose isomerase from Pseudomonas stutzeri in complexs with L-rhamnose and D-allose provide insights into broad substrate specificity,” J. Mol. Biol. 365(5): 1505-1516 (2007). |
Youngleson et al., “Homology between hydroxybutyryl and hydroxyacyl coenzyme A dehydrogenase enzymes from Clostridium acetobutylicum fermentation and vertebrate fatty acid beta-oxidation pathways,” J. Bacteriol. 171(12):6800-6807 (1989). |
Yu et al., “sucAB and sucCD are mutually essential genes in Escherichia coli,” FEMS Microbiol. Lett. 254(2):245-250 (2006). |
Yun et al., “The genes for anabolic 2-oxoglutarate: ferredoxin oxidoreductse from hydrogenobacter thermophilus TK-6,” Biochem. Biophys. Res. Commun. 282(2):589-594 (2001) |
Yun et al., “Omega-Amino acid:pyruvate transaminase from Alcaligenes denitrificans Y2k-2: a new catalyst for kinetic resolution of beta-amino acids and amines,” Appl. Environ. Microbiol. 70 4 :2529-2534 (2004). |
Zeiher and Randall, “Identification and Characterization of Mitochondrial Acetyl-Coenzyme A Hydrolase from Pisum sativum L. Seedlings,” Plant Physiol. 94:20-27 (1990). |
Zhang et al., “2-Oxoacid: Ferredoxin Oxidoreductase from the Thermoacidophilic Archaeon, Sulfolobus sp. Strain 71,” J. Biochem. 120:587-599 (1996). |
Zhang et al., “A new logic for DNA engineering using recombination in Escherichia coli,” Nat. Genet. 20:123-128 (1998). |
Zhang et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening,” Proc. Natl. Acad. Sci. U.S.A. 94:4504-4509 (1997). |
Zhang et al., “Isolation and Properties of a levo-lactonase from Fusarium proliferatum ECD2002: a robust biocatalyst for production of chiral lactones,” App. Microbiol. Biotechnol. 75(5):1087-1094 (2007). |
Zhang, et al., “Kinetic and mechanistic characterization of the polyhydroxybutyrate synthase from Ralstonia eutropha,” Biomacromolecules 1(2):244-251 (2000). |
Zhao et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol. 16(3):258-261 (1998). |
Zhou et al., “Engineering a native homoethanol pathway in Escherichia coli B for ethanol production,” Biotechnol. Lett. 30:335-342 2008. |
Zhou et al., Isolation, crystallization and preliminary X-ray analysis of a methanol-induced corrinoid protein from Moorella thermoacetica. Acta Cryst. F61:537-540 (2005). |
Zhou et al., “The remarkable structural and functional organization of the eukaryotic pyruvate dehydrogenase complexes,” Proc. Natl. Acad. Sci. USA 98:14802-14807 (2001). |
Zhou et al., “Functional replacement of the Escherichia coli D-(−)-lactate dehydrogenase gene (IdhA) with the L-(+)-lactate dehydrogenase gene (IdhL) from Pediococcus acidilactici,” Appl. Environ. Micro. 69:2237-2244 (2003). |
Zhuang et al., “The YbgC protein encoded by the ybgC gene of the tol-pal gene cluster of Haemophilus influenzae catalyzes acyl-coenzyme A thioester hydrolysis,” FEBS Lett. 516:161-163 2002. |
Four pages from URL: shigen.nig.ac.jp/ecoli/pec/genes.List.DetailAction.do (Printed Dec. 21, 2009). |
One page from URL: expressys.de/. (Printed Dec. 21, 2009). |
Two page from URL: openwetware.org/wiki/Synthetic—Biology:BioBricks, Synthetic Biology:BioBricks, portal for information relating to the Registry of Standard Biological Parts (Printed Dec. 21, 2009). |
Two pages from URL: www.genome.jp/dbget-bin/www—bget?cdf:CD2966 (Printed Dec. 21, 2009). |
Two pages from URL: www.genome.jp/dbget-bin/www—bget?cpe:CPE2531 (Printed Dec. 21, 2009). |
Two pages from URL: www.genome.jp/dbget-bin/www—bget?ctc:CTC01366 (Printed Dec. 21, 2009). |
Two pages from URL: www.genome.jp/dbget-bin/www—bget?cth:Cthe—0423 (Printed Mar. 4, 2010). |
Two pages from URL: scientificamerican.com/article.cfm?id=turning-bacteria-into-plastic-factories-replacing-fossil-fuels (Printed Feb. 17, 2011). |
Gene Bridges, “Quick & Easy BAC Modification Kit by Red®/ET® Recombination,” Technical Protocol, Cat. No. K001, Version 2.6 (2007). |
Kakimoto et al., “Beta-aminoisobutyrate-alpha-ketoglutarate transaminase in relation to beta-aminoisobutyric aciduria,” Biochim. Biophys. Acta. 156(2):374-380 (1968). |
Kato and Asano, “3-Methylaspartate ammonia-lyase as a marker enzyme of the mesaconate pathway for (S)-glutamate fermentation in Enterobacteriaceae,” Arch. Microbiol. 168(6):457-463 (1997) |
Kizer et al., “Application of Functional Genomics to Pathway Optimization for Increased Isoprenoid Production,” Appl. Environ. Microbiol. 74(10):3229-3241 (2008). |
Fishbein and Bessman, “Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of γ-lactones. II. Metal Ion effects, kinetics, and equilibra,” J. Biol. Chem. 241(21):4842-4847 (1966). |
Perez-Prior et al., “Reactivity of lactones and GHB formation,” J. Org. Chem. 70(2):420-426 (2005). |
Number | Date | Country | |
---|---|---|---|
20110217742 A1 | Sep 2011 | US |
Number | Date | Country | |
---|---|---|---|
61264598 | Nov 2009 | US |